Sars-cov-2 entry inhibitors

WO2024206939A3PCT designated stage expired Publication Date: 2024-11-14UNIV OF FLORIDA RESEARCH FOUNDATION INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/022392
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-30
Filing Date
2024-03-29
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current therapeutic approaches for COVID-19, such as vaccines and antiviral drugs, face challenges due to rapid viral evolution and reduced efficacy against variants, particularly in immunocompromised individuals, with no FDA-approved entry inhibitors available to prevent SARS-CoV-2 attachment or internalization.

Method used

Development of small molecule inhibitors targeting the SARS-CoV-2 spike protein's receptor binding domain (RBD) and S2 subunit to block attachment to the ACE2 receptor and membrane fusion, using a luminescence-based pseudo virus assay and high-throughput screening to identify compounds that prevent viral entry.

Benefits of technology

The identified compounds effectively inhibit SARS-CoV-2 entry into cells, offering alternative treatment modalities that complement existing therapies and potentially address the limitations of current vaccines and antiviral drugs, particularly against emerging variants.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024022392_14112024_PF_FP_ABST
    Figure US2024022392_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides compounds of the formulae herein (e.g., Formulae (I'), (I)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof, which inhibit viral entry. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, and methods of treating or preventing diseases by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, or pharmaceutical compositions thereof.
Need to check novelty before this filing date? Find Prior Art

Description

SARS-COV-2 ENTRY INHIBITORSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority under 35 U.S.C. § 119(e) to U.S. Provisional Application Number 63 / 493,108, filed March 30, 2023, titled SARS-COV-2 ENTRY INHIBITORS, the contents of which are incorporated herewith by reference in their entirety.GOVERNMENT SUPPORT

[0002] This invention was made with government support under Grant No. AI171954 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND OF THE INVENTION

[0003] The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for COVID-19, remains a worldwide public health threat. SARS-CoV-2 is characterized by rapid viral evolution with increasingly transmissible and infectious variants, presenting challenges for management with currently FDA approved SARS-CoV-2 vaccines.1 3Additionally, immunocompromised individuals or individuals susceptible to adverse reactions to vaccines may not benefit from vaccination.

[0004] A wide variety of therapeutic approaches have been pursued in efforts to thwart the global COVID-19 pandemic. Much attention has focused on the disruption of RNA processing and replication, intracellular processes that follow attachment of SARS-CoV-2 to the angiotensin converting enzyme 2 (ACE2) receptor and subsequent internalization of the virus. Intracellular-acting drugs developed and approved for human use include Paxlovid™ (nirmatrelvir) and Lagevrio™ (molnupiravir). Additionally, the combination of monoclonal antibodies tixagevimab-cilgavimab has been studied18- 20. The tixagevimab-cilgavimab trial was completed prior to the emergence of the omicron variant and its derived subvariants, which rapidly became predominant in most parts of the world. Some in vitro studies have also suggested that tixagevimab-cilgavimab have reduced levels of protection vs. newer variants21, with some serious adverse events reported19,20. Other small molecules, such as Remdesivir and Molnupiravir (two nucleoside analogs), have been approved for use, but no entry inhibitors have to date gained FDA approval3. Thus, there is immense interest in the development of novel therapeutic agents that target different aspects of viral replication.SUMMARY OF THE INVENTION

[0005] Disruption of upstream extracellular events, in particular the prevention of attachment or internalization of SARS-CoV-2, would provide alternative treatment modalities or complement approved therapies. The envelope spike (S) protein, which attaches to ACE2 through its receptor binding domain (RBD), is the site of much of the rapid viral evolution, with mutations correlatingwith the increased transmissibility of the viral variants1,2. Prevention of viral internalization may occur by blocking S-RBD / ACE2 attachment or by blocking other events that precede viral entry.

[0006] Two pathways have been described for SARS-CoV-2 entry into target cells: the cell surface and endosomal pathways4(Fig 1A). Both pathways involve the sequential activity of two subunits of the S protein, SI and S2 (Fig IB). The receptor binding domain (RBD) of the SI subunit binds a functional ACE2 receptor on the target cell4. The S2 subunit allows the fusion of the cell and viral membranes, upon conformational changes triggered by proteolytic activation at the S1 / S2 boundary and dissociation of SI. The S protein may be cleaved either by the cell surface transmembrane serine protease 2 (TMPRSS2), or by endosomal proteases triggered by low pH, such as Cathepsin B / L4. Small molecule inhibitors that can block the binding / attachment of the SI RBD to ACE2 receptor and / or the fusion mediated by S2 domain would allow limiting infection, virus propagation, and transmissibility.

[0007] A luminescence-based pseudo virus assay (Fig 1C) followed by a robust high-throughput screen (HTS) has been used to identify SARS-CoV-2 entry inhibitors, testing 2030 small molecules from multiple libraries (Fig ID). Screening hits were identified based on their performance in the pseudo virus screen, in cytotoxicity counter screens, and in wild-type SARS-CoV-2 infectivity assays5. The HTS assay is phenotypic in nature, i.e., the screen provides information regarding whether viral entry is prevented, regardless of mechanism. Eleven hits were identified for further study, with a focus on structure activity relationship (SAR) studies, optimization of properties for eventual in vivo use, and studies of their precise mechanism of action.

[0008] Accordingly, in one aspect, the present disclosure provides compounds of Formula (I'):or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, wherein A is CR4or N, and L, L11, L12, R1, R3, R4, and R5are as defined herein.

[0009] In another aspect, the present disclosure provides compounds of Formula (I):or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, wherein A is CR4or N, and L, R1, R2, R3, R4, and R5are as defined herein.

[0010] In another aspect, the present disclosure provides pharmaceutical compositions comprising a compound disclosed herein. In some embodiments, the pharmaceutical composition comprises an excipient.

[0011] In another aspect, the present disclosure provides methods of treating or preventing a disease in a subject in need thereof, comprising administering to the subject in need thereof a provided compound or pharmaceutical composition. In certain embodiments, the disease is associated with a viral infection (e.g., a coronavirus (e.g., SARS-CoV-2)). In certain embodiments, the disease is associated with modulation of PIKfyve (e.g., cancer (e.g., B-cell cancer, non-Hodgkin’s lymphoma, follicular lymphoma), Amyotrophic Lateral Sclerosis, Crohn’s Disease, Rheumatoid Arthritis).

[0012] In another aspect, the present disclosure provides methods of inhibiting entry of a virus in a subject in need thereof or in a cell, tissue, or biological sample, comprising administering to the subject in need thereof or contacting the cell, tissue, or biological sample with an effective amount of a provided compound or pharmaceutical composition. In certain embodiments, the cell, tissue, or biological sample is in vivo. In certain embodiments, the cell, tissue, or biological sample is in vitro.

[0013] In another aspect, the present disclosure provides methods of inhibiting PIKfyve in a subject in need thereof or in a cell, tissue, or biological sample, comprising administering to the subject in need thereof or contacting the cell, tissue, or biological sample with an effective amount of a provided compound or pharmaceutical composition. In certain embodiments, the cell, tissue, or biological sample is in vivo. In certain embodiments, the cell, tissue, or biological sample is in vitro.

[0014] In another aspect, the present disclosure provides kits comprising a provided compound or pharmaceutical composition disclosed herein and instructions for its use.

[0015] It should be appreciated that the foregoing concepts, and the additional concepts discussed below, may be arranged in any suitable combination, as the present disclosure is not limited in this respect. Further, other advantages and novel features of the present disclosure will become apparent from the following detailed description of various non-limiting embodiments when considered in conjunction with the accompanying drawings.BRIEF DESCRIPTION OF THE DRAWINGS

[0016] FIG. 1 shows the activity of various test compounds, including compounds of this disclosure, in an attachment assay, with comparison to a non-claimed commercially availble compound designated “SR-580”. This reference compound SR-580 has the chemical name A2-(4-chlorophenyl)- 6-morpholino-N4-(2-morpholinoethyl)-l,3,5-triazine-2,4-diamine and CAS Registry Number 452074- 67-8. Compounds (or DMSO) were preincubated with MLV-SARS-2 S for 20 mins at 37°C followed by 40 mins at 4°C. Compounds were then incubated with pre-chilled Vero CCL81 cells and spinoculated at 2100 g, for 1 hour at 4°C. After washing with cold PBS to remove unattached virions and / or drugs bound to virions, fresh medium (without compounds) was added. Cells were then furtherincubated at 37°C for 48 hours, before luciferase activity was measured using Bright-Glo reagent. sACE2: soluble ACE2. Shown is mean ± SEM of n=l-4.

[0017] FIG. 2 shows that various test compounds, including compounds of this disclosure, do not impact Cathepsin L activity. Reference compound SR-580 (N2-(4-chlorophenyl)-6-morpholino-N4-(2- morpholinoethyl)-1,3,5-triazine-2,4-diamine) and claimed compounds shown do not impact Cathepsin L-induced S protein cleavage. Compounds were used at 2 μM. +: positive control, - : negative control. Shown is representative of n=l-3 experiments.

[0018] FIG. 3 shows that various test compounds, including compounds of this disclosure, do not impact TMPRSS2 activity. Reference compound SR-580 (N2-(4-chlorophenyl)-6-morpholino-N4-(2- morpholinoethyl)-1,3,5-triazine-2,4-diamine) and claimed compounds do not impact TMPRSS2 L- induced S protein cleavage. Compounds were used at 2 μM, Camostat Mesylate was used at 5 μM. Shown is n=l.

[0019] FIGs. 4A-4B show the activity of a selected compound (Compound 42, SR-37644) against wild-type live SARS-CoV2 (original strain, WA-01) in a NanoLuc Luciferase (nLuc) assay (FIG. 4A), and compared to remdesivir (FIG. 4B). EC50values were calculated with a 4-parameter logistic model (XLfit, IBDS).DEFINITIONS

[0020] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991) . As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

[0021] Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Michael B. Smith, March ’s Advanced Organic Chemistry, 7thEdition, John Wiley & Sons, Inc., New York, 2013; Richard C. Larock, Comprehensive Organic Transformations, John Wiley & Sons, Inc., New York, 2018; and Carruthers, Some Modem Methods of Organic Synthesis, 3rdEdition, Cambridge University Press, Cambridge,1987.

[0022] Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various stereoisomeric forms, e.g., enantiomers and / or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S.H., Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ, of Notre Dame Press, Notre Dame, IN 1972). The invention additionally encompasses compounds as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers. The term “isomers” is intended to include diastereoisomers, enantiomers, regioisomers, structural isomers, rotational isomers, tautomers, and the like. All such isomers of such compounds herein are expressly included in the present invention.

[0023] When a range of values (“range”) is listed, it encompasses each value and sub-range within the range. A range is inclusive of the values at the two ends of the range unless otherwise provided. For example “C1-6alkyl” encompasses, C1, C2, C3, C4, C5, C6, C1-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and C5-6alkyl.

[0024] The term “aliphatic” refers to alkyl, alkenyl, alkynyl, and carbocyclic groups. Likewise, the term “heteroaliphatic” refers to heteroalkyl, heteroalkenyl, heteroalkynyl, and heterocyclic groups.

[0025] The term “alkyl” refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms (“C1-20alkyl”). In some embodiments, an alkyl group has 1 to 12 carbon atoms (“C1-12alkyl”). In some embodiments, an alkyl group has 1 to 10 carbon atoms (“C1-10alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C1-9alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C1-8alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C1-7alkyl”). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“C1-6alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C1-5alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C1-4alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C1-3alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C1-2alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“C1alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C2-6alkyl”). Examples of C1-6alkyl groups include methyl (C1), ethyl (C2), propyl (C3) (e.g., n-propyl, isopropyl), butyl (C4) (e.g., n-butyl, tert-butyl, sec-butyl, isobutyl), pentyl (C5) (e.g., n- pentyl, 3-pentanyl, amyl, neopentyl, 3-methyl-2- butanyl, tert-amyl), and hexyl (C6) (e.g., n-hexyl). Additional examples of alkyl groups include n- heptyl (C7), n-octyl (C8), n-dodecyl (C12), and the like. Unless otherwise specified, each instance of an alkyl group is independently unsubstituted (an “unsubstituted alkyl”) or substituted (a “substitutedalkyl”) with one or more substituents (e.g., halogen, such as F). In certain embodiments, the alkyl group is an unsubstituted C1-12alkyl (such as unsubstituted C1-6alkyl, e.g., -CH3(Me), unsubstituted ethyl (Et), unsubstituted propyl (Pr, e.g., unsubstituted n-propyl (n-Pr), unsubstituted isopropyl (z'-Pr)), unsubstituted butyl (Bu, e.g., unsubstituted n -butyl (zz-Bu), unsubstituted tert-butyl (tert-Bu or t-Bu), unsubstituted sec-butyl (sec-Bu or s-Bu), unsubstituted isobutyl (z'-Bu)). In certain embodiments, the alkyl group is a substituted Ci-12 alkyl (such as substituted C1-6alkyl, e.g., -CH2F, -CHF2, -CF3, - CH2CH2F, -CH2CHF2, -CH2CF3, or benzyl (Bn)).

[0026] The term “haloalkyl” is a substituted alkyl group, wherein one or more of the hydrogen atoms are independently replaced by a halogen, e.g., fluoro, bromo, chloro, or iodo. “Perhaloalkyl” is a subset of haloalkyl and refers to an alkyl group wherein all of the hydrogen atoms are independently replaced by a halogen, e.g., fluoro, bromo, chloro, or iodo. In some embodiments, the haloalkyl moiety has 1 to 20 carbon atoms (“C1-20haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 10 carbon atoms (“C1-10haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 9 carbon atoms (“C1-9haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 8 carbon atoms (“C1-8haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 7 carbon atoms (“C1-7haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 6 carbon atoms (“C1-6haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 5 carbon atoms (“C1-5haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 4 carbon atoms (“C1-4haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 3 carbon atoms (“C1-3haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 2 carbon atoms (“C1-2haloalkyl”). In some embodiments, all of the haloalkyl hydrogen atoms are independently replaced with fluoro to provide a “perfluoroalkyl” group. In some embodiments, all of the haloalkyl hydrogen atoms are independently replaced with chloro to provide a “perchloroalkyl” group. Examples of haloalkyl groups include -CHF2, -CH2F, -CF3, -CH2CF3, -CF2CF3, -CF2CF2CF3, -CCI3, -CFCI2, -CF2C1, and the like.

[0027] The term “heteroalkyl” refers to an alkyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (e.g., inserted between adjacent carbon atoms of) and / or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkyl group refers to a saturated group having from 1 to 20 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC1-20alkyl”). In certain embodiments, a heteroalkyl group refers to a saturated group having from 1 to 12 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC1-12alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 11 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC1-11alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 10 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC1-10alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 9 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC1-9alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 8 carbon atoms and 1 or more heteroatoms within the parentchain (“heteroC1-8alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 7 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC1-7alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 6 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC1-6alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 5 carbon atoms and 1 or 2 heteroatoms within the parent chain (“heteroC1-5alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 4 carbon atoms and lor 2 heteroatoms within the parent chain (“heteroC1-4alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 3 carbon atoms and 1 heteroatom within the parent chain (“heteroC1-3alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 2 carbon atoms and 1 heteroatom within the parent chain (“heteroC1-2alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 carbon atom and 1 heteroatom (“heteroC1alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 2 to 6 carbon atoms and 1 or 2 heteroatoms within the parent chain (“heteroC2-6alkyl”). Unless otherwise specified, each instance of a heteroalkyl group is independently unsubstituted (an “unsubstituted heteroalkyl”) or substituted (a “substituted heteroalkyl”) with one or more substituents. In certain embodiments, the heteroalkyl group is an unsubstituted heteroCi-12 alkyl. In certain embodiments, the heteroalkyl group is a substituted heteroC1-12alkyl.

[0028] The term “alkenyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms and one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds). In some embodiments, an alkenyl group has 2 to 20 carbon atoms (“C2-20alkenyl”). In some embodiments, an alkenyl group has 2 to 12 carbon atoms (“C2-12alkenyl”). In some embodiments, an alkenyl group has 2 to 11 carbon atoms (“C2-11 alkenyl”). In some embodiments, an alkenyl group has 2 to 10 carbon atoms (“C2-10alkenyl”). In some embodiments, an alkenyl group has 2 to 9 carbon atoms (“C2-9alkenyl”). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C2-8alkenyl”). In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C2-7alkenyl”). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C2-6alkenyl”). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C2-5alkenyl”). In some embodiments, an alkenyl group has 2 to 4 carbon atoms (“C2-4alkenyl”). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C2-3 alkenyl”). In some embodiments, an alkenyl group has 2 carbon atoms (“C2alkenyl”). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C2-4alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C2-6alkenyl groups include the aforementioned C2-4alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (C8), octatrienyl (C8), and the like. Unless otherwise specified, each instance of an alkenyl group is independently unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents. In certain embodiments, the alkenyl group is an unsubstituted C2-20alkenyl. In certainembodiments, the alkenyl group is a substituted C2-20alkenyl. In an alkenyl group, a C=C double bond for which the stereochemistry is not specified (e.g., -CH=CHCH3 or) may be in the (E)- or(Z) -configuration.

[0029] The term “heteroalkenyl” refers to an alkenyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (e.g., inserted between adjacent carbon atoms of) and / or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkenyl group refers to a group having from 2 to 20 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“hetero C2-20alkenyl”). In certain embodiments, a heteroalkenyl group refers to a group having from 2 to 12 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC2-12alkenyl”). In certain embodiments, a heteroalkenyl group refers to a group having from 2 to 11 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC1-11alkenyl”). In certain embodiments, a heteroalkenyl group refers to a group having from 2 to 10 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC2-10alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 9 carbon atoms at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC2-9alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 8 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC2-8alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 7 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC2-7alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC2-6alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 5 carbon atoms, at least one double bond, and 1 or 2 heteroatoms within the parent chain (“heteroC2-5alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 4 carbon atoms, at least one double bond, and 1 or 2 heteroatoms within the parent chain (“heteroC2-4alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 3 carbon atoms, at least one double bond, and 1 heteroatom within the parent chain (“heteroC2-3alkenyl”). In some embodiments, a heteroalkenyl group has 2 carbon atoms, at least one double bond, and 1 heteroatom within the parent chain (“heteroC2alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or 2 heteroatoms within the parent chain (“heteroC2-6alkenyl”). Unless otherwise specified, each instance of a heteroalkenyl group is independently unsubstituted (an “unsubstituted heteroalkenyl”) or substituted (a “substituted heteroalkenyl”) with one or more substituents. In certain embodiments, the heteroalkenyl group is an unsubstituted heteroC2-20alkenyl. In certain embodiments, the heteroalkenyl group is a substituted heteroC2-20alkenyl.

[0030] The term “alkynyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms and one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triplebonds) (“C1-20alkynyl”). In some embodiments, an alkynyl group has 2 to 10 carbon atoms (“C2 -10alkynyl”). In some embodiments, an alkynyl group has 2 to 9 carbon atoms (“C2 -9alkynyl”). In some embodiments, an alkynyl group has 2 to 8 carbon atoms (“C2-8alkynyl”). In some embodiments, an alkynyl group has 2 to 7 carbon atoms (“C2 -7alkynyl”). In some embodiments, an alkynyl group has 2 to 6 carbon atoms (“C2-6alkynyl”). In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C2-5alkynyl”). In some embodiments, an alkynyl group has 2 to 4 carbon atoms (“C2-4alkynyl”). In some embodiments, an alkynyl group has 2 to 3 carbon atoms (“C2-3alkynyl”). In some embodiments, an alkynyl group has 2 carbon atoms (“C2alkynyl”). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). Examples of C2-4alkynyl groups include, without limitation, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. Examples of C2-6alkenyl groups include the aforementioned C2-4alkynyl groups as well as pentynyl (C5), hexynyl (C6), and the like. Additional examples of alkynyl include heptynyl (C7), octynyl (C8), and the like. Unless otherwise specified, each instance of an alkynyl group is independently unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents. In certain embodiments, the alkynyl group is an unsubstituted C2-20alkynyl. In certain embodiments, the alkynyl group is a substituted C2-20alkynyl.

[0031] The term “heteroalkynyl” refers to an alkynyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (e.g., inserted between adjacent carbon atoms of) and / or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkynyl group refers to a group having from 2 to 20 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC2-20alkynyl”). In certain embodiments, a heteroalkynyl group refers to a group having from 2 to 10 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC2- 10 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 9 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC2-9alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 8 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC2-s alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 7 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC2-7alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC2-6alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 5 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain (“heteroC2-5alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 4 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain (“heteroC2-4alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 3 carbon atoms, at least one triple bond, and 1 heteroatom within the parent chain (“heteroC2-3alkynyl”). In some embodiments, a heteroalkynyl group has 2 carbon atoms, at least one triple bond, and 1 heteroatom within the parent chain (“heteroC2alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 6carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain (“heteroC2-6alkynyl”). Unless otherwise specified, each instance of a heteroalkynyl group is independently unsubstituted (an “unsubstituted heteroalkynyl”) or substituted (a “substituted heteroalkynyl”) with one or more substituents. In certain embodiments, the heteroalkynyl group is an unsubstituted heteroC2-20alkynyl. In certain embodiments, the heteroalkynyl group is a substituted heteroC2-20alkynyl.

[0032] The term “carbocyclyl” or “carbocyclic” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 14 ring carbon atoms (“C3-14carbocyclyl”) and zero heteroatoms in the non-aromatic ring system. In some embodiments, a carbocyclyl group has 3 to 14 ring carbon atoms (“C3 -14carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 13 ring carbon atoms (“C3 -13carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 12 ring carbon atoms (“C3-12carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 11 ring carbon atoms (“C3 -11carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 10 ring carbon atoms (“C3 -10carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms (“C3-8carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 7 ring carbon atoms (“C3 -7carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C3-6carbocyclyl”). In some embodiments, a carbocyclyl group has 4 to 6 ring carbon atoms (“C4-6carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 6 ring carbon atoms (“C5-6carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C5 -10carbocyclyl”). Exemplary C3-6carbocyclyl groups include cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. Exemplary C3-8carbocyclyl groups include the aforementioned C3-6carbocyclyl groups as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), and the like. Exemplary C3-10carbocyclyl groups include the aforementioned C3-8carbocyclyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro- IH-indenyl (C9), decahydronaphthalenyl (C10), spiro[4.5]decanyl (C10), and the like. Exemplary C3 -8carbocyclyl groups include the aforementioned C3-10carbocyclyl groups as well as cycloundecyl (C11), spiro[5.5]undecanyl (C11), cyclododecyl (C12), cyclododecenyl (C12), cyclotridecane (C13), cyclotetradecane (C14), and the like. As the foregoing examples illustrate, in certain embodiments, the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or polycyclic (e.g., containing a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) or tricyclic system (“tricyclic carbocyclyl”)) and can be saturated or can contain one or more carbon-carbon double or triple bonds. “Carbocyclyl” also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system. Unlessotherwise specified, each instance of a carbocyclyl group is independently unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a “substituted carbocyclyl”) with one or more substituents. In certain embodiments, the carbocyclyl group is an unsubstituted C3-14carbocyclyl. In certain embodiments, the carbocyclyl group is a substituted C3-14carbocyclyl.

[0033] In some embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 14 ring carbon atoms (“C3-14cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 10 ring carbon atoms (“C3 -10cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C3-8cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C3-6cycloalkyl”). In some embodiments, a cycloalkyl group has 4 to 6 ring carbon atoms (“C4-6cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C5-6cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C5-10cycloalkyl”). Examples of C5-6cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C5). Examples of C3-6cycloalkyl groups include the aforementioned C5-6cycloalkyl groups as well as cyclopropyl (C3) and cyclobutyl (C4). Examples of C3-8cycloalkyl groups include the aforementioned C3-6cycloalkyl groups as well as cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents. In certain embodiments, the cycloalkyl group is an unsubstituted C3-14cycloalkyl. In certain embodiments, the cycloalkyl group is a substituted C3-14cycloalkyl. In certain embodiments, the carbocyclyl includes 0, 1, or 2 C=C double bonds in the carbocyclic ring system, as valency permits.

[0034] The term “heterocyclyl” or “heterocyclic” refers to a radical of a 3- to 14-membered nonaromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“3-14 membered heterocyclyl”). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or polycyclic (e.g., a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”) or tricyclic system (“tricyclic heterocyclyl”)), and can be saturated or can contain one or more carbon-carbon double or triple bonds. Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or both rings. “Heterocyclyl” also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system. Unless otherwise specified, each instance of heterocyclyl is independently unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents. In certain embodiments, the heterocyclyl group is an unsubstituted 3-14 membered heterocyclyl. In certainembodiments, the heterocyclyl group is a substituted 3-14 membered heterocyclyl. In certain embodiments, the heterocyclyl is substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl, wherein 1 , 2, or 3 atoms in the heterocyclic ring system are independently oxygen, nitrogen, or sulfur, as valency permits.

[0035] In some embodiments, a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1 -4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclyl”). In some embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.

[0036] Exemplary 3-membered heterocyclyl groups containing 1 heteroatom include azirdinyl, oxiranyl, and thiiranyl. Exemplary 4-membered heterocyclyl groups containing 1 heteroatom include azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclyl groups containing 1 heteroatom include tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2, 5-dione. Exemplary 5-membered heterocyclyl groups containing 2 heteroatoms include dioxolanyl, oxathiolanyl and dithiolanyl. Exemplary 5 -membered heterocyclyl groups containing 3 heteroatoms include triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing 1 heteroatom include piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6- membered heterocyclyl groups containing 3 heteroatoms include triazinyl. Exemplary 7-membered heterocyclyl groups containing 1 heteroatom include azepanyl, oxepanyl and thiepanyl. Exemplary 8- membered heterocyclyl groups containing 1 heteroatom include azocanyl, oxecanyl and thiocanyl. Exemplary bicyclic heterocyclyl groups include indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, tetrahydrobenzofuranyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl, decahydro- 1,8- naphthyridinyl, octahydropyrrolo[3,2-b]pyrrole, indolinyl, phthalimidyl, naphthalimidyl, chromanyl, chromenyl, lH-benzo[e][l,4]diazepinyl, 1,4,5 ,7-tetrahydropyrano[3,4-b]pyrrolyl, 5,6-dihydro-4H- furo[3,2-b]pyrrolyl, 6,7-dihydro-5H-furo[3,2-b]pyranyl, 5,7-dihydro-4H-thieno[2,3-c]pyranyl, 2,3-dihydro-lH-pyrrolo[2,3-b]pyridinyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 4,5,6,7-tetrahydro-lH-pyrrolo- [2,3-b]pyridinyl, 4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl, 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl, l,2,3,4-tetrahydro-l,6-naphthyridinyl, and the like.

[0037] The term “aryl” refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 7t electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“ C6-14aryl”). In some embodiments, an aryl group has 6 ring carbon atoms (“C6aryl”; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms (“C10aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms (“C14aryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Unless otherwise specified, each instance of an aryl group is independently unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents. In certain embodiments, the aryl group is an unsubstituted C6-14aryl. In certain embodiments, the aryl group is a substituted C6-14aryl.

[0038] “Aralkyl” is a subset of “alkyl” and refers to an alkyl group substituted by an aryl group, wherein the point of attachment is on the alkyl moiety.

[0039] The term “heteroaryl” refers to a radical of a 5-14 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 7t electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-14 membered heteroaryl”). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. “Heteroaryl” includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused polycyclic (aryl / heteroaryl) ring system. Polycyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, e.g., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5 -indolyl). In certain embodiments, the heteroaryl is substituted or unsubstituted, 5- or 6-membered, monocyclic heteroaryl, wherein 1, 2, 3, or 4 atoms in the heteroarylring system are independently oxygen, nitrogen, or sulfur. In certain embodiments, the heteroaryl is substituted or unsubstituted, 9- or 10-membered, bicyclic heteroaryl, wherein 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently oxygen, nitrogen, or sulfur.

[0040] In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents. In certain embodiments, the heteroaryl group is an unsubstituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl group is a substituted 5-14 membered heteroaryl.

[0041] Exemplary 5-membered heteroaryl groups containing 1 heteroatom include pyrrolyl, furanyl, and thiophenyl. Exemplary 5-membered heteroaryl groups containing 2 heteroatoms include imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing 3 heteroatoms include triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing 4 heteroatoms include tetrazolyl. Exemplary 6- membered heteroaryl groups containing 1 heteroatom include pyridinyl. Exemplary 6-membered heteroaryl groups containing 2 heteroatoms include pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing 3 or 4 heteroatoms include triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing 1 heteroatom include azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Exemplary tricyclic heteroaryl groups include phenanthridinyl, dibenzofuranyl, carbazolyl, acridinyl, phenothiazinyl, phenoxazinyl, and phenazinyl.

[0042] “Heteroaralkyl” is a subset of “alkyl” and refers to an alkyl group substituted by a heteroaryl group, wherein the point of attachment is on the alkyl moiety.

[0043] The term “unsaturated bond” refers to a double or triple bond.

[0044] The term “unsaturated” or “partially unsaturated” refers to a moiety that includes at least one double or triple bond.

[0045] The term “saturated” or “fully saturated” refers to a moiety that does not contain a double or triple bond, e.g., the moiety only contains single bonds.

[0046] Affixing the suffix “-ene” to a group indicates the group is a divalent moiety, e.g., alkylene is the divalent moiety of alkyl, alkenylene is the divalent moiety of alkenyl, alkynylene is the divalent moiety of alkynyl, heteroalkylene is the divalent moiety of heteroalkyl, heteroalkenylene is the divalent moiety of heteroalkenyl, heteroalkynylene is the divalent moiety of heteroalkynyl, carbocyclylene is the divalent moiety of carbocyclyl, heterocyclylene is the divalent moiety of heterocyclyl, arylene is the divalent moiety of aryl, and heteroarylene is the divalent moiety of heteroaryl.

[0047] A group is optionally substituted unless expressly provided otherwise. The term “optionally substituted” refers to being substituted or unsubstituted. In certain embodiments, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted. “Optionally substituted” refers to a group which is substituted or unsubstituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” heteroalkyl, “substituted” or “unsubstituted” heteroalkenyl, “substituted” or “unsubstituted” heteroalkynyl, “substituted” or “unsubstituted” carbocyclyl, “substituted” or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or “substituted” or “unsubstituted” heteroaryl group). In general, the term “substituted” means that at least one hydrogen present on a group is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. The term “substituted” is contemplated to include substitution with all permissible substituents of organic compounds and includes any of the substituents described herein that results in the formation of a stable compound. The present invention contemplates any and all such combinations in order to arrive at a stable compound. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and / or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety. The invention is not limited in any manner by the exemplary substituents described herein.

[0048] Exemplary carbon atom substituents include halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -ORaa, -ON(Rbb)2, -N(Rbb)2, -N(Rbb)3+X-, -N(ORcc)Rbb, -SH, -SRaa, -SSRCC, -C(=O)Raa, -CO2H, -CHO, -C(ORCC)2, -CO2Raa, -OC(=O)Raa, -OCO2Raa, -C(=O)N(Rbb)2, -OC(=O)N(Rbb)2, -NRbbC(=O)Raa, -NRbbCO2Raa, -NRbbC(=O)N(Rbb)2, -C(=NRbb)Raa, -C(=NRbb)ORaa, -OC(=NRbb)Raa, -OC(=NRbb)ORaa, -C(=NRbb)N(Rbb)2, -OC(=NRbb)N(Rbb)2, -NRbbC(=NRbb)N(Rbb)2, -C(=O)NRbbSO2Raa, -NRbbSO2Raa, -SO2N(Rbb)2, -SO2Raa, -SO2ORaa, -OSO2Raa, -S(=O)Raa, -OS(=O)Raa, -Si(Raa)3, -OSi(Raa)3-C(=S)N(Rbb)2, -C(=O)SRaa, -C(=S)SRaa, -SC(=S)SRaa, -SC(=O)SRaa, -OC(=O)SRaa, -SC(=O)ORaa, -SC(=O)Raa, -P(=O)(Raa)2, -P(=O)(ORCC)2, -OP(=O)(Raa)2, -OP(=O)(ORCC)2, -P(=O)(N(Rbb)2)2, -OP(=O)(N(Rbb)2)2, -NRbbP(=O)(Raa)2, -NRbbP(=O)(ORcc)2, -NRbbP(=O)(N(Rbb)2)2, -P(RCC)2, -P(ORCC)2, -P(RCC)3+X-, -P(ORCC)3+X-, -P(RCC)4, -P(ORCC)4, -OP(RCC)2, -OP(RCC)3+X-, -OP(ORCC)2, -OP(ORCC)3+X-, -OP(RCC)4, -OP(ORCC)4, -B(Raa)2, -B(ORCC)2, -BRaa(ORcc), C1-20alkyl, C1-20perhaloalkyl, C1-20alkenyl, C1-20alkynyl, heteroC1-20alkyl, heteroC1-20alkenyl, heteroC1-20alkynyl, C3-10carbocyclyl, 3- 14 membered heterocyclyl, C6-i4aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; wherein X“ is a counterion; or two geminal hydrogens on a carbon atom are replaced with the group =0, =S, =NN(Rbb)2, =NNRbbC(=O)Raa, =NNRbbC(=O)ORaa, =NNRbbS(=O)2Raa, =NRbb, or =NORCC; wherein: each instance of Raais, independently, selected from C1-20alkyl, C1-20perhaloalkyl, C1-20alkenyl, C1-20alkynyl, hetero C1-20alkyl, heteroC1-20alkenyl, heteroC1-20alkynyl, C3-10carbocyclyl, 3- 14 membered heterocyclyl, C6-14aryl, and 5-14 membered heteroaryl, or two Raagroups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each of the alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; each instance of Rbbis, independently, selected from hydrogen, -OH, -ORaa, -N(RCC)2, -CN, -C(=O)Raa, -C(=O)N(RCC)2, -CO2Raa, -SO2Raa, -C(=NRcc)ORaa, -C(=NRCC)N(RCC)2, -SO2N(RCC)2, -SO2RCC, -SO2ORCC, -SORaa, -C(=S)N(RCC)2, -C(=O)SRCC, -C(=S)SRCC, -P(=O)(Raa)2, -P(=O)(ORCC)2, -P(=O)(N(RCC)2)2, CI-20 alkyl, C1-20perhaloalkyl, C1-20alkenyl, C1-20alkynyl, heteroC1-20alkyl, heteroC1-20alkenyl, heteroC1-20alkynyl, C3-10carbocyclyl, 3-14 membered heterocyclyl, C6-14aryl, and 5-14 membered heteroaryl, or two Rbbgroups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; each instance of Rccis, independently, selected from hydrogen, C1-20alkyl, C1-20perhaloalkyl, C1-20alkenyl, C1-20alkynyl, heteroC1-20alkyl, heteroC1-20alkenyl, heteroC1-20alkynyl, C3-10carbocyclyl, 3-14 membered heterocyclyl, Ce 16aryl, and 5-14 membered heteroaryl, or two Rccgroups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; each instance of Rddis, independently, selected from halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -ORee, -ON(Rff)2, -N(Rff)2, -N(Rff)3+X“, -N(ORee)Rff, -SH, -SRee, -SSRee, -C(=O)Ree, -CO2H, -CO2Ree, -OC(=O)Ree, -OCO2Ree, -C(=O)N(Rff)2, -OC(=O)N(Rff)2, -NRffC(=O)Ree, -NRffCO2Ree, -NRffC(=O)N(Rff)2, -C(=NRff)ORee, -OC(=NRff)Ree, -OC(=NRff)ORee, -C(=NRff)N(Rff)2, -OC(=NRff)N(Rff)2, -NRffC(=NRff)N(Rff)2, -NRffSO2Ree, -SO2N(Rff)2, -SO2Ree, -SO2ORee, -OSO2Ree, -S(=O)Ree, -Si(Ree)3, -OSi(Ree)3, -C(=S)N(Rff)2, -C(=O)SRee, -C(=S)SRee, -SC(=S)SRee, -P(=O)(ORee)2, -P(=O)(Ree)2, -OP(=O)(Ree)2, -OP(=O)(ORee)2, C1-10alkyl, C1-10perhaloalkyl, C1-10alkenyl, C1-10alkynyl, heteroCi-ioalkyl, heteroCi-ioalkenyl, hetero C1-10alkynyl, C3-10carbocyclyl, 3-10 membered heterocyclyl, C6-10aryl, and 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups, or two geminal Rddsubstituents are joined to form =0 or =S; wherein X“ is a counterion; each instance of Reeis, independently, selected from C1-10alkyl, C1-10perhaloalkyl, C1-10alkenyl, C1-10alkynyl, heteroC1-10alkyl, heteroC1-10alkenyl, heteroC1-10alkynyl, C3-10carbocyclyl, C6-10aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups; each instance of Rffis, independently, selected from hydrogen, C1-10alkyl, C1-10perhaloalkyl, C1-10alkenyl, C1-10alkynyl, heteroC1-10alkyl, heteroC1-10alkenyl, heteroC1-10alkynyl, C3-10carbocyclyl, 3-10 membered heterocyclyl, C6-10aryl, and 5-10 membered heteroaryl, or two Rffgroups are joined to form a 3-10 membered heterocyclyl or 5-10 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups; each instance of Rggis, independently, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -O C1-6alkyl, -ON( C1-6alkyl)2, -N( C1-6alkyl)2, -N( C1-6alkyl)3+X-, -NH( C1-6alkyl)2+X-, — NH2( C1-6alkyl)+X“, -NH3+X-, -N(O C1-6alkyl)( C1-6alkyl), -N(OH)(C1-6alkyl), -NH(OH), -SH, -SC1-6alkyl, -SS( C1-6alkyl), -C(=O)(C1-6alkyl), -CO2H, -CO2( C1-6alkyl), -OC(=O)(C1-6alkyl), -C)CO2( C1-6alkyl), -C(=O)NH2, -C(=O)N( C1-6alkyl)2, -OC(=O)NH( C1-6alkyl), -NHC(=O)( C1-6alkyl), -N(C1-6alkyl)C(=O)( C1-6alkyl), -NHCO2( C1-6alkyl), — NHC(=O)N( C1-6alkyl)2, -NHC(=O)NH(C1-6alkyl), -NHC(=O)NH2, -C(=NH)O(C1-6alkyl), -OC(=NH)(C1-6alkyl), — OC(=NH)O C1-6, alkyl, -C(=NH)N(C1-6alkyl)2, -C(=NH)NH( C1-6alkyl), -C(=NH)NH2, — OC(=NH)N( C1-6alkyl)2, -OC(NH)NH( C1-6alkyl), -OC(NH)NH2, -NHC(NH)N( C1-6alkyl)2, -NHC(=NH)NH2, -NHSO2( C1-6alkyl), -SO2N( C1-6alkyl)2, -SO2NH( C1-6alkyl), -SO2NH2, -SO2C1-6alkyl, -SC2O C1-6alkyl,-OSO2C1-6alkyl, -SOC1-6alkyl, -Si(C1-6alkyl)3, -OSilC1-6alkyl)3-C(=S)N(C1-6alkyl)2, C(=S)NH(C1-6alkyl), C(=S)NH2, -C(=O)S(C1-6alkyl), -C(=S)SC1-6alkyl, -SC(=S)SC1-6alkyl, -P(=O)(OC1-6alkyl)2, -P(=O)(C1-6alkyl)2, -OP(=O)(C1-6alkyl)2, -OP(=O)(OC1-6alkyl)2, C1-10alkyl, C1-10perhaloalkyl, C1-10alkenyl, C1-10alkynyl, heteroC1-10alkyl, heteroC1-10alkenyl, heteroC1-10alkynyl, C3-10carbocyclyl, C6-10aryl, 3-10 membered heterocyclyl, or 5-10 membered heteroaryl; or two geminal Rggsubstituents can be joined to form =0 or =S; and each X" is a counterion.

[0049] In certain embodiments, each carbon atom substituent is independently halogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6alkyl, -ORaa, -SRaa, -N(Rbb)2, -CN, -SCN, -NO2, -C(=O)Raa, -CO2Raa, -C(=O)N(Rbb)2, -OC(=O)Raa, -OCO2Raa, -OC(=O)N(Rbb)2, -NRbbC(=O)Raa, -NRbbCO2Raa, or -NRbbC(=O)N(Rbb)2. In certain embodiments, each carbon atom substituent is independently halogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, -ORaa, -SRaa, -N(Rbb)2, -CN, -SCN, -NO2, -C(=O)Raa, -CO2Raa, -C(=O)N(Rbb)2, -OC(=O)Raa, -OCO2Raa, -OC(=O)N(Rbb)2, -NRbbC(=O)Raa, -NRbbCO2Raa, or -NRbbC(=O)N(Rbb)2, wherein Raais hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, an oxygen protecting group (e.g., silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, or benzoyl) when attached to an oxygen atom, or a sulfur protecting group (e.g., acetamidomethyl, t-Bu, 3-nitro-2-pyridine sulfenyl, 2-pyridine- sulfenyl, or triphenylmethyl) when attached to a sulfur atom; and each Rbbis independently hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, or a nitrogen protecting group (e.g., Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, or Ts). In certain embodiments, each carbon atom substituent is independently halogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6alkyl, -ORaa, -SRaa, -N(Rbb)2, -CN, -SCN, or -NO2. In certain embodiments, each carbon atom substituent is independently halogen, substituted (e.g., substituted with one or more halogen moieties) or unsubstituted C1-10alkyl, -ORaa, -SRaa, -N(Rbb)2, - CN, -SCN, or -NO2, wherein Raais hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, an oxygen protecting group (e.g., silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, or benzoyl) when attached to an oxygen atom, or a sulfur protecting group (e.g., acetamidomethyl, t-Bu, 3-nitro-2-pyridine sulfenyl, 2-pyridine- sulfenyl, or triphenylmethyl) when attached to a sulfur atom; and each Rbbis independently hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, or a nitrogen protecting group (e.g., Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, or Ts).

[0050] In certain embodiments, the molecular weight of a carbon atom substituent is lower than 250, lower than 200, lower than 150, lower than 100, or lower than 50 g / mol. In certain embodiments, a carbon atom substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, iodine, oxygen, sulfur, nitrogen, and / or silicon atoms. In certain embodiments, a carbon atom substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, iodine, oxygen, sulfur, and / or nitrogen atoms. Incertain embodiments, a carbon atom substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, and / or iodine atoms. In certain embodiments, a carbon atom substituent consists of carbon, hydrogen, fluorine, and / or chlorine atoms.

[0051] The term “halo” or “halogen” refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iodo, -I).

[0052] The term “hydroxyl” or “hydroxy” refers to the group -OH. The term “substituted hydroxyl” or “substituted hydroxyl,” by extension, refers to a hydroxyl group wherein the oxygen atom directly attached to the parent molecule is substituted with a group other than hydrogen, and includes groups selected from -ORaa, -ON(Rbb)2, -OC(=O)SRaa, -OC(=O)Raa, -OCO2Raa, -OC(=O)N(Rbb)2, -OC(=NRbb)Raa, -OC(=NRbb)ORaa, -OC(=NRbb)N(Rbb)2, -OS(=O)Raa, -OSO2Raa, -OSi(Raa)3, -OP(RCC)2, -OP(RCC)3+X-, -OP(ORCC)2, -OP(ORCC)3+X-, -OP(=O)(Raa)2, -OP(=O)(ORCC)2, and -OP(=O)(N(Rbb))2, wherein X“, Raa, Rbb, and Rccare as defined herein.

[0053] The term “thiol” or “thio” refers to the group -SH. The term “substituted thiol” or “substituted thio,” by extension, refers to a thiol group wherein the sulfur atom directly attached to the parent molecule is substituted with a group other than hydrogen, and includes groups selected from - SRaa, -S=SRCC, -SC(=S)SRaa, -SC(=S)ORaa, -SC(=S) N(Rbb)2, -SC(=O)SRaa, -SC(=O)ORaa, - SC(=O)N(Rbb)2, and -SC(=O)Raa, wherein Raaand Rccare as defined herein.

[0054] The term “amino” refers to the group -NH2. The term “substituted amino,” by extension, refers to a monosubstituted amino, a disubstituted amino, or a trisubstituted amino. In certain embodiments, the “substituted amino” is a monosubstituted amino or a disubstituted amino group.

[0055] The term “monosubstituted amino” refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with one hydrogen and one group other than hydrogen, and includes groups selected from -NH(Rbb), -NHC(=O)Raa, -NHCO2Raa, -NHC(=O)N(Rbb)2, -NHC(=NRbb)N(Rbb)2, -NHSO2Raa, -NHP(=O)(ORCC)2, and -NHP(=O)(N(Rbb)2)2, wherein Raa, Rbband Rccare as defined herein, and wherein Rbbof the group -NH(Rbb) is not hydrogen.

[0056] The term “disubstituted amino” refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with two groups other than hydrogen, and includes groups selected from -N(Rbb)2, -NRbbC(=O)Raa, -NRbbCO2Raa, -NRbbC(=O)N(Rbb)2, -NRbbC(=NRbb)N(Rbb)2, -NRbbSO2Raa, -NRbbP(=O)(ORcc)2, and -NRbbP(=O)(N(Rbb)2)2, wherein Raa, Rbb, and Rccare as defined herein, with the proviso that the nitrogen atom directly attached to the parent molecule is not substituted with hydrogen.

[0057] The term “trisubstituted amino” refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with three groups, and includes groups selected from -N(Rbb)3and -N(Rbb)3+X“, wherein Rbband X“ are as defined herein.

[0058] The term “sulfonyl” refers to a group selected from -SO2N(Rbb)2, -SO2Raa, and -SO2ORaa, wherein Raaand Rbbare as defined herein.

[0059] The term “sulfinyl” refers to the group -S(=O)Raa, wherein Raais as defined herein.

[0060] The term “acyl” refers to a group having the general formula -C(=O)RX1, -C(=O)ORX1,wherein RX1is hydrogen; halogen; substituted or unsubstituted hydroxyl; substituted or unsubstituted thiol; substituted or unsubstituted amino; substituted or unsubstituted acyl, cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkyl; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkenyl; substituted or unsubstituted alkynyl; substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aliphaticoxy, heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy, heteroaryloxy, aliphaticthioxy, heteroaliphaticthioxy, alkylthioxy, heteroalkylthioxy, arylthioxy, heteroarylthioxy, mono- or di- aliphaticamino, mono- or di- heteroaliphaticamino, mono- or di- alkylamino, mono- or di- heteroalkylamino, mono- or di-arylamino, or mono- or di-heteroarylamino; or two RX1groups taken together form a 5- to 6-membered heterocyclic ring. Exemplary acyl groups include aldehydes (-CHO), carboxylic acids (-CO2H), ketones, acyl halides, esters, amides, imines, carbonates, carbamates, and ureas. Acyl substituents include, but are not limited to, any of the substituents described herein, that result in the formation of a stable moiety (e.g., aliphatic, alkyl, alkenyl, alkynyl, heteroaliphatic, heterocyclic, aryl, heteroaryl, acyl, oxo, imino, thiooxo, cyano, isocyano, amino, azido, nitro, hydroxyl, thiol, halo, aliphaticamino, heteroaliphaticamino, alkylamino, heteroalkylamino, arylamino, heteroarylamino, alkylaryl, arylalkyl, aliphaticoxy, heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy, heteroaryloxy, aliphaticthioxy, heteroaliphaticthioxy, alkylthioxy, heteroalkylthioxy, arylthioxy, heteroarylthioxy, acyloxy, and the like, each of which may or may not be further substituted).

[0061] The term “carbonyl” refers to a group wherein the carbon directly attached to the parent molecule is sp2hybridized, and is substituted with an oxygen, nitrogen or sulfur atom, e.g., a group selected from ketones (-C(=O)Raa), carboxylic acids (-CO2H), aldehydes (-CHO), esters (-CO2Raa, -C(=O)SRaa, -C(=S)SRaa), amides (-C(=O)N(Rbb)2, -C(=O)NRbbSO2Raa, -C(=S)N(Rbb)2), and imines (-C(=NRbb)Raa, -C(=NRbb)ORaa), -C(=NRbb)N(Rbb)2), wherein Raaand Rbbare as defined herein.

[0062] The term “silyl” refers to the group -Si(Raa)2, wherein Raais as defined herein.

[0063] The term “phosphino” refers to the group -P(RCC)2, wherein Rccis as defined herein.

[0064] The term “phosphono” refers to the group - (P=O)(ORCC)2, wherein Raaand Rccare as defined herein.

[0065] The term “phosphoramido” refers to the group -O(P=O)(N(Rbb)2)2, wherein each Rbbis as defined herein.

[0066] The term “oxo” refers to the group =0, and the term “thiooxo” refers to the group =S.

[0067] Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include hydrogen, -OH, -ORaa, -N(RCC)2, -CN, -C(=O)Raa, -C(=O)N(RCC)2, -CO2Raa, -SO2Raa, -C(=NRbb)Raa, -C(=NRcc)ORaa, -C(=NRCC)N(RCC)2, -SO2N(RCC)2, -SO2RCC, -SO2ORCC, -SOFT. -C(=S)N(RCC)2, -C(=O)SRCC, -C(=S)SRCC, -P(=O)(ORCC)2, -P(=O)(Raa)2, -P(=O)(N(RCC)2)2, CI2Oalkyl, C1-20perhaloalkyl, C1-20alkenyl, C1-20alkynyl, hetero C1-20alkyl, hetero C1-20alkenyl, hetero Ci- 20 alkynyl, C3-10carbocyclyl, 3-14 membered heterocyclyl, C6-14aryl, and 5-14 membered heteroaryl, or two Rccgroups attached to an N atom are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups, and wherein Raa, Rbb, Rccand Rddare as defined above.

[0068] In certain embodiments, each nitrogen atom substituent is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6alkyl, -C(=O)Raa, -CO2Raa, -C(=O)N(Rbb)2, or a nitrogen protecting group. In certain embodiments, each nitrogen atom substituent is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, -C(=O)Raa, -CO2Raa, -C(=O)N(Rbb)2, or a nitrogen protecting group, wherein Raais hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, or an oxygen protecting group when attached to an oxygen atom; and each Rbbis independently hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, or a nitrogen protecting group. In certain embodiments, each nitrogen atom substituent is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6alkyl or a nitrogen protecting group.

[0069] In certain embodiments, the substituent present on the nitrogen atom is a nitrogen protecting group (also referred to herein as an “amino protecting group”). Nitrogen protecting groups include -OH, -ORaa, -N(RCC)2, -C(=O)Raa, -C(=O)N(RCC)2, -CO2Raa, -SO2Raa, -C(=NRcc)Raa, -C(=NRcc)ORaa, -C(=NRCC)N(RCC)2, -SO2N(RCC)2, -SO2RCC, -SO2ORCC, -SOFT. -C(=S)N(RCC)2, -C(=O)SRCC, -C(=S)SRCC, C1-10alkyl (e.g., aralkyl, heteroaralkyl), C1-20alkenyl, C1-20alkynyl, hetero C1-20alkyl, hetero C1-20alkenyl, hetero C1-20alkynyl, C3-10carbocyclyl, 3-14 membered heterocyclyl, C6-14aryl, and 5-14 membered heteroaryl groups, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups, and wherein Raa, Rbb, Rccand Rddare as defined herein. Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rdedition, John Wiley & Sons, 1999, incorporated herein by reference.

[0070] For example, in certain embodiments, at least one nitrogen protecting group is an amide group (e.g., a moiety that include the nitrogen atom to which the nitrogen protecting groups (e.g., -C(=O)Raa) is directly attached). In certain such embodiments, each nitrogen protecting group, together with the nitrogen atom to which the nitrogen protecting group is attached, is independentlyselected from the group consisting of formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3 -pyridylcarboxamide, N- benzoylphenylalanyl derivatives, benzamide, p-phenylbenzamide, o-nitophenylacetamide, o- nitrophenoxyacetamide, acetoacetamide, (A’-dithiobenzyloxyacylamino)acetamide, 3-(p- hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o- nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3- methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine derivatives, o-nitrobenzamide, and o-(benzoyloxymethyl)benzamide.

[0071] In certain embodiments, at least one nitrogen protecting group is a carbamate group (e.g., a moiety that includes the nitrogen atom to which the nitrogen protecting groups (e.g., -C(=O)ORaa) is directly attached). In certain such embodiments, each nitrogen protecting group, together with the nitrogen atom to which the nitrogen protecting group is attached, is independently selected from the group consisting of methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9-(2- sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9- (10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4- methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), l-(l-adamantyl)-l-methylethyl carbamate (Adpoc), l,l-dimethyl-2-haloethyl carbamate, l,l-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), 1,1- dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1 -methyl- l-(4-biphenylyl)ethyl carbamate (Bpoc), l-(3,5-di-t-butylphenyl)-l-methylethyl carbamate (t-Bumeoc), 2-(2'~ and 4'-py ridy l)cthy 1 carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC or Boc), 1- adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1 -isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p- methoxybenzyl carbamate (Moz), p-nitobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(l,3-dithianyl)]methyl carbamate (Dmoc), 4- methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), 1,1 -dime thyl-2-cy anoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5- benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m- nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6- nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, t-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxyacylvinyl carbamate, o-(N,N -dimethylcarboxamido)benzyl carbamate, l,l-dimethyl-3-(N ,N -dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p’-methoxyphenylazo)benzyl carbamate, 1 -methylcyclobutyl carbamate, 1 -methylcyclohexyl carbamate, 1 -methyl- 1 -cyclopropylmethyl carbamate, 1 -methyl- 1- (3,5-dimethoxyphenyl)ethyl carbamate, 1 -methyl- 1-(p-phenylazophenyl)ethyl carbamate, 1 -methyl- 1- phenylethyl carbamate, 1 -methyl- l-(4-pyridyl)ethyl carbamate, phenyl carbamate, p- (phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzyl carbamate.

[0072] In certain embodiments, at least one nitrogen protecting group is a sulfonamide group (e.g., a moiety that include the nitrogen atom to which the nitrogen protecting groups (e.g., -S(=O)2Raa) is directly attached). In certain such embodiments, each nitrogen protecting group, together with the nitrogen atom to which the nitrogen protecting group is attached, is independently selected from the group consisting of p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4- methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4- methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4- methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4- methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4- (4',8'-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.

[0073] In certain embodiments, each nitrogen protecting group, together with the nitrogen atom to which the nitrogen protecting group is attached, is independently selected from the group consisting of phenothiazinyl-(10)-acyl derivatives, N’-p-toluenesulfonylaminoacyl derivatives, N’- phenylaminothioacyl derivatives, N-benzoylphenylalanyl derivatives, N-acetylmethionine derivatives, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimidc, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimidc, N-2,5-dimethylpyrrole, N-1 , 1 ,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5- substituted l,3-dimethyl-l,3,5-triazacyclohexan-2-one, 5-substituted 1, 3 -dibenzyl- 1,3,5 - triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2- (trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(l-isopropyl-4-nitro-2-oxo- 3-pyroolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4- methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4- methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7-dichloro-9- fluorenylmethyleneamine, N-ferrocenylmethylamino (Fem), N-2-picolylamino N’-oxide, N- 1,1- dimethylthiomethyleneamine, N-benzylideneamine, N-p-methoxybenzylideneamine, N- diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N-(A’,A’- dime thylaminome thy lene) amine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5- chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-l -cyclohexenyl)amine, N-borane derivatives, N- diphenylborinic acid derivatives, N-[phenyl(pentaacylchromium- or tungsten)acyl]amine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxidc, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o- nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2- nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys). In some embodiments, two instances of a nitrogen protecting group together with the nitrogen atoms to which the nitrogen protecting groups are attached are N,N’-isopropylidenediamine.

[0074] In certain embodiments, at least one nitrogen protecting group is Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, or Ts.

[0075] In certain embodiments, each oxygen atom substituent is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, -C(=O)Raa, -CO2R”, -C(=O)N(Rbb)2, or an oxygen protecting group. In certain embodiments, each oxygen atom substituents is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6alkyl, -C(=O)Raa, -CO2R”, -C(=O)N(Rbb)2, or an oxygen protecting group, wherein Raais hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, or an oxygen protecting group when attached to an oxygen atom; and each Rbbis independently hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, or a nitrogen protecting group. In certain embodiments, each oxygen atom substituent is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6alkyl or an oxygen protecting group.

[0076] In certain embodiments, the substituent present on an oxygen atom is an oxygen protecting group (also referred to herein as an “hydroxyl protecting group”). Oxygen protecting groups include -Raa, -N(Rbb)2, -C(=O)SRaa, -C(=O)Raa, -CO2Raa, -C(=O)N(Rbb)2, -C(=NRbb)Raa, -C(=NRbb)ORaa, -C(=NRbb)N(Rbb)2, -S(=O)Raa, -SO2Raa, -Si(Raa)3, -P(RCC)2, -P(RCC)3+X’, -P(ORCC)2, -P(ORCC)3+X-, -P(=O)(Raa)2, -P(=O)(ORCC)2, and -P(=O)(N(Rbb) 2)2, wherein X“, Raa, Rbb, and Rccare as defined herein. Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rdedition, John Wiley & Sons, 1999, incorporated herein by reference.

[0077] In certain embodiments, each oxygen protecting group, together with the oxygen atom to which the oxygen protecting group is attached, is selected from the group consisting of methyl, methoxymethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p- methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2- trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1 -methoxy cyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4- methoxytetrahydrothiopyranyl S,S-dioxide, l-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), 1 ,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8- trimethyl-4,7-methanobenzofuran-2-yl, 1 -ethoxy ethyl, l-(2-chloroethoxy)ethyl, 1 -methyl- 1- methoxy ethyl, 1 -methyl- 1 -benzyloxy ethyl, 1 -methyl- 1 -benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4- dinitrophenyl, benzyl (Bn), p-methoxybenzyl (PMB), 3,4-dimethoxybenzyl, o-nitrobenzyl, p- nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3- methyl-2-picolyl N -oxido, diphenylmethyl, p,p’-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, a-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p- methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4’ - bromophenacyloxyphenyl)diphenylmethyl, 4,4',4"-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4"-tris(levulinoyloxyphenyl)methyl, 4,4',4"-tris(benzoyloxyphenyl)methyl, 4,4’-Dimethoxy-3"’- [N-(imidazolylmethyl) ]trityl Ether (IDTr-OR), 4,4’-Dimethoxy-3"’-[N- (imidazolylethyl)carbamoyl]trityl Ether (lETr-OR), l,l-bis(4-methoxyphenyl)-r-pyrenylmethyl, 9- anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, l,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS), t- butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxy acetate, triphenylmethoxy acetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate (levulinate), 4,4- (ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4- methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate), methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), ethyl carbonate, 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec), 2- (triphenylphosphonio) ethyl carbonate (Peoc), isobutyl carbonate, vinyl carbonate, allyl carbonate, t- butyl carbonate (BOC or Boc), p-nitrophenyl carbonate, benzyl carbonate, p-methoxybenzyl carbonate, 3,4-dimethoxybenzyl carbonate, o-nitrobenzyl carbonate, p-nitrobenzyl carbonate, 5- benzyl thiocarbonate, 4-ethoxy-l-napththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4- azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2- (methylthiomethoxy)ethyl carbonate (MTMEC-OR), 4-(methylthiomethoxy)butyrate, 2- (methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(l,l,3,3- tetramethylbutyl)phenoxyacetate, 2,4-bis( 1 , 1 -dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate, o-(methoxyacyl)benzoate, a-naphthoate, nitrate, alkyl N,N,N'’-tetramethylphosphorodiamidate, alkyl N -phenylcarbamate, borate,dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts).

[0078] In certain embodiments, at least one oxygen protecting group is silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, or benzoyl.

[0079] In certain embodiments, each sulfur atom substituent is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, -C(=O)Raa, -CO2Raa, -C(=O)N(Rbb)2, or a sulfur protecting group. In certain embodiments, each sulfur atom substituent is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, -C(=O)Raa, -CO2Raa, -C(=O)N(Rbb)2, or a sulfur protecting group, wherein Raais hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, or an oxygen protecting group when attached to an oxygen atom; and each Rbbis independently hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10alkyl, or a nitrogen protecting group. In certain embodiments, each sulfur atom substituent is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6alkyl or a sulfur protecting group.

[0080] In certain embodiments, the substituent present on a sulfur atom is a sulfur protecting group (also referred to as a “thiol protecting group”). In some embodiments, each sulfur protecting group is selected from the group consisting of -Raa, -N(Rbb)2, -C(=O)SRaa, -C(=O)Raa, -CCER”, -C(=O)N(Rbb)2, -C(=NRbb)Raa, -C(=NRbb)ORaa, -C(=NRbb)N(Rbb)2, -S(=O)Raa, -SO2Raa, -Si(Raa)3, -P(RCC)2, -P(RCC)3+X“, -P(ORCC)2, -P(ORCC)3+X“, -P(=O)(Raa)2, -P(=O)(ORCC)2, and -P(=O)(N(Rbb) 2)2, wherein Raa, Rbb, and Rccare as defined herein. Sulfur protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rdedition, John Wiley & Sons, 1999, incorporated herein by reference.

[0081] In certain embodiments, the molecular weight of a substituent is lower than 250, lower than 200, lower than 150, lower than 100, or lower than 50 g / mol. In certain embodiments, a substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, iodine, oxygen, sulfur, nitrogen, and / or silicon atoms. In certain embodiments, a substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, iodine, oxygen, sulfur, and / or nitrogen atoms. In certain embodiments, a substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, and / or iodine atoms. In certain embodiments, a substituent consists of carbon, hydrogen, fluorine, and / or chlorine atoms. In certain embodiments, a substituent comprises 0, 1, 2, or 3 hydrogen bond donors. In certain embodiments, a substituent comprises 0, 1, 2, or 3 hydrogen bond acceptors.

[0082] A “counterion” or “anionic counterion” is a negatively charged group associated with a positively charged group in order to maintain electronic neutrality. An anionic counterion may be monovalent (e.g., including one formal negative charge). An anionic counterion may also be multivalent (e.g., including more than one formal negative charge), such as divalent or trivalent. Exemplary counterions include halide ions (e.g., F-, CI-, Br , I"), NO3", CIO4, OH- , H2PO4- , HCO3-, HSO4- , sulfonate ions (e.g., methansulfonate, trifluoromethanesulfonate, p-toluenesulfonate,benzenesulfonate, 10-camphor sulfonate, naphthalene-2-sulfonate, naphthalene- 1 -sulfonic acid-5- sulfonate, ethan-1 -sulfonic acid-2-sulfonate, and the like), carboxylate ions (e.g., acetate, propanoate, benzoate, glycerate, lactate, tartrate, glycolate, gluconate, and the like), BE4-, PF4-, P F6AsF6- SbF6-, B[3,5-(CF3)2C6H3]4]-, B(C6F5)4“, BPh4 , A1(OC(CF3)3)4-, and carborane anions (e.g., CB11H12- or (HCB11Me5Br6 )- ). Exemplary counterions which may be multivalent include CO32- HPO42-, PO43-, B4O72-, SO42-, S2O32-, carboxylate anions (e.g., tartrate, citrate, fumarate, maleate, malate, malonate, gluconate, succinate, glutarate, adipate, pimelate, suberate, azelate, sebacate, salicylate, phthalates, aspartate, glutamate, and the like), and carboranes.

[0083] A “leaving group” (LG) is an art-understood term referring to an atomic or molecular fragment that departs with a pair of electrons in heterolytic bond cleavage, wherein the molecular fragment is an anion or neutral molecule. As used herein, a leaving group can be an atom or a group capable of being displaced by a nucleophile. See e.g., Smith, March Advanced Organic Chemistry 6th ed. (501-502). Exemplary leaving groups include, but are not limited to, halo (e.g., fluoro, chloro, bromo, iodo) and activated substituted hydroxyl groups (e.g., -OC(=O)SRaa, -OC(=O)Raa, -OCO2Raa, -OC(=O)N(Rbb)2, -OC(=NRbb)Raa, -OC(=NRbb)ORaa, -OC(=NRbb)N(Rbb)2, -OS(=O)Raa, -OSO2Raa, - OP(RCC)2, -OP(RCC)3, -OP(=O)2Raa, -OP(=O)(Raa)2, -OP(=O)(ORCC)2, -OP(=O)2N(Rbb)2, and - OP(=O)(NRbb)2, wherein Raa, Rbb, and Rccare as defined herein). Additional examples of suitable leaving groups include, but are not limited to, halogen alkoxycarbonyloxy, aryloxycarbonyloxy, alkanesulfonyloxy, arenesulfonyloxy, alkyl-carbonyloxy (e.g., acetoxy), arylcarbonyloxy, aryloxy, methoxy, A,O-dimethylhydroxylamino, pixyl, and haloformates. In some embodiments, the leaving group is a sulfonic acid ester, such as toluenesulfonate (tosylate, -OTs), methanesulfonate (mesylate, -OMs), p-bromobenzenesulfonyloxy (brosylate, -OBs), -OS(=O)2(CF2)3CF3(nonaflate, -ONf), or trifluoromethanesulfonate (triflate, -OTf). In some embodiments, the leaving group is a brosylate, such as p-bromobenzenesulfonyloxy. In some embodiments, the leaving group is a nosylate, such as 2-nitrobenzenesulfonyloxy. In some embodiments, the leaving group is a sulfonate-containing group. In some embodiments, the leaving group is a tosylate group. In some embodiments, the leaving group is a phosphineoxide (e.g., formed during a Mitsunobu reaction) or an internal leaving group such as an epoxide or cyclic sulfate. Other non-limiting examples of leaving groups are water, ammonia, alcohols, ether moieties, thioether moieties, zinc halides, magnesium moieties, diazonium salts, and copper moieties.

[0084] Use of the phrase “at least one instance” refers to 1, 2, 3, 4, or more instances, but also encompasses a range, e.g., for example, from 1 to 4, from 1 to 3, from 1 to 2, from 2 to 4, from 2 to 3, or from 3 to 4 instances, inclusive.

[0085] A “non-hydrogen group” refers to any group that is defined for a particular variable that is not hydrogen.

[0086] These and other exemplary substituents are described in more detail in the Detailed Description, Examples, and Claims. The invention is not limited in any manner by the above exemplary listing of substituents.

[0087] As used herein, the term “salt” refers to any and all salts and encompasses pharmaceutically acceptable salts. The term “salt” refers to ionic compounds that result from the neutralization reaction of an acid and a base. A salt is composed of one or more cations (positively charged ions) and one or more anions (negative ions) so that the salt is electrically neutral (without a net charge). Salts of the compounds of this disclosure include those derived from inorganic and organic acids and bases. Examples of acid addition salts are salts of an amino group formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange. Other salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, hippurate, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, and N+C1-4alkyl)4salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further salts include ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.

[0088] The term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this disclosure include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid or with organic acids, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate,citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2- hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, and NACi 4 alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.

[0089] The term “solvate” refers to forms of the compound, or a salt thereof, that are associated with a solvent, usually by a solvolysis reaction. This physical association may include hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like. The compounds described herein may be prepared, e.g., in crystalline form, and may be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include both stoichiometric solvates and non-stoichiometric solvates. In certain instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Representative solvates include hydrates, ethanolates, and methanolates.

[0090] The term “hydrate” refers to a compound that is associated with water. Typically, the number of the water molecules contained in a hydrate of a compound is in a definite ratio to the number of the compound molecules in the hydrate. Therefore, a hydrate of a compound may be represented, for example, by the general formula R x H2O, wherein R is the compound, and x is a number greater than 0. A given compound may form more than one type of hydrate, including, e.g., monohydrates (x is 1), lower hydrates (x is a number greater than 0 and smaller than 1, e.g., hemihydrates (R 0.5 H2O)), and polyhydrates (x is a number greater than 1, e.g., dihydrates (R-2 H2O) and hexahydrates (R-6H2O)).

[0091] The term “polymorph” refers to a crystalline form of a compound (or a salt, hydrate, or solvate thereof). All polymorphs have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate. Various polymorphs of a compound can be prepared by crystallization under different conditions.

[0092] The term “co-crystal” refers to a crystalline structure comprising at least two different components (e.g., a compound and an acid), wherein each of the components is independently anatom, ion, or molecule. In certain embodiments, none of the components is a solvent. In certain embodiments, at least one of the components is a solvent. A co-crystal of a compound and an acid is different from a salt formed from a compound and the acid. In the salt, a compound is complexed with the acid in a way that proton transfer (e.g., a complete proton transfer) from the acid to a compound easily occurs at room temperature. In the co-crystal, however, a compound is complexed with the acid in a way that proton transfer from the acid to a herein does not easily occur at room temperature. In certain embodiments, in the co-crystal, there is substantially no proton transfer from the acid to a compound. In certain embodiments, in the co-crystal, there is partial proton transfer from the acid to a compound. Co-crystals may be useful to improve the properties (e.g., solubility, stability, and ease of formulation) of a compound.

[0093] The term “tautomers” or “tautomeric” refers to two or more interconvertible compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa). The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Tautomerizations (z.e., the reaction providing a tautomeric pair) may catalyzed by acid or base. Exemplary tautomerizations include keto-to-enol, amide-to-imide, lactam-to-lactim, enamine-to-imine, and enamine-to-(a different enamine) tautomerizations.

[0094] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.”

[0095] Stereoisomers that are not mirror images of one another are termed “diastereomers,” and those that are non-superimposable mirror images of each other are termed “enantiomers.” When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture.”

[0096] The term “isotopically labeled compound” refers to a derivative of a compound that only structurally differs from the compound in that at least one atom of the derivative includes at least one isotope enriched above (e.g., enriched 3-, 10-, 30-, 100-, 300-, 1,000-, 3,000- or 10,000-fold above) its natural abundance, whereas each atom of the compound includes isotopes at their natural abundances. In certain embodiments, the isotope enriched above its natural abundance is2H. In certain embodiments, the isotope enriched above its natural abundance is13C,15N, or18O.

[0097] The term “produugs” refers to compounds that have cleavable groups and become by solvolysis or under physiological conditions the compounds described herein, which arepharmaceutically active in vivo. Such examples include choline ester derivatives and the like, N- alkylmorpholine esters and the like. Other derivatives of the compounds described herein have activity in both their acid and acid derivative forms, but in the acid sensitive form often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgaard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides.

[0098] The terms “pharmaceutical composition,” “composition,” and “formulation” are used interchangeably.

[0099] A “subject” to which administration is contemplated refers to a human (i.e., male or female of any age group, e.g., pediatric subject (e.g., infant, child, or adolescent) or adult subject (e.g., young adult, middle-aged adult, or senior adult)) or non-human animal. In certain embodiments, the nonhuman animal is a mammal (e.g., primate (e.g., cynomolgus monkey or rhesus monkey), commercially relevant mammal (e.g., cattle, pig, horse, sheep, goat, cat, or dog), or bird (e.g., commercially relevant bird, such as chicken, duck, goose, or turkey)). In certain embodiments, the non-human animal is a fish, reptile, or amphibian. The non-human animal may be a male or female at any stage of development. The non-human animal may be a transgenic animal or genetically engineered animal. The term “patient” refers to a human subject in need of treatment of a disease.

[0100] The term “biological sample” refers to any sample including tissue samples (such as tissue sections and needle biopsies of a tissue); cell samples (e.g., cytological smears (such as Pap or blood smears) or samples of cells obtained by microdissection); samples of whole organisms (such as samples of yeasts or bacteria); or cell fractions, fragments or organelles (such as obtained by lysing cells and separating the components thereof by centrifugation or otherwise). Other examples of biological samples include blood, serum, urine, semen, fecal matter, cerebrospinal fluid, interstitial fluid, mucous, tears, sweat, pus, biopsied tissue (e.g., obtained by a surgical biopsy or needle biopsy), nipple aspirates, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biomolecules that is derived from a first biological sample.

[0101] The term “administer,” “administering,” or “administration” refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a compound described herein, or a pharmaceutical composition thereof, in or on a subject.

[0102] The terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease described herein. In some embodiments, treatment may be administered after one or more signs or symptoms of the disease have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease. For example, treatment may be administered to a susceptible subject prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of exposure to a pathogen).Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence.

[0103] The term “prevent,” “preventing,” or “prevention” refers to a prophylactic treatment of a subject who is not and was not with a disease but is at risk of developing the disease or who was with a disease, is not with the disease, but is at risk of regression of the disease. In certain embodiments, the subject is at a higher risk of developing the disease or at a higher risk of regression of the disease than an average healthy member of a population. In some embodiments, the subject is at risk of developing a disease or condition due to environmental factors (e.g., exposure to the sun).

[0104] An “effective amount” of a compound described herein refers to an amount sufficient to elicit the desired biological response. An effective amount of a compound described herein may vary depending on such factors as the desired biological endpoint, severity of side effects, disease, or disorder, the identity, pharmacokinetics, and pharmacodynamics of the particular compound, the condition being treated, the mode, route, and desired or required frequency of administration, the species, age and health or general condition of the subject. In certain embodiments, an effective amount is a therapeutically effective amount. In certain embodiments, an effective amount is a prophylactic treatment. In certain embodiments, an effective amount is the amount of a compound described herein in a single dose. In certain embodiments, an effective amount is the combined amounts of a compound described herein in multiple doses. In certain embodiments, the desired dosage is delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage is delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).

[0105] In certain embodiments, an effective amount of a compound for administration one or more times a day to a 70 kg adult human comprises about 0.0001 mg to about 3000 mg, about 0.0001 mg to about 2000 mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to about 1000 mg, about 0.01 mg to about 1000 mg, about 0.1 mg to about 1000 mg, about 1 mg to about 1000 mg, about 1 mg to about 100 mg, about 10 mg to about 1000 mg, or about 100 mg to about 1000 mg, of a compound per unit dosage form.

[0106] It will be appreciated that dose ranges as described herein provide guidance for the administration of provided pharmaceutical compositions to an adult. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.

[0107] A “therapeutically effective amount” of a compound described herein is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition. The term “therapeutically effective amount” canencompass an amount that improves overall therapy, reduces or avoids symptoms, signs, or causes of the condition, and / or enhances the therapeutic efficacy of another therapeutic agent. In certain embodiments, a therapeutically effective amount is an amount sufficient for treating a disease or disorder associated with associated with a viral infection (e.g., a coronavirus (e.g., SARS-CoV-2)) in a subject in need thereof. In certain embodiments, a therapeutically effective amount is an amount sufficient for inhibiting entry of a virus in a subject in need thereof or in a cell, tissue, or biological sample (e.g., by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or at least about 100%).

[0108] A “prophylactically effective amount” of a compound is an amount sufficient to prevent a condition, or one or more signs and / or symptoms associated with the condition or prevent its recurrence. In certain embodiments, the prophylactically effective amount is an amount that improves overall prophylaxis and / or enhances the prophylactic efficacy of another prophylactic agent. In certain embodiments, a prophylactically effective amount is an amount sufficient for preventing a disease or disorder associated with a viral infection (e.g., a coronavirus (e.g., SARS-CoV-2)) in a subject in need thereof. In certain embodiments, a prophylactically effective amount is an amount effective for reducing the risk of developing a disease or disorder associated with a viral infection (e.g., a coronavirus (e.g., SARS-CoV-2)) in a subject in need thereof. In certain embodiments, a prophylactically effective amount is an amount sufficient for inhibiting entry of a virus in a subject in need thereof or in a cell, tissue, or biological sample (e.g., by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or at least about 100%).

[0109] A “proliferative disease” refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells (Walker, Cambridge Dictionary of Biology, Cambridge University Press: Cambridge, UK, 1990). A proliferative disease may be associated with: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location (e.g., metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); or 4) the pathological angiogenesis as in proliferative retinopathy and tumor metastasis. Exemplary proliferative diseases include cancers (i.e., “malignant neoplasms”), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases.

[0110] The term “angiogenesis” refers to the physiological process through which new blood vessels form from pre-existing vessels. Angiogenesis is distinct from vasculogenesis, which is the de novo formation of endothelial cells from mesoderm cell precursors. The first vessels in a developing embryo form through vasculogenesis, after which angiogenesis is responsible for most blood vessel growth during normal or abnormal development. Angiogenesis is a vital process in growth anddevelopment, as well as in wound healing and in the formation of granulation tissue. However, angiogenesis is also a fundamental step in the transition of tumors from a benign state to a malignant one, leading to the use of angiogenesis inhibitors in the treatment of cancer. Angiogenesis may be chemically stimulated by angiogenic proteins, such as growth factors (e.g., VEGF). “Pathological angiogenesis” refers to abnormal (e.g., excessive or insufficient) angiogenesis that amounts to and / or is associated with a disease.

[0111] The terms “neoplasm” and “tumor” are used herein interchangeably and refer to an abnormal mass of tissue wherein the growth of the mass surpasses and is not coordinated with the growth of a normal tissue. A neoplasm or tumor may be “benign” or “malignant,” depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), rate of growth, local invasion, and metastasis. A “benign neoplasm” is generally well differentiated, has characteristically slower growth than a malignant neoplasm, and remains localized to the site of origin. In addition, a benign neoplasm does not have the capacity to infiltrate, invade, or metastasize to distant sites. Exemplary benign neoplasms include, but are not limited to, lipoma, chondroma, adenomas, acrochordon, senile angiomas, seborrheic keratoses, lentigos, and sebaceous hyperplasias. In some cases, certain “benign” tumors may later give rise to malignant neoplasms, which may result from additional genetic changes in a subpopulation of the tumor’s neoplastic cells, and these tumors are referred to as “pre-malignant neoplasms.” An exemplary pre-malignant neoplasm is a teratoma. In contrast, a “malignant neoplasm” is generally poorly differentiated (anaplasia) and has characteristically rapid growth accompanied by progressive infiltration, invasion, and destruction of the surrounding tissue. Furthermore, a malignant neoplasm generally has the capacity to metastasize to distant sites. The term “metastasis,” “metastatic,” or “metastasize” refers to the spread or migration of cancerous cells from a primary or original tumor to another organ or tissue and is typically identifiable by the presence of a “secondary tumor” or “secondary cell mass” of the tissue type of the primary or original tumor and not of that of the organ or tissue in which the secondary (metastatic) tumor is located. For example, a prostate cancer that has migrated to bone is said to be metastasized prostate cancer and includes cancerous prostate cancer cells growing in bone tissue.

[0112] The term “cancer” refers to a class of diseases characterized by the development of abnormal cells that proliferate uncontrollably and have the ability to infiltrate and destroy normal body tissues. See e.g., Stedman’s Medical Dictionary, 25th ed.; Hensyl ed.; Williams & Wilkins: Philadelphia, 1990. Exemplary cancers include, but are not limited to, acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); choriocarcinoma;chordoma; craniopharyngioma; colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma); connective tissue cancer; epithelial carcinoma; ependymoma; endotheliosarcoma (e.g., Kaposi’s sarcoma, multiple idiopathic hemorrhagic sarcoma); endometrial cancer (e.g., uterine cancer, uterine sarcoma); esophageal cancer (e.g., adenocarcinoma of the esophagus, Barrett’s adenocarcinoma); Ewing’s sarcoma; ocular cancer (e.g., intraocular melanoma, retinoblastoma); familiar hypereosinophilia; gall bladder cancer; gastric cancer (e.g., stomach adenocarcinoma); gastrointestinal stromal tumor (GIST); germ cell cancer; head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma), throat cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer)); hematopoietic cancers (e.g., leukemia such as acute lymphocytic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myelocytic leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL)); lymphoma such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and nonHodgkin lymphoma (NHL) (e.g., B-cell NHL such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma), follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphomas (e.g., mucosa-associated lymphoid tissue (MALT) lymphomas, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (i.e., Waldenstrom’s macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B -lymphoblastic lymphoma and primary central nervous system (CNS) lymphoma; and T-cell NHL such as precursor T-lymphoblastic lymphoma / leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sezary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous panniculitis-like T- cell lymphoma, and anaplastic large cell lymphoma); a mixture of one or more leukemia / lymphoma as described above; and multiple myeloma (MM)), heavy chain disease (e.g., alpha chain disease, gamma chain disease, mu chain disease); hemangioblastoma; hypopharynx cancer; inflammatory myofibroblastic tumors; immunocytic amyloidosis; kidney cancer (e.g., nephroblastoma a.k.a. Wilms’ tumor, renal cell carcinoma); liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma); lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung); leiomyosarcoma (LMS); mastocytosis (e.g., systemic mastocytosis); muscle cancer; myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a. myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)); neuroblastoma; neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis); neuroendocrine cancer (e.g., gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoidtumor); osteosarcoma (e.g., bone cancer); ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (e.g., pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors); penile cancer (e.g., Paget’s disease of the penis and scrotum); pinealoma; primitive neuroectodermal tumor (PNT); plasma cell neoplasia; paraneoplastic syndromes; intraepithelial neoplasms; prostate cancer (e.g., prostate adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer; skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)); small bowel cancer (e.g., appendix cancer); soft tissue sarcoma (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; small intestine cancer; sweat gland carcinoma; synovioma; testicular cancer (e.g., seminoma, testicular embryonal carcinoma); thyroid cancer (e.g., papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid cancer); urethral cancer; vaginal cancer; and vulvar cancer (e.g., Paget’s disease of the vulva).

[0113] The terms “inflammatory disease” and “inflammatory condition” are used interchangeably herein, and refer to a disease or condition caused by, resulting from, or resulting in inflammation. Inflammatory diseases and conditions include those diseases, disorders or conditions that are characterized by signs of pain (dolor, from the generation of noxious substances and the stimulation of nerves), heat (calor, from vasodilatation), redness (rubor, from vasodilatation and increased blood flow), swelling (tumor, from excessive inflow or restricted outflow of fluid), and / or loss of function (functio laesa, which can be partial or complete, temporary or permanent. Inflammation takes on many forms and includes, but is not limited to, acute, adhesive, atrophic, catarrhal, chronic, cirrhotic, diffuse, disseminated, exudative, fibrinous, fibrosing, focal, granulomatous, hyperplastic, hypertrophic, interstitial, metastatic, necrotic, obliterative, parenchymatous, plastic, productive, proliferous, pseudomembranous, purulent, sclerosing, seroplastic, serous, simple, specific, subacute, suppurative, toxic, traumatic, and / or ulcerative inflammation. The term “inflammatory disease” may also refer to a dysregulated inflammatory reaction that causes an exaggerated response by macrophages, granulocytes, and / or T-lymphocytes leading to abnormal tissue damage and / or cell death. An inflammatory disease can be either an acute or chronic inflammatory condition and can result from infections or non-infectious causes. Inflammatory diseases include, without limitation, atherosclerosis, arteriosclerosis, autoimmune disorders, multiple sclerosis, systemic lupus erythematosus, polymyalgia rheumatica (PMR), gouty arthritis, degenerative arthritis, tendonitis, bursitis, psoriasis, cystic fibrosis, arthrosteitis, rheumatoid arthritis, inflammatory arthritis, Sjogren’s syndrome, giant cell arteritis, progressive systemic sclerosis (scleroderma), ankylosing spondylitis, polymyositis, dermatomyositis, pemphigus, pemphigoid, diabetes (e.g., Type I), myasthenia gravis, Hashimoto’s thyroiditis, Graves’ disease, Goodpasture’s disease, mixed connective tissue disease, sclerosing cholangitis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, perniciousanemia, inflammatory dermatoses, usual interstitial pneumonitis (UIP), asbestosis, silicosis, bronchiectasis, berylliosis, talcosis, pneumoconiosis, sarcoidosis, desquamative interstitial pneumonia, lymphoid interstitial pneumonia, giant cell interstitial pneumonia, cellular interstitial pneumonia, extrinsic allergic alveolitis, Wegener’s granulomatosis and related forms of angiitis (temporal arteritis and polyarteritis nodosa), inflammatory dermatoses, hepatitis, delayed-type hypersensitivity reactions (e.g., poison ivy dermatitis), pneumonia, respiratory tract inflammation, Adult Respiratory Distress Syndrome (ARDS), encephalitis, immediate hypersensitivity reactions, asthma, hayfever, allergies, acute anaphylaxis, rheumatic fever, glomerulonephritis, pyelonephritis, cellulitis, cystitis, chronic cholecystitis, ischemia (ischemic injury), reperfusion injury, allograft rejection, host-versus-graft rejection, appendicitis, arteritis, blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis, chorioamnionitis, conjunctivitis, dacryoadenitis, dermatomyositis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, gingivitis, ileitis, iritis, laryngitis, myelitis, myocarditis, nephritis, omphalitis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, pharyngitis, pleuritis, phlebitis, pneumonitis, proctitis, prostatitis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, testitis, tonsillitis, urethritis, urocystitis, uveitis, vaginitis, vasculitis, vulvitis, vulvovaginitis, angitis, chronic bronchitis, osteomyelitis, optic neuritis, temporal arteritis, transverse myelitis, necrotizing fasciitis, and necrotizing enterocolitis. An ocular inflammatory disease includes, but is not limited to, post-surgical inflammation.

[0114] Additional exemplary inflammatory conditions include, but are not limited to, inflammation associated with acne, anemia (e.g., aplastic anemia, hemolytic autoimmune anemia), asthma, arteritis (e.g., polyarteritis, temporal arteritis, periarteritis nodosa, Takayasu’s arteritis), arthritis (e.g., crystalline arthritis, osteoarthritis, psoriatic arthritis, gouty arthritis, reactive arthritis, rheumatoid arthritis and Reiter’s arthritis), ankylosing spondylitis, amylosis, amyotrophic lateral sclerosis, autoimmune diseases, allergies or allergic reactions, atherosclerosis, bronchitis, bursitis, chronic prostatitis, conjunctivitis, Chagas disease, chronic obstructive pulmonary disease, cermatomyositis, diverticulitis, diabetes (e.g., type I diabetes mellitus, Type II diabetes mellitus), a skin condition (e.g., psoriasis, eczema, burns, dermatitis, pruritus (itch)), endometriosis, Guillain-Barre syndrome, infection, ischemic heart disease, Kawasaki disease, glomerulonephritis, gingivitis, hypersensitivity, headaches (e.g., migraine headaches, tension headaches), ileus (e.g., postoperative ileus and ileus during sepsis), idiopathic thrombocytopenic purpura, interstitial cystitis (painful bladder syndrome), gastrointestinal disorder (e.g., selected from peptic ulcers, regional enteritis, diverticulitis, gastrointestinal bleeding, eosinophilic gastrointestinal disorders (e.g., eosinophilic esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic colitis), gastritis, diarrhea, gastroesophageal reflux disease (GORD, or its synonym GERD), inflammatory bowel disease (IBD) (e.g., Crohn’s disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, ischemic colitis, diversion colitis, Behcet’s syndrome, indeterminate colitis) and inflammatory bowel syndrome (IBS)),lupus, multiple sclerosis, morphea, myasthenia gravis, myocardial ischemia, nephrotic syndrome, pemphigus vulgaris, pernicious anemia, peptic ulcers, polymyositis, primary biliary cirrhosis, neuroinflammation associated with brain disorders (e.g., Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease), prostatitis, chronic inflammation associated with cranial radiation injury, pelvic inflammatory disease, reperfusion injury, regional enteritis, rheumatic fever, systemic lupus erythematosus, scleroderma, sarcoidosis, spondyloarthopathies, Sjogren’s syndrome, thyroiditis, transplantation rejection, tendonitis, trauma or injury (e.g., frostbite, chemical irritants, toxins, scarring, burns, physical injury), vasculitis, vitiligo and Wegener’s granulomatosis. In certain embodiments, the inflammatory disorder is selected from arthritis (e.g., rheumatoid arthritis), inflammatory bowel disease, inflammatory bowel syndrome, asthma, psoriasis, endometriosis, interstitial cystitis and prostatitis. In certain embodiments, the inflammatory condition is an acute inflammatory condition (e.g., for example, inflammation resulting from infection). In certain embodiments, the inflammatory condition is a chronic inflammatory condition (e.g., conditions resulting from asthma, arthritis and inflammatory bowel disease). The compounds may also be useful in treating inflammation associated with trauma and non-inflammatory myalgia. The compounds disclosed herein may also be useful in treating inflammation associated with cancer

[0115] Immune disorders, such as auto-immune disorders, include, but are not limited to, arthritis (including rheumatoid arthritis, spondyloarthopathies, gouty arthritis, degenerative joint diseases such as osteoarthritis, systemic lupus erythematosus, Sjogren’s syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet’s disease, haemolytic autoimmune anaemias, multiple sclerosis, amyotrophic lateral sclerosis, amylosis, acute painful shoulder, psoriatic, and juvenile arthritis), asthma, atherosclerosis, osteoporosis, bronchitis, tendonitis, bursitis, skin condition (e.g., psoriasis, eczema, burns, dermatitis, pruritus (itch)), enuresis, eosinophilic disease, gastrointestinal disorder (e.g., selected from peptic ulcers, regional enteritis, diverticulitis, gastrointestinal bleeding, eosinophilic gastrointestinal disorders (e.g., eosinophilic esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic colitis), gastritis, diarrhea, gastroesophageal reflux disease (GORD, or its synonym GERD), inflammatory bowel disease (IBD) (e.g., Crohn’s disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behcet’s syndrome, indeterminate colitis) and inflammatory bowel syndrome (IBS)), and disorders ameliorated by a gastroprokinetic agent (e.g., ileus, postoperative ileus and ileus during sepsis; gastroesophageal reflux disease (GORD, or its synonym GERD); eosinophilic esophagitis, gastroparesis such as diabetic gastroparesis; food intolerances and food allergies and other functional bowel disorders, such as non-ulcerative dyspepsia (NUD) and non-cardiac chest pain (NCCP, including costo-chondritis)).

[0116] The term “neurological disease” refers to any disease of the nervous system, including diseases that involve the central nervous system (brain, brainstem and cerebellum), the peripheral nervous system (including cranial nerves), and the autonomic nervous system (parts of which are located in both central and peripheral nervous system). Neurodegenerative diseases refer to a type ofneurological disease marked by the loss of nerve cells, including, but not limited to, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, tauopathies (including frontotemporal dementia), and Huntington’s disease. Examples of neurological diseases include, but are not limited to, headache, stupor and coma, dementia, seizure, sleep disorders, trauma, infections, neoplasms, neuro-ophthalmology, movement disorders, demyelinating diseases, spinal cord disorders, and disorders of peripheral nerves, muscle and neuromuscular junctions. Addiction and mental illness, include, but are not limited to, bipolar disorder and schizophrenia, are also included in the definition of neurological diseases. Further examples of neurological diseases include acquired epileptiform aphasia; acute disseminated encephalomyelitis; adrenoleukodystrophy; agenesis of the corpus callosum; agnosia; Aicardi syndrome; Alexander disease; Alpers’ disease; alternating hemiplegia; Alzheimer’s disease; amyotrophic lateral sclerosis; anencephaly; Angelman syndrome; angiomatosis; anoxia; aphasia; apraxia; arachnoid cysts; arachnoiditis; Arnold-Chiari malformation; arteriovenous malformation; Asperger syndrome; ataxia telangiectasia; attention deficit hyperactivity disorder; autism; autonomic dysfunction; back pain; Batten disease; Behcet’s disease; Bell’s palsy; benign essential blepharospasm; benign focal; amyotrophy; benign intracranial hypertension; Binswanger’s disease; blepharospasm; Bloch Sulzberger syndrome; brachial plexus injury; brain abscess; bbrain injury; brain tumors (including glioblastoma multiforme); spinal tumor; Brown-Sequard syndrome; Canavan disease; carpal tunnel syndrome (CTS); causalgia; central pain syndrome; central pontine myelinolysis; cephalic disorder; cerebral aneurysm; cerebral arteriosclerosis; cerebral atrophy; cerebral gigantism; cerebral palsy; Charcot-Marie-Tooth disease; chemotherapy-induced neuropathy and neuropathic pain; Chiari malformation; chorea; chronic inflammatory demyelinating polyneuropathy (CIDP); chronic pain; chronic regional pain syndrome; Coffin Lowry syndrome; coma, including persistent vegetative state; congenital facial diplegia; corticobasal degeneration; cranial arteritis; craniosynostosis; Creutzfeldt- Jakob disease; cumulative trauma disorders; Cushing’s syndrome; cytomegalic inclusion body disease (CIBD); cytomegalovirus infection; dancing eyes- dancing feet syndrome; Dandy-Walker syndrome; Dawson disease; De Morsier’s syndrome; Dejerine-Klumpke palsy; dementia; dermatomyositis; diabetic neuropathy; diffuse sclerosis; dysautonomia; dysgraphia; dyslexia; dystonias; early infantile epileptic encephalopathy; empty sella syndrome; encephalitis; encephaloceles; encephalotrigeminal angiomatosis; epilepsy; Erb’s palsy; essential tremor; Fabry’s disease; Fahr’s syndrome; fainting; familial spastic paralysis; febrile seizures; Fisher syndrome; Friedreich’s ataxia; frontotemporal dementia and other “tauopathies”; Gaucher’s disease; Gerstmann’s syndrome; giant cell arteritis; giant cell inclusion disease; globoid cell leukodystrophy; Guillain-Barre syndrome; HTLV-1 associated myelopathy; Hallervorden-Spatz disease; head injury; headache; hemifacial spasm; hereditary spastic paraplegia; heredopathia atactica polyneuritiformis; herpes zoster oticus; herpes zoster; Hirayama syndrome; HIV-associated dementia and neuropathy (see also neurological manifestations of AIDS); holoprosencephaly; Huntington’s disease and other polyglutamine repeat diseases; hydranencephaly; hydrocephalus; hypercortisolism;hypoxia; immune-mediated encephalomyelitis; inclusion body myositis; incontinentia pigmenti; infantile; phytanic acid storage disease; Infantile Refsum disease; infantile spasms; inflammatory myopathy; intracranial cyst; intracranial hypertension; Joubert syndrome; Kearns-Sayre syndrome; Kennedy disease; Kinsbourne syndrome; Klippel Feil syndrome; Krabbe disease; Kugelberg- Welander disease; kuru; Lafora disease; Lambert-Eaton myasthenic syndrome; Landau-Kleffner syndrome; lateral medullary (Wallenberg) syndrome; learning disabilities; Leigh’s disease; Lennox- Gastaut syndrome; Lesch-Nyhan syndrome; leukodystrophy; Lewy body dementia; lissencephaly; locked-in syndrome; Lou Gehrig’s disease (aka motor neuron disease or amyotrophic lateral sclerosis); lumbar disc disease; lyme disease-neurological sequelae; Machado-Joseph disease; macrencephaly; megalencephaly; Melkersson-Rosenthal syndrome; Menieres disease; meningitis; Menkes disease; metachromatic leukodystrophy; microcephaly; migraine; Miller Fisher syndrome; mini-strokes; mitochondrial myopathies; Mobius syndrome; monomelic amyotrophy; motor neurone disease; moyamoya disease; mucopolysaccharidoses; multi-infarct dementia; multifocal motor neuropathy; multiple sclerosis and other demyelinating disorders; multiple system atrophy with postural hypotension; muscular dystrophy; myasthenia gravis; myelinoclastic diffuse sclerosis; myoclonic encephalopathy of infants; myoclonus; myopathy; myotonia congenital; narcolepsy; neurofibromatosis; neuroleptic malignant syndrome; neurological manifestations of AIDS; neurological sequelae of lupus; neuromyotonia; neuronal ceroid lipofuscinosis; neuronal migration disorders; Niemann-Pick disease; O’Sullivan-McLeod syndrome; occipital neuralgia; occult spinal dysraphism sequence; Ohtahara syndrome; olivopontocerebellar atrophy; opsoclonus myoclonus; optic neuritis; orthostatic hypotension; overuse syndrome; paresthesia; Parkinson’s disease; paramyotonia congenita; paraneoplastic diseases; paroxysmal attacks; Parry Romberg syndrome; Pelizaeus-Merzbacher disease; periodic paralyses; peripheral neuropathy; painful neuropathy and neuropathic pain; persistent vegetative state; pervasive developmental disorders; photic sneeze reflex; phytanic acid storage disease; Pick’s disease; pinched nerve; pituitary tumors; polymyositis; porencephaly; Post-Polio syndrome; postherpetic neuralgia (PHN); postinfectious encephalomyelitis; postural hypotension; Prader-Willi syndrome; primary lateral sclerosis; prion diseases; progressive; hemifacial atrophy; progressive multifocal leukoencephalopathy; progressive sclerosing poliodystrophy; progressive supranuclear palsy; pseudotumor cerebri; Ramsay-Hunt syndrome (Type I and Type II); Rasmussen’s Encephalitis; reflex sympathetic dystrophy syndrome; Refsum disease; repetitive motion disorders; repetitive stress injuries; restless legs syndrome; retrovirus-associated myelopathy; Rett syndrome; Reye’s syndrome; Saint Vitus Dance; Sandhoff disease; Schilder’s disease; schizencephaly; septo-optic dysplasia; shaken baby syndrome; shingles; Shy-Drager syndrome; Sjogren’s syndrome; sleep apnea; Soto’s syndrome; spasticity; spina bifida; spinal cord injury; spinal cord tumors; spinal muscular atrophy; stiff-person syndrome; stroke; Sturge-Weber syndrome; subacute sclerosing panencephalitis; subarachnoid hemorrhage; subcortical arteriosclerotic encephalopathy; sydenham chorea; syncope; syringomyelia; tardive dyskinesia; Tay-Sachs disease;temporal arteritis; tethered spinal cord syndrome; Thomsen disease; thoracic outlet syndrome; tic douloureux; Todd’s paralysis; Tourette syndrome; transient ischemic attack; transmissible spongiform encephalopathies; transverse myelitis; traumatic brain injury; tremor; trigeminal neuralgia; tropical spastic paraparesis; tuberous sclerosis; vascular dementia (multi-infarct dementia); vasculitis including temporal arteritis; Von Hippel-Lindau Disease (VHL); Wallenberg’s syndrome; Werdnig- Hoffman disease; West syndrome; whiplash; Williams syndrome; Wilson’s disease; and Zellweger syndrome.DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

[0117] The aspects described herein are not limited to specific embodiments, systems, compositions, methods, or configurations, and as such can, of course, vary. The terminology used herein is for the purpose of describing particular aspects only and, unless specifically defined herein, is not intended to be limiting.Compounds

[0118] In one aspect, the present disclosure provides a compound of Formula (I'):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein:A is CR4or N;L is -C(=O)-, -SO2-, -C(=O)C(R11)2-, or -C(R11)2C(=O)-;L12is absent or -C(R12)2-;R1is optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of R2is independently hydrogen, optionally substituted alkyl, or two occurrences of R2are joined together with their intervening carbon atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring; two occurrences of R3are joined together with their intervening nitrogen atom to form an optionally substituted heterocyclic ring;R4is hydrogen, halogen, or optionally substituted alkyl;RNis hydrogen, optionally substituted alkyl, or a nitrogen protecting group, or RNand R4are joined together with their intervening atoms to form an optionally substituted heterocyclic ring;R5is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of R11is independently hydrogen, optionally substituted alkyl, or two occurrences of R11are joined together with their intervening carbon atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring; each occurrence of R12is independently hydrogen, optionally substituted alkyl, or two occurrences of R12are joined together with their intervening carbon atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring; and each occurrence of n is independently 0, 1 , or 2, provided that at least one occurrence of n is not 0.

[0119] In another aspect, the present disclosure provides a compound of Formula (I):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein:A is CR4or N;L is — C(=O)— or -SO2-;R1is optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of R2is independently hydrogen, optionally substituted alkyl, or two occurrences of R2are joined together with their intervening carbon atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring; two occurrences of R3are joined together with their intervening nitrogen atom to form an optionally substituted heterocyclic ring;R4is hydrogen, halogen, or optionally substituted alkyl; andR5is optionally substituted aryl.

[0120] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof. In some embodiments, R1is substituted aryl or substituted heteroaryl.

[0121] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-i):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0122] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-ii):-ii), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0123] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-iii):-a.iii), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0124] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-iv):-iv), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0125] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-v):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0126] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-vi):-vi), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0127] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-vii):-vii), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0128] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-viii):-viii), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0129] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-ix):-ix), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0130] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-x):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0131] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xi):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0132] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xii):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0133] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xiii):-xiii), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0134] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xiv):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0135] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xv):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0136] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xvi):-xvi), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0137] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xvii):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0138] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xviii):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0139] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xix):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0140] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xx):-xx), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0141] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xxi):-xxi), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0142] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xxii):-xxii), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0143] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xxiii):-xxiii), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.In some embodiments of Formulae (I-a-i) to (I-a-xiii), (I-a-xxii), and (I-a-xxiii), R5is of formula:wherein each of R5A, R5B, R5C, R5D, and R5Eis independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, or -ORA, or R5Band R5Cor R5Dand R5Care joined with their intervening atoms to form optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments of Formulae (I-a-i) to (I-a-xiii), (I-a-xxii), and (I-a-xxiii), R5is of formula (v), and R5Cis halogen, optionally substituted alkyl, -CN, or -ORA. In some embodiments of Formulae (I-a-i) to (I-a-xiii), (I-a-xxii), and (I-a-xxiii), R5is of formula (v), and R5Cis halogen, optionally substituted C1-3alkyl, -CN, or -O(optionally substituted C1-3alkyl ). In some embodiments of Formulae (I-a-i) to (I-a-xiii), (I-a-xxii), and (I-a-xxiii), R5is of formula (v), and R5Cis halogen, unsubstituted C1-3alkyl, -CN, or -O(substituted C1-3alkyl ). In some embodiments of Formulae (I-a-i) to (I-a-xiii), (I-a-xxii), and (I-a-xxiii), R5is of formula (v), and R5Cis -Cl, methyl, - CN, or -OCF3. In some embodiments of Formulae (I-a-i) to (I-a-xiii), (I-a-xxii), and (I-a-xxiii), R5is of formula (v), and R5Bor R5Dis halogen or optionally substituted alkyl. In some embodiments of Formulae (I-a-i) to (I-a-xiii), (I-a-xxii), and (I-a-xxiii), R5is of formula (v), and R5Bor R5Dis halogen or optionally substituted C1-3alkyl. In some embodiments of Formulae (I-a-i) to (I-a-xiii), (I-a-xxii), and (I-a-xxiii), R5is of formula (v), and R5Bor R5Dis halogen or unsubstituted C1-3alkyl. In some embodiments of Formulae (I-a-i) to (I-a-xiii), (I-a-xxii), and (I-a-xxiii), R5is of formula (v), and R5Bor R5Dis halogen or methyl. In some embodiments of Formulae (I-a-i) to (I-a-xiii), (I-a-xxii), and (I-a- xxiii), R5is of formula (v), and R5Bor R5Dis -Cl or methyl. In some embodiments of Formulae (I-a-i) to (I-a-xiii), (I-a-xxii), and (I-a-xxiii), R5Band R5Cor R5Dand R5Care joined with their intervening atoms to form optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

[0144] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xxiv):-xxiv), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0145] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-a-xxv):-xxv), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0146] In certain embodiments of Formulae (I-a-i) to (I-a-xxv), R1is pyridinyl or isoxazolyl substituted with halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, and / or -ORA. In certain embodiments of Formulae (I-a-i) to (I-a-xxv), R1is pyridinyl or isoxazolyl substituted with halogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted carbocyclyl, and / or -ORA.

[0147] In certain embodiments of Formulae (I-a-i) to (I-a-xxv), R1is of formula:wherein each R13is independently halogen, optionally substituted alkyl, optionally substituted carbocyclyl, or -ORA; yl is 0, 1, 2, 3 ae(I-a-i) to (I-a-xxv), R1is of formula:, wherein each R13is independently halogen, optionally substituted Cm alkyl, optionally substituted C3-4carbocyclyl, or -O(optionally substituted Cm alkyl); yl is 0, 1, or 2; and y2 is 0, 1, or 2. In certain embodiments of Formulae (I-a-i) to (I-a-xxv), R1is of formula:is independently optionally substituted Cm alkyl, optionally substituted C3-4 carbocyclyl, or - O(optionally substituted Cm alkyl); yl is 0, 1, iments ofFormulae (I-a-i) to (I-a-xxv), R1is of formula:, wherein each R13is independently unsubstituted Cm alkyl, unsubstituted C3-4 carbocyclyl, or -O(unsubstituted Cm alkyl); yl is 0, 1, or 2; and y2 is 0, 1, or 2. In certain embodiments of Formulae (I-a-i) to (I-a-xxv), R1is

[0148] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0149] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-i):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0150] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-ii):-ii),or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0151] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-iii):-iii), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0152] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-iv):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0153] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-v):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0154] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-vi):-vi), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0155] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-vii):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0156] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-viii):-viii), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0157] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-ix):-ix), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0158] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-x):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0159] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-xi):-xi), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0160] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-xii):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0161] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-xiii):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0162] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-xiv):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0163] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-xv):-xv), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0164] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-xvi):-xvi),or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0165] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-xvii):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0166] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-xviii):-xviii), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0167] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-b-xix):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0168] In some embodiments, the compound of Formulae (I') or (I) is of Formulae (I-f-i) to (I-f-iii):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein each R13is independently halogen, optionally substituted alkyl, optionally substituted carbocyclyl, or -ORA; yl is 0, 1, 2, 3, or 4; and y2 is 0, 1, or 2.

[0169] In some embodiments, the compound of Formulae (I') or (I) is of Formulae (I-f-iv) to (I-f-vi):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein each R13is independently halogen, optionally substituted alkyl, optionally substituted carbocyclyl, or -ORA; yl is 0, 1, 2, 3, or 4; and y2 is 0, 1, or 2.

[0170] In some embodiments, the compound of Formulae (I') or (I) is of Formulae (I-f-vii) to (I-f-ix):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein each R13is independently halogen, optionally substituted alkyl, optionally substituted carbocyclyl, or -ORA; yl is 0, 1, 2, 3, or 4; and y2 is 0, 1, or 2.

[0171] In some embodiments, the compound of Formulae (I') or (I) is of Formulae (I-f-x) to (I-f-xii):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein each R13is independently halogen, optionally substituted alkyl, optionally substituted carbocyclyl, or -ORA; yl is 0, 1, 2, 3, or 4; and y2 is 0, 1, or 2.

[0172] In some embodiments, the compound of Formulae (I') or (I) is of Formulae (I-f-xiii) to (I-f- xv):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein each R13is independently halogen, optionally substituted alkyl, optionally substituted carbocyclyl, or -ORA; yl is 0, 1, 2, 3, or 4; and y2 is 0, 1, or 2.

[0173] In some embodiments of Formulae (I-f-i) to (I-f-xv), each R13is independently halogen, optionally substituted Cm alkyl, optionally substituted C3-4 carbocyclyl, or -O(optionally substituted Cm alkyl); yl is 0, 1, or 2; and y2 is 0, 1, or 2. In some embodiments of Formulae (I-f-i) to (I-f-xv), each R13is independently optionally substituted Cm alkyl, optionally substituted C3-4 carbocyclyl, or - O(optionally substituted Cm alkyl); yl is 0, 1, or 2; and y2 is 0, 1, or 2. In some embodiments of Formulae (I-f-i) to (I-f-xv), each R13is independently unsubstituted Cm alkyl, unsubstituted C3-4 carbocyclyl, or -O(unsubstituted Cm alkyl); yl is 0, 1, or 2; and y2 is 0, 1, or 2. In some embodiments of Formulae (I-f-i) to (I-f-xv), R1is

[0174] In some embodiments of Formulae (I-f-i) to (I-f-xv), R5is phenyl substituted with halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, - CN, and / or -ORA. In some embodiments of Formulae (I-f-i) to (I-f-xv), R5is phenyl substituted with halogen, optionally substituted alkyl, -CN, and / or -ORA. In some embodiments of Formulae (I-f-i) to (I-f-xv), R5is phenyl substituted with halogen, optionally substituted Cm alkyl, -CN, and / or - O(optionally substituted Cm alkyl ). In some embodiments of Formulae (I-f-i) to (I-f-xv), R5is phenyl substituted with halogen, unsubstituted Cm alkyl, -CN, and / or -O(substituted Cm alkyl ).

[0175] In some embodiments of Formulae (I-f-i) to (I-f-xv), R5is of formula:wherein each of R5A, R5B, R5C, R5D, and R5Eis independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, or -ORA, or R5Band R5Cor R5Dand R5Care joined with their intervening atoms to form optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments of Formulae (I-f-i) to (I-f-xv), R5is of formula (v), and R5Cis halogen, optionally substituted alkyl, -CN, or -ORA. In some embodiments of Formulae (I-f-i) to (I-f-xv), R5Cis halogen, optionally substituted Cm alkyl, -CN, or -O(optionally substituted Cm alkyl ). In some embodimentsof Formulae (I-f-i) to (I-f-xv), R5Cis halogen, unsubstituted C1-3alkyl, -CN, or -O(substituted C1-3alkyl ). In some embodiments of Formulae (I-f-i) to (I-f-xv), R5Cis -Cl, methyl, -CN, or -OCF3. In some embodiments of Formulae (I-f-i) to (I-f-xv), R5is of formula (v), and R5Bor R5Dis halogen or optionally substituted alkyl. In some embodiments of Formulae (I-f-i) to (I-f-xv), R5Bor R5Dis halogen or optionally substituted C1-3alkyl. In some embodiments of Formulae (I-f-i) to (I-f-xv), R5Bor R5Dis halogen or unsubstituted C1-3alkyl. In some embodiments of Formulae (I-f-i) to (I-f-xv), R5Bor R5Dis halogen or methyl. In some embodiments of Formulae (I-f-i) to (I-f-xv), R5Bor R5Dis -Cl or methyl. In some embodiments of Formulae (I-f-i) to (I-f-xv), R5Band R5Cor R5Dand R5Care joined with their intervening atoms to form optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.L and R11

[0176] As generally described herein for compounds of Formula (I'), L is -C(=O)-, -SO2-, -C(=O)C(R11)2- or -C(R11)2C(=O)-.

[0177] As generally described herein for compounds of Formula (I), L is -C(=O)- or -SO2-.

[0178] In certain embodiments of Formula (I'), L is -C(=O)-, -C(=O)C(R11)2-, or -C(R11)2C(=O)-. In certain embodiments of Formula (I'), L is -C(=O)C(R11)2- or -C(R11)2C(=O)-. In certain embodiments of Formula (I'), L is -C(=O)C(R11)2-. In certain embodiments of Formula (I'), L is -C(=O)CH(R11)2-. In certain embodiments of Formula (I'), L is -C(=O)CH2- In certain embodiments of Formula (I'), L is -C(=O)CH(CH3)-. In certain embodiments of Formula (I'), L is -C(R11)2C(=O)-.

[0179] In certain embodiments of Formulae (I') or (I), L is -C(=O)- or -SO2-. In certain embodiments of Formulae (I') or (I), L is -C(=O)-. In certain embodiments of Formula (I'), L is — C(=O)— . In certain embodiments of Formula (I), L is -C(=O)-. In certain embodiments of Formulae (I') or (I), L is -SO2-.

[0180] As generally described herein for compounds of Formula (I'), each occurrence of R11is independently hydrogen, optionally substituted alkyl, or two occurrences of R11are joined together with their intervening carbon atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring.

[0181] In certain embodiments of Formula (I'), at least one occurrence of R11is hydrogen. In certain embodiments of Formula (I'), at least one occurrence of R11is optionally substituted alkyl. In certain embodiments of Formula (I'), at least one occurrence of R11is substituted alkyl. In certain embodiments of Formula (I'), at least one occurrence of R11is unsubstituted alkyl. In certain embodiments of Formula (I'), at least one occurrence of R11is optionally substituted C1-6alkyl. In certain embodiments of Formula (I'), at least one occurrence of R11is substituted C1-6alkyl. In certain embodiments of Formula (I'), at least one occurrence of R11is unsubstituted C1-6alkyl. In certain embodiments of Formula (I'), at least one occurrence of R11is optionally substituted C1-3alkyl. Incertain embodiments of Formula (I'), at least one occurrence of R11is substituted Cm alkyl. In certain embodiments of Formula (I'), at least one occurrence of R11is unsubstituted Cm alkyl. In certain embodiments of Formula (I'), at least one occurrence of R11is -CH3. In certain embodiments of Formula (I'), two occurrences of R11are joined together with their intervening carbon atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring.

[0182] In certain embodiments of Formula (I'), each occurrence of R11is independently hydrogen. In certain embodiments of Formula (I'), one occurrence of R11is independently hydrogen, and one occurrence of R11is independently optionally substituted alkyl. In certain embodiments of Formula (I'), one occurrence of R11is independently hydrogen, and one occurrence of R11is independently optionally substituted Cm alkyl. In certain embodiments of Formula (I'), one occurrence of R11is independently hydrogen, and one occurrence of R11is independently unsubstituted Cm alkyl. In certain embodiments of Formula (I'), one occurrence of R11is independently hydrogen, and one occurrence of R11is independently -CH3.L12and R12

[0183] As generally described herein for compounds of Formula (I'), L12is absent or -C(R12)2-.

[0184] In some embodiments of Formula (I'), L12is absent. In some embodiments of Formula (I'), L12is - C(R12)2- . In some embodiments of Formula (I'), L12is -CH(R12)-. In some embodiments of Formula (I'), L12is -CH2-. In some embodiments of Formula (I'), L12is -CH(CH3)-.

[0185] As generally described herein for compounds of Formula (I'), each occurrence of R12is independently hydrogen, optionally substituted alkyl, or two occurrences of R12are joined together with their intervening carbon atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring.

[0186] In certain embodiments of Formula (I'), at least one occurrence of R12is hydrogen. In certain embodiments of Formula (I'), at least one occurrence of R12is optionally substituted alkyl. In certain embodiments of Formula (I'), at least one occurrence of R12is substituted alkyl. In certain embodiments of Formula (I'), at least one occurrence of R12is unsubstituted alkyl. In certain embodiments of Formula (I'), at least one occurrence of R12is optionally substituted C1-6alkyl. In certain embodiments of Formula (I'), at least one occurrence of R12is substituted C1-6alkyl. In certain embodiments of Formula (I'), at least one occurrence of R12is unsubstituted C1-6alkyl. In certain embodiments of Formula (I'), at least one occurrence of R12is optionally substituted C1-3alkyl. In certain embodiments of Formula (I'), at least one occurrence of R12is substituted C1-3alkyl. In certain embodiments of Formula (I'), at least one occurrence of R12is unsubstituted C1-3alkyl. In certain embodiments of Formula (I'), at least one occurrence of R12is -CH3. In certain embodiments of Formula (I'), two occurrences of R12are joined together with their intervening carbon atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring.

[0187] In certain embodiments of Formula (I'), each occurrence of R12is independently hydrogen. In certain embodiments of Formula (I'), one occurrence of R12is independently hydrogen, and one occurrence of R12is independently optionally substituted alkyl. In certain embodiments of Formula (I'), one occurrence of R12is independently hydrogen, and one occurrence of R12is independently optionally substituted C1-3alkyl. In certain embodiments of Formula (I'), one occurrence of R12is independently hydrogen, and one occurrence of R12is independently unsubstituted Cm alkyl. In certain embodiments of Formula (I'), one occurrence of R12is independently hydrogen, and one occurrence of R12is independently -CH3.R1

[0188] As generally described herein, R1is optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, R1is optionally substituted heterocyclyl or optionally substituted aryl. In certain embodiments, R1is optionally substituted heterocyclyl or optionally substituted heteroaryl. In certain embodiments, R1is optionally substituted aryl or optionally substituted heteroaryl. In certain embodiments, R1is substituted aryl or substituted heteroaryl.

[0189] In certain embodiments, R1is optionally substituted heterocyclyl. In certain embodiments, R1is optionally substituted, monocyclic heterocyclyl (e.g., optionally substituted, monocyclic, 3- to 10- membered heterocyclyl). In certain embodiments, R1is optionally substituted, polycyclic heterocyclyl (e.g., optionally substituted, bicyclic or bicyclic, 3- to 14-membered heterocyclyl). In certain embodiments, R1is optionally substituted saturated heterocyclyl. In certain embodiments, R1is optionally substituted azirdinyl, optionally substituted oxiranyl, optionally substituted thiiranyl, optionally substituted azetidinyl, optionally substituted oxetanyl, optionally substituted thietanyl, optionally substituted tetrahydrofuranyl, optionally substituted dihydrofuranyl, optionally substituted tetrahydrothiophenyl, optionally substituted dihydrothiophenyl, optionally substituted pyrrolidinyl, optionally substituted dihydropyrrolyl, optionally substituted pyrrolyl-2,5-dionyl, optionally substituted imidazolidin-2-onyl, optionally substituted dioxolanyl, optionally substituted oxathiolanyl, optionally substituted dithiolanyl, optionally substituted triazolinyl, optionally substituted oxadiazolinyl, optionally substituted thiadiazolinyl, optionally substituted piperidinyl, optionally substituted tetrahydropyranyl, optionally substituted dihydropyridinyl, optionally substituted thianyl, optionally substituted piperazinyl, optionally substituted morpholinyl, optionally substituted dithianyl, optionally substituted dioxanyl, optionally substituted triazinyl, optionally substituted azepanyl, optionally substituted oxepanyl, optionally substituted thiepanyl, optionally substituted azocanyl, optionally substituted oxecanyl, optionally substituted thiocanyl, optionally substituted indolinyl, optionally substituted isoindolinyl, optionally substituted dihydrobenzofuranyl, optionally substituted dihydrobenzothienyl, optionally substituted tetrahydrobenzothienyl, optionally substituted tetrahydrobenzofuranyl, optionally substituted tetrahydroindolyl, optionally substitutedtetrahydroquinolinyl, optionally substituted tetrahydroisoquinolinyl, optionally substituted decahydroquinolinyl, optionally substituted decahydroisoquinolinyl, optionally substituted octahydrochromenyl, optionally substituted octahydroisochromenyl, optionally substituted decahydronaphthyridinyl, optionally substituted decahydro-1, 8-naphthyridinyl, optionally substituted octahydropyrrolo[3,2-b]pyrrole, optionally substituted indolinyl, optionally substituted phthalimidyl, optionally substituted naphthalimidyl, optionally substituted chromanyl, optionally substituted chromenyl, optionally substituted lH-benzo[e][l,4]diazepinyl, optionally substituted 1,4,5,7-tetra- hydropyrano[3,4-b]pyrrolyl, optionally substituted 5,6-dihydro-4H-furo[3,2-b]pyrrolyl, optionally substituted 6,7-dihydro-5H-furo[3,2-b]pyranyl, optionally substituted 5,7-dihydro-4H-thieno[2,3- c]pyranyl, optionally substituted 2,3-dihydro-lH-pyrrolo[2,3-b]pyridinyl, optionally substituted 2,3- dihydrofuro[2,3-b]pyridinyl, optionally substituted 4,5,6,7-tetrahydro-lH-pyrrolo[2,3-b]pyridinyl, optionally substituted 4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl, optionally substituted 4,5,6,7-tetrahydro- thieno[3,2-b]pyridinyl, or optionally substituted l,2,3,4-tetrahydro-l,6-naphthyridinyl. In certain embodiments, R1is substituted heterocyclyl. In certain embodiments, R1is substituted saturated heterocyclyl. In certain embodiments, R1is optionally substituted azirdinyl, optionally substituted azetidinyl, optionally substituted pyrrolidinyl, optionally substituted dihydropyrrolyl, optionally substituted pyrrolyl-2, 5-dione, optionally substituted imidazolidin-2-onyl, optionally substituted piperidinyl, optionally substituted dihydropyridinyl, optionally substituted piperazinyl, optionally substituted morpholinyl, optionally substituted azepanyl, optionally substituted azocanyl, optionally substituted indolinyl, optionally substituted isoindolinyl, optionally substituted tetrahydroindolyl, optionally substituted tetrahydroquinolinyl, optionally substituted tetrahydroisoquinolinyl, optionally substituted decahydroquinolinyl, optionally substituted decahydroisoquinolinyl, optionally substituted decahydronaphthyridinyl, or optionally substituted decahydro-1, 8-naphthyridinyl. In certain embodiments, R1is optionally substituted imidazolidin-2-onyl. In certain embodiments, R1is

[0190] In certain embodiments, R1is -N(Rla)2, wherein two occurrences of Rlaare joined together with their intervening nitrogen atom to form an optionally substituted heterocyclic ring. In certain embodiments, R1is -N(Rla)2, and two occurrences of Rlaare joined together with their intervening nitrogen atom to form an optionally substituted, monocyclic heterocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered heterocyclyl). In certain embodiments, R1is -N(Rla)2, and two occurrences of Rlaare joined together with their intervening nitrogen atom to form an optionally substituted, polycyclic heterocyclyl (e.g., optionally substituted, bicyclic or tricyclic, 3- to 14- membered heterocyclyl). In certain embodiments, R1is -N(Rla)2, and two occurrences of Rlaare joined together with their intervening nitrogen atom to form an optionally substituted saturated heterocyclyl. In certain embodiments, R1is -N(Rla)2, and two occurrences of Rlaare joined togetherwith their intervening nitrogen atom to form an optionally substituted azirdinyl, optionally substituted azetidinyl, optionally substituted pyrrolidinyl, optionally substituted dihydropyrrolyl, optionally substituted pyrrolyl-2, 5-dione, optionally substituted imidazolidin-2-onyl, optionally substituted piperidinyl, optionally substituted dihydropyridinyl, optionally substituted piperazinyl, optionally substituted morpholinyl, optionally substituted azepanyl, optionally substituted azocanyl, optionally substituted indolinyl, optionally substituted isoindolinyl, optionally substituted tetrahydroindolyl, optionally substituted tetrahydroquinolinyl, optionally substituted tetrahydroisoquinolinyl, optionally substituted decahydroquinolinyl, optionally substituted decahydroisoquinolinyl, optionally substituted decahydronaphthyridinyl, or optionally substituted decahydro-1, 8-naphthyridinyl. In certain embodiments, R1is -N(Rla)2, and two occurrences of Rlaare joined together with their intervening nitrogen atom to form a substituted heterocyclyl. In certain embodiments, R1is -N(Rla)2, and two occurrences of Rlaare joined together with their intervening nitrogen atom to form a substituted saturated heterocyclyl. In certain embodiments, R1is -N(Rla)2, and two occurrences of Rlaare joined together with their intervening nitrogen atom to form a heterocyclyl substituted with one or more of halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -ORA, -SCN, -SRA, -SSRA, -Ns, -NO, - N(RA)2, -NO2, -C(=O)RA, -C(=O)ORA, -C(=O)SRA, -C(=O)N(RA)2, -C(=NRA)RA, -C(=NRA)ORA, - C(=NRA)SRA, -C(=NRA)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)SRA, -S(=0)N(RA)2, -S(=O)2RA, - S(=O)2ORA, -S(=O)2SRA, -S(=O)2N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)SRA, - 0C(=0)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)SRA, -0C(=NRA)N(RA)2, - OS(=O)RA, -OS(=O)ORA, -OS(=O)SRA, -0S(=0)N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, - OS(=O)2SRA, -OS(=O)2N(RA)2, -0N(RA)2, -SC(=O)RA, -SC(=O)ORA, -SC(=O)SRA, - SC(=0)N(RA)2, -SC(=NRA)RA, -SC(=NRA)ORA, -SC(=NRA)SRA, -SC(=NRA)N(RA)2, - NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)SRA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, - NRAC(=NRA)ORA, -NRAC(=NRA)SRA, -NRAC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, - NRAS(=O)SRA, -NRAS(=0)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2SRA, - NRAS(=O)2N(RA)2, -Si(RA)3, -Si(RA)2ORA, -Si(RA)(ORA)2, -Si(ORA)3, -OSi(RA)3, -OSi(RA)2ORA, - 0Si(RA)(0RA)2, -OSi(ORA)3, and / or -B(0RA)2 groups. In certain embodiments, R1is -N(Rla)2, and two occurrences of Rlaare joined together with their intervening nitrogen atom to form an optionally substituted imidazolidin-2-onyl.

[0191] In certain embodiments, R1is optionally substituted aryl. In certain embodiments, R1is optionally substituted C6-14aryl. In certain embodiments, R1is optionally substituted phenyl. In certain embodiments, R1is substituted phenyl. In certain embodiments, R1is phenyl substituted with one or more of halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionallysubstituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -ORA, -SCN, -SRA, -SSRA, -N3, - NO, -N(RA)2, -NO2, -C(=O)RA, -C(=O)ORA, -C(=O)SRA, -C(=O)N(RA)2, -C(=NRA)RA, - C(=NRA)ORA, -C(=NRA)SRA, -C(=NRA)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)SRA, - S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, -S(=O)2SRA, -S(=O)2N(RA)2, -OC(=O)RA, -OC(=O)ORA, - OC(=O)SRA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)SRA, - OC(=NRA)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)SRA, -OS(=O)N(RA)2, -OS(=O)2RA, - OS(=O)2ORA, -OS(=O)2SRA, -OS(=O)2N(RA)2, -ON(RA)2, -SC(=O)RA, -SC(=O)ORA, -SC(=O)SRA, -SC(=O)N(RA)2, -SC(=NRA)RA, -SC(=NRA)ORA, -SC(=NRA)SRA, -SC(=NRA)N(RA)2, - NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)SRA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, - NRAC(=NRA)ORA, -NRAC(=NRA)SRA, -NRAC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, - NRAS(=O)SRA, -NRAS(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2SRA, - NRAS(=O)2N(RA)2, -Si(RA)3, -Si(RA)2ORA, -Si(RA)(ORA)2, -Si(ORA)3, -OSi(RA)3, -OSi(RA)2ORA, - OSi(RA)(ORA)2, -OSi(ORA)3, and / or -B(ORA)2groups.

[0192] In certain embodiments, R1is phenyl substituted with halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, and / or -ORA. In certain embodiments, R1is phenyl substituted with halogen, optionally substituted carbocyclyl, and / or -ORA.

[0193] In certain embodiments, R1is phenyl substituted with halogen. In certain embodiments, R1is phenyl substituted with -F, -Cl, -Br, and / or -I. In certain embodiments, R1is phenyl substituted with -F. In certain embodiments, R1is phenyl substituted with -Cl. In certain embodiments, R1is phenyl substituted with -Br. In certain embodiments, R1is phenyl substituted with -I. In certain

[0194] In certain embodiments, R1is phenyl substituted with optionally substituted alkyl. In certain embodiments, R1is phenyl substituted with optionally substituted C1-12alkyl. In certain embodiments, R1is phenyl substituted with optionally substituted C1-6alkyl. In certain embodiments, R1is phenyl substituted with unsubstituted C1-6alkyl. In certain embodiments, R1is phenyl substituted with substituted C1-6alkyl. In certain embodiments, R1is phenyl substituted with optionally substituted methyl, optionally substituted ethyl, optionally substituted n-propyl, optionally substituted isopropyl, optionally substituted n-butyl, optionally substituted tert-butyl, optionally substituted sec-butyl,optionally substituted isobutyl, optionally substituted n-pentyl, optionally substituted 3-pentanyl, optionally substituted amyl, optionally substituted neopentyl, optionally substituted 3-methyl-2- butanyl, optionally substituted tert-amyl, or optionally substituted n -hexyl. In certain embodiments, R1is phenyl substituted with optionally substituted methyl. In certain embodiments, R1is phenyl substituted with substituted methyl. In certain embodiments, R1is phenyl substituted with unsubstituted methyl. In certain embodiments, R1is phenyl substituted with optionally substituted ethyl. In certain embodiments, R1is phenyl substituted with substituted ethyl. In certain embodiments, R1is phenyl substituted with unsubstituted ethyl. In certain embodiments, R1is phenyl substituted with optionally substituted isopropyl. In certain embodiments, R1is phenyl substituted with substituted isopropyl. In certain embodiments, R1is phenyl substituted with unsubstituted isopropyl. In certain embodiments, R1is phenyl substituted with optionally substituted tert-butyl. In certain embodiments, R1is phenyl substituted with substituted tert-butyl. In certain embodiments, R1is phenyl substituted with unsubstituted tert-butyl. In certain embodiments, R1is phenyl substituted with methyl, ethyl, isopropyl, or tert-butyl.

[0195] In certain embodiments, R1is phenyl substituted with optionally substituted alkyl substituted with at least one halogen. In certain embodiments, R1is phenyl substituted with optionally substituted Ci-12 alkyl substituted with at least one halogen. In certain embodiments, R1is phenyl substituted with optionally substituted C1-6alkyl substituted with at least one halogen. In certain embodiments, R1is phenyl substituted with substituted C1-6alkyl substituted with at least one halogen. In certain embodiments, R1is phenyl substituted with optionally substituted methyl substituted with at least one halogen, optionally substituted ethyl substituted with at least one halogen, optionally substituted n- propyl substituted with at least one halogen, optionally substituted isopropyl substituted with at least one halogen, optionally substituted n-butyl substituted with at least one halogen, optionally substituted tert-butyl substituted with at least one halogen, optionally substituted sec-butyl substituted with at least one halogen, optionally substituted isobutyl substituted with at least one halogen, optionally substituted n - pentyl substituted with at least one halogen, optionally substituted 3-pentanyl substituted with at least one halogen, optionally substituted amyl substituted with at least one halogen, optionally substituted neopentyl substituted with at least one halogen, optionally substituted 3-methyl- 2-butanyl substituted with at least one halogen, optionally substituted tert-amyl substituted with at least one halogen, or optionally substituted n -hexyl substituted with at least one halogen.

[0196] In certain embodiments, R1is phenyl substituted with optionally substituted alkyl substituted with at least one -F. In certain embodiments, R1is phenyl substituted with optionally substituted alkyl substituted with at least one -F. In certain embodiments, R1is phenyl substituted with optionally substituted C1-12alkyl substituted with at least one -F. In certain embodiments, R1is phenyl substituted with optionally substituted C1-6alkyl substituted with at least one -F. In certain embodiments, R1is phenyl substituted with substituted C1-6alkyl substituted with at least one -F. In certain embodiments, R1is phenyl substituted with optionally substituted methyl substituted with atleast one -F, optionally substituted ethyl substituted with at least one -F, optionally substituted n- propyl substituted with at least one -F, optionally substituted isopropyl substituted with at least one - F, optionally substituted n-butyl substituted with at least one -F, optionally substituted tert-butyl substituted with at least one -F, optionally substituted sec-butyl substituted with at least one -F, optionally substituted isobutyl substituted with at least one -F, optionally substituted n-pentyl substituted with at least one -F, optionally substituted 3-pentanyl substituted with at least one -F, optionally substituted amyl substituted with at least one -F, optionally substituted neopentyl substituted with at least one -F, optionally substituted 3-methyl-2-butanyl substituted with at least one -F, optionally substituted tert-amyl substituted with at least one -F, or optionally substituted n -hexyl substituted with at least one -F. In certain embodiments, R1is phenyl substituted with trifluoromethyl. In certain embodiments, R1is phenyl substituted with methyl or trifluoromethyl. In certain embodiments, R1is phenyl substituted with methyl, trifluoromethyl, ethyl, isopropyl, or tert-butyl.

[0197] In certain embodiments, R1is phenyl substituted with -ORA. In certain embodiments, R1is phenyl substituted with -O(optionally substituted alkyl). In certain embodiments, R1is phenyl substituted with -O(optionally substituted C1-12alkyl). In certain embodiments, R1is phenyl substituted with -O(optionally substituted C1-6alkyl). In certain embodiments, R1is phenyl substituted with -O(unsubstituted C1-6alkyl). In certain embodiments, R1is phenyl substituted with - O(substituted C1-6alkyl). In certain embodiments, R1is phenyl substituted with -O(optionally substituted methyl, optionally substituted ethyl, optionally substituted n-propyl, optionally substituted isopropyl, optionally substituted n-butyl, optionally substituted tert-butyl, optionally substituted sec- butyl, optionally substituted isobutyl, optionally substituted n-pentyl, optionally substituted 3- pentanyl, optionally substituted amyl, optionally substituted neopentyl, optionally substituted 3- methyl-2-butanyl, optionally substituted tert-amyl, or optionally substituted n-hexyl). In certain embodiments, R1is phenyl substituted with -OCH3. In certain embodiments, R1is

[0198] In certain embodiments, R1is phenyl substituted with -ORAsubstituted with at least one halogen. In certain embodiments, R1is phenyl substituted with -O(optionally substituted alkyl substituted with at least one halogen). In certain embodiments, R1is phenyl substituted with - O(optionally substituted C1-12alkyl substituted with at least one halogen). In certain embodiments, R1is phenyl substituted with -O(optionally substituted C1-6alkyl substituted with at least one halogen). In certain embodiments, R1is phenyl substituted with -O(substituted C1-6alkyl substituted with at least one halogen). In certain embodiments, R1is phenyl substituted with -O(optionally substitutedmethyl substituted with at least one halogen, optionally substituted ethyl substituted with at least one halogen, optionally substituted n-propyl substituted with at least one halogen, optionally substituted isopropyl substituted with at least one halogen, optionally substituted n-butyl substituted with at least one halogen, optionally substituted tert-butyl substituted with at least one halogen, optionally substituted sec-butyl substituted with at least one halogen, optionally substituted isobutyl substituted with at least one halogen, optionally substituted n-pentyl substituted with at least one halogen, optionally substituted 3-pentanyl substituted with at least one halogen, optionally substituted amyl substituted with at least one halogen, optionally substituted neopentyl substituted with at least one halogen, optionally substituted 3-methyl-2-butanyl substituted with at least one halogen, optionally substituted tert-amyl substituted with at least one halogen, or optionally substituted n -hexyl substituted with at least one halogen).

[0199] In certain embodiments, R1is phenyl substituted with -ORAsubstituted with at least one -F. In certain embodiments, R1is phenyl substituted with -O(optionally substituted alkyl substituted with at least one -F). In certain embodiments, R1is phenyl substituted with -O(optionally substituted C1-12alkyl substituted with at least one -F). In certain embodiments, R1is phenyl substituted with -O(optionally substituted C1-6alkyl substituted with at least one -F). In certain embodiments, R1is phenyl substituted with -O(substituted C1-6alkyl substituted with at least one -F). In certain embodiments, R1is phenyl substituted with -O(optionally substituted methyl substituted with at least one -F, optionally substituted ethyl substituted with at least one -F, optionally substituted n-propyl substituted with at least one -F, optionally substituted isopropyl substituted with at least one -F, optionally substituted n-butyl substituted with at least one -F, optionally substituted tert-butyl substituted with at least one -F, optionally substituted S ec-butyl substituted with at least one -F, optionally substituted isobutyl substituted with at least one -F, optionally substituted n-pentyl substituted with at least one -F, optionally substituted 3-pentanyl substituted with at least one -F, optionally substituted amyl substituted with at least one -F, optionally substituted neopentyl substituted with at least one -F, optionally substituted 3-methyl-2-butanyl substituted with at least one -F, optionally substituted tert-amyl substituted with at least one -F, or optionally substituted n -hexyl substituted with at least one -F). In certain embodiments, R1is phenyl substituted with -OCF3. In certain embodiments, R1is phenyl substituted with -OMe and / or -OCF3.

[0200] In certain embodiments, R1is phenyl substituted with optionally substituted carbocyclyl. In certain embodiments, R1is phenyl substituted with optionally substituted, monocyclic carbocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered carbocyclyl). In certain embodiments, R1is phenyl substituted with optionally substituted, polycyclic carbocyclyl (e.g., optionally substituted, bicyclic or tricyclic, 3- to 14-membered carbocyclyl). In certain embodiments, R1is phenyl substituted with optionally substituted saturated carbocyclyl. In certain embodiments, R1is phenyl substituted with optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclohexyl, optionally substituted cycloheptyl,optionally substituted cyclooctyl, optionally substituted cyclononyl, or optionally substituted cyclodecyl. In certain embodiments, R1is phenyl substituted with optionally substituted cyclopropyl. In certain embodiments, R1is phenyl substituted with substituted carbocyclyl. In certain embodiments, R1is phenyl substituted with substituted saturated carbocyclyl. In certain embodiments, R1is phenyl substituted with unsubstituted carbocyclyl. In certain embodiments, R1is phenyl substituted with unsubstituted saturated carbocyclyl. In certain embodiments, R1is phenyl substituted with optionally substituted cyclopropyl. In certain embodiments, R1is phenyl substituted with substituted cyclopropyl. In certain embodiments, R1is phenyl substituted with unsubstituted cyclopropyl. In certain embodiments,

[0201] In certain embodiments, R1is phenyl substituted with optionally substituted alkenyl. In certain embodiments, R1is phenyl substituted with optionally substituted alkynyl. In certain embodiments, R1is phenyl substituted with optionally substituted heteroalkyl. In certain embodiments, R1is phenyl substituted with optionally substituted heteroalkenyl. In certain embodiments, R1is phenyl substituted with optionally substituted heteroalkynyl. In certain embodiments, R1is unsubstituted phenyl.

[0202] In certain embodiments, R1is optionally substituted heteroaryl. In certain embodiments, R1is optionally substituted 5-14 membered heteroaryl. In certain embodiments, R1is optionally substituted monocyclic heteroaryl. In certain embodiments, R1is optionally substituted 5- to 6-membered, monocyclic heteroaryl. In certain embodiments, R1is optionally substituted pyrrolyl, optionally substituted furanyl, optionally substituted thiophenyl, optionally substituted imidazolyl, optionally substituted pyrazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, optionally substituted triazolyl, optionally substituted oxadiazolyl, optionally substituted thiadiazolyl, or optionally substituted tetrazolyl. In certain embodiments, R1is optionally substituted pyridinyl, optionally substituted pyridazinyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted tetrazinyl, optionally substituted oxepinyl, or optionally substituted thiepinyl. In certain embodiments, R1is optionally substituted bicyclic heteroaryl (e.g. optionally substituted bicyclic, 9- or 10-membered heteroaryl, wherein 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently oxygen, nitrogen, or sulfur). In certain embodiments, R1is optionally substituted indolyl, optionally substituted isoindolyl, optionally substituted indazolyl, optionally substituted benzotriazolyl, optionally substituted benzothiophenyl, optionally substituted isobenzothiophenyl, optionally substituted benzofuranyl, optionally substituted benzoisofuranyl, optionally substituted benzimidazolyl, optionally substituted benzoxazolyl, optionally substituted benzisoxazolyl, optionally substituted benzoxadiazolyl, optionally substituted benzthiazolyl, optionally substituted benzisothiazolyl, optionally substituted benzthiadiazolyl, optionally substituted indolizinyl, optionallysubstituted purinyl. In certain embodiments, R1is optionally substituted naphthyridinyl, optionally substituted pteridinyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted cinnolinyl, optionally substituted quinoxalinyl, optionally substituted phthalazinyl, or optionally substituted quinazolinyl. In certain embodiments, R1is optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted indolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted pyrrolyl, optionally substituted furanyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted benzimidazolyl, or optionally substituted indazolyl. In certain embodiments, R1is optionally substituted heteroaryl substituted with one or more of halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -ORA, -SCN, -SRA, -SSRA, -N3, -NO, -N(RA)2, -NO2, -C(=O)RA, -C(=O)ORA, -B(ORA)2groups.

[0203] In certain embodiments, R1is optionally substituted pyridinyl, optionally substituted oxazolyl, or optionally substituted isoxazolyl. In certain embodiments, R1is optionally substituted pyridinyl or optionally substituted oxazolyl. In certain embodiments, R1is optionally substituted pyridinyl or optionally substituted isoxazolyl. In certain embodiments, R1is optionally substituted pyridinyl. In certain embodiments, R1is optionally substituted oxazolyl. In certain embodiments, R1is optionally substituted isoxazolyl. In certain embodiments, R1is substituted pyridinyl, substituted oxazolyl, or substituted isoxazolyl. In certain embodiments, R1is substituted pyridinyl or substituted oxazolyl. In certain embodiments, R1is substituted pyridinyl or substituted isoxazolyl. In certain embodiments, R1is substituted pyridinyl. In certain embodiments, R1is substituted oxazolyl. In certain embodiments, R1is substituted isoxazolyl.

[0204] In certain embodiments, R1is heteroaryl substituted with halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl,optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, -ORA, -SRA, and / or -N(RA)2- In certain embodiments, R1is heteroaryl substituted with halogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted carbocyclyl, -ORA, -SRA, and / or -N(RA)2- In certain embodiments, R1is heteroaryl substituted with - ORA, -SRA, -NHRA, and / or -NCH3RA. In certain embodiments, R1is heteroaryl substituted with halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, and / or -ORA. In certain embodiments, R1is heteroaryl substituted with halogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted carbocyclyl, and / or -ORA.

[0205] In certain embodiments, R1is pyridinyl or isoxazolyl substituted with halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, -ORA, -SRA, and / or -N(RA)2- In certain embodiments, R1is pyridinyl or isoxazolyl substituted with halogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted carbocyclyl, -ORA, -SRA, and / or -N(RA)2- In certain embodiments, R1is pyridinyl or isoxazolyl substituted with -ORA, -SRA, -NHRA, and / or -NCH3RA. In certain embodiments, R1is pyridinyl or isoxazolyl substituted with halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, and / or -ORA. In certain embodiments, R1is pyridinyl or isoxazolyl substituted with halogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted carbocyclyl, and / or -ORA.

[0206] In certain embodiments, R1is heteroaryl substituted with halogen. In certain embodiments, R1is heteroaryl substituted with -F, -Cl, -Br, and / or -I. In certain embodiments, R1is heteroaryl substituted with -F. In certain embodiments, R1is heteroaryl substituted with -Cl. In certain embodiments, R1is heteroaryl substituted with -Br. In certain embodiments, R1is heteroaryl substituted with -I.

[0207] In certain embodiments, R1is heteroaryl substituted with optionally substituted alkyl. In certain embodiments, R1is heteroaryl substituted with optionally substituted C1-12alkyl. In certain embodiments, R1is heteroaryl substituted with optionally substituted C1-6alkyl. In certain embodiments, R1is heteroaryl substituted with unsubstituted C1-6alkyl. In certain embodiments, R1is heteroaryl substituted with substituted C1-6alkyl. In certain embodiments, R1is heteroaryl substituted with optionally substituted methyl, optionally substituted ethyl, optionally substituted n-propyl, optionally substituted isopropyl, optionally substituted n-butyl, optionally substituted tert-butyl, optionally substituted sec-butyl, optionally substituted isobutyl, optionally substituted n-pentyl, optionally substituted 3-pentanyl, optionally substituted amyl, optionally substituted neopentyl,optionally substituted 3-methyl-2-butanyl, optionally substituted tert-amyl, or optionally substituted n -hexyl. In certain embodiments, R1is heteroaryl substituted with optionally substituted methyl. In certain embodiments, R1is heteroaryl substituted with substituted methyl. In certain embodiments, R1is heteroaryl substituted with unsubstituted methyl. In certain embodiments, R1is heteroaryl substituted with optionally substituted ethyl. In certain embodiments, R1is heteroaryl substituted with substituted ethyl. In certain embodiments, R1is heteroaryl substituted with unsubstituted ethyl. In certain embodiments, R1is heteroaryl substituted with optionally substituted isopropyl. In certain embodiments, R1is heteroaryl substituted with substituted isopropyl. In certain embodiments, R1is heteroaryl substituted with unsubstituted isopropyl. In certain embodiments, R1is heteroaryl substituted with optionally substituted tert-butyl. In certain embodiments, R1is heteroaryl substituted with substituted tert-butyl. In certain embodiments, R1is heteroaryl substituted with unsubstituted tert-butyl. In certain embodiments, R1is heteroaryl substituted with methyl, ethyl, isopropyl, or tertbutyl.

[0208] In certain embodiments, R1is heteroaryl substituted with optionally substituted alkyl substituted with at least one halogen. In certain embodiments, R1is heteroaryl substituted with optionally substituted C1-12alkyl substituted with at least one halogen. In certain embodiments, R1is heteroaryl substituted with optionally substituted C1-6alkyl substituted with at least one halogen. In certain embodiments, R1is heteroaryl substituted with substituted C1-6alkyl substituted with at least one halogen. In certain embodiments, R1is heteroaryl substituted with optionally substituted methyl substituted with at least one halogen, optionally substituted ethyl substituted with at least one halogen, optionally substituted n-propyl substituted with at least one halogen, optionally substituted isopropyl substituted with at least one halogen, optionally substituted n-butyl substituted with at least one halogen, optionally substituted tert-butyl substituted with at least one halogen, optionally substituted sec-butyl substituted with at least one halogen, optionally substituted isobutyl substituted with at least one halogen, optionally substituted n-pentyl substituted with at least one halogen, optionally substituted 3-pentanyl substituted with at least one halogen, optionally substituted amyl substituted with at least one halogen, optionally substituted neopentyl substituted with at least one halogen, optionally substituted 3-methyl-2-butanyl substituted with at least one halogen, optionally substituted tert-amyl substituted with at least one halogen, or optionally substituted n-hexyl substituted with at least one halogen.

[0209] In certain embodiments, R1is heteroaryl substituted with optionally substituted alkyl substituted with at least one -F. In certain embodiments, R1is heteroaryl substituted with optionally substituted alkyl substituted with at least one -F. In certain embodiments, R1is heteroaryl substituted with optionally substituted C1-12alkyl substituted with at least one -F. In certain embodiments, R1is heteroaryl substituted with optionally substituted C1-6alkyl substituted with at least one -F. In certain embodiments, R1is heteroaryl substituted with substituted C1-6alkyl substituted with at least one -F. In certain embodiments, R1is heteroaryl substituted with optionally substituted methyl substitutedwith at least one -F, optionally substituted ethyl substituted with at least one -F, optionally substituted n-propyl substituted with at least one -F, optionally substituted isopropyl substituted with at least one -F, optionally substituted n-butyl substituted with at least one -F, optionally substituted tert-butyl substituted with at least one -F, optionally substituted sec-butyl substituted with at least one -F, optionally substituted isobutyl substituted with at least one -F, optionally substituted n-pentyl substituted with at least one -F, optionally substituted 3-pentanyl substituted with at least one -F, optionally substituted amyl substituted with at least one -F, optionally substituted neopentyl substituted with at least one -F, optionally substituted 3-methyl-2-butanyl substituted with at least one -F, optionally substituted tert-amyl substituted with at least one -F, or optionally substituted n -hexyl substituted with at least one -F. In certain embodiments, R1is heteroaryl substituted with trifluoromethyl. In certain embodiments, R1is heteroaryl substituted with methyl or trifluoromethyl. In certain embodiments, R1is heteroaryl substituted with methyl, trifluoromethyl, ethyl, isopropyl, or tert-butyl.

[0210] In certain embodiments, R1is heteroaryl substituted with -ORA. In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted alkyl). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted Cm alkyl). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted C1-6alkyl). In certain embodiments, R1is heteroaryl substituted with -O(unsubstituted C1-6alkyl). In certain embodiments, R1is heteroaryl substituted with -O(substituted C1-6alkyl). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted methyl, optionally substituted ethyl, optionally substituted n-propyl, optionally substituted isopropyl, optionally substituted n-butyl, optionally substituted tert-butyl, optionally substituted sec- butyl, optionally substituted isobutyl, optionally substituted n-pentyl, optionally substituted 3- pentanyl, optionally substituted amyl, optionally substituted neopentyl, optionally substituted 3- methyl-2-butanyl, optionally substituted tert-amyl, or optionally substituted n-hexyl). In certain embodiments, R1is heteroaryl substituted with -OCH3. In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted, monocyclic carbocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered carbocyclyl)). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted, polycyclic carbocyclyl (e.g., optionally substituted, bicyclic or tricyclic, 3- to 14-membered carbocyclyl)). In certain embodiments, R1is heteroaryl substituted with - O(optionally substituted saturated carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted cyclopropyl), -O(optionally substituted cyclobutyl), -O(optionally substituted cyclopentyl), -O(optionally substituted cyclohexyl), -O(optionally substituted cycloheptyl), -O(optionally substituted cyclooctyl), -O(optionally substituted cyclononyl), or - O(optionally substituted cyclodecyl). In certain embodiments, R1is heteroaryl substituted with - O(optionally substituted cyclopropyl). In certain embodiments, R1is heteroaryl substituted with - O(substituted carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -O(substitutedsaturated carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -O(unsubstituted carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -O(unsubstituted saturated carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -O(substituted cyclopropyl). In certain embodiments, R1is heteroaryl substituted with -O(unsubstituted cyclopropyl).

[0211] In certain embodiments, R1is heteroaryl substituted with -ORAsubstituted with at least one halogen. In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted alkyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with - O(optionally substituted Cm alkyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted C1-6alkyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -O(substituted C1-6alkyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with - O(optionally substituted methyl substituted with at least one halogen, optionally substituted ethyl substituted with at least one halogen, optionally substituted n-propyl substituted with at least one halogen, optionally substituted isopropyl substituted with at least one halogen, optionally substituted n-butyl substituted with at least one halogen, optionally substituted tert-butyl substituted with at least one halogen, optionally substituted sec-butyl substituted with at least one halogen, optionally substituted isobutyl substituted with at least one halogen, optionally substituted n-pentyl substituted with at least one halogen, optionally substituted 3-pentanyl substituted with at least one halogen, optionally substituted amyl substituted with at least one halogen, optionally substituted neopentyl substituted with at least one halogen, optionally substituted 3-methyl-2-butanyl substituted with at least one halogen, optionally substituted tert-amyl substituted with at least one halogen, or optionally substituted n -hexyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted, monocyclic carbocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered carbocyclyl substituted with at least one halogen) substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted, polycyclic carbocyclyl (e.g., optionally substituted, bicyclic or tricyclic, 3- to 14-membered carbocyclyl substituted with at least one halogen) substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted saturated carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted cyclopropyl substituted with at least one halogen), -O(optionally substituted cyclobutyl substituted with at least one halogen), -O(optionally substituted cyclopentyl substituted with at least one halogen), -O(optionally substituted cyclohexyl substituted with at least one halogen), -O(optionally substituted cycloheptyl substituted with at least one halogen), -O(optionally substituted cyclooctyl substituted with at least one halogen), - O(optionally substituted cyclononyl substituted with at least one halogen), or -O(optionally substituted cyclodecyl substituted with at least one halogen). In certain embodiments, R1is heteroarylsubstituted with -O(optionally substituted cyclopropyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -O(substituted carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -O(substituted saturated carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -O(unsubstituted carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -O(unsubstituted saturated carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -O(substituted cyclopropyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with - O(unsubstituted cyclopropyl substituted with at least one halogen).

[0212] In certain embodiments, R1is heteroaryl substituted with -ORAsubstituted with at least one - F. In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted alkyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted C1-12alkyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted C1-6alkyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -O( substituted C1-6alkyl substituted with at least one - F). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted methyl substituted with at least one -F, optionally substituted ethyl substituted with at least one -F, optionally substituted n-propyl substituted with at least one -F, optionally substituted isopropyl substituted with at least one -F, optionally substituted n-butyl substituted with at least one -F, optionally substituted tert-butyl substituted with at least one -F, optionally substituted sec-butyl substituted with at least one -F, optionally substituted isobutyl substituted with at least one -F, optionally substituted n-pentyl substituted with at least one -F, optionally substituted 3-pentanyl substituted with at least one -F, optionally substituted amyl substituted with at least one -F, optionally substituted neopentyl substituted with at least one -F, optionally substituted 3-methyl-2-butanyl substituted with at least one -F, optionally substituted tert-amyl substituted with at least one -F, or optionally substituted n -hexyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -OCF3. In certain embodiments, R1is heteroaryl substituted with -OMe and / or -OCF3. In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted carbocyclyl substituted with at least one - F). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted, monocyclic carbocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered carbocyclyl substituted with at least one -F) substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted, polycyclic carbocyclyl (e.g., optionally substituted, bicyclic or tricyclic, 3- to 14-membered carbocyclyl substituted with at least one -F) substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted saturated carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted cyclopropyl substituted with at least one -F), -O(optionally substituted cyclobutyl substituted with at least one -F), -O(optionally substituted cyclopentyl substituted with atleast one -F), -O(optionally substituted cyclohexyl substituted with at least one -F), -O(optionally substituted cycloheptyl substituted with at least one -F), -O(optionally substituted cyclooctyl substituted with at least one -F), -O(optionally substituted cyclononyl substituted with at least one - F), or -O(optionally substituted cyclodecyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -O(optionally substituted cyclopropyl substituted with at least one - F). In certain embodiments, R1is heteroaryl substituted with -O( substituted carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -O(substituted saturated carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -O(unsubstituted carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -O(unsubstituted saturated carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -O(substituted cyclopropyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -O(unsubstituted cyclopropyl substituted with at least one -F).

[0213] In certain embodiments, R1is heteroaryl substituted with -SRA. In certain embodiments, R1is heteroaryl substituted with -S (optionally substituted alkyl). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted Cm alkyl). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted C1-6alkyl). In certain embodiments, R1is heteroaryl substituted with -S(unsubstituted C1-6alkyl). In certain embodiments, R1is heteroaryl substituted with -S(substituted C1-6alkyl). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted methyl, optionally substituted ethyl, optionally substituted n-propyl, optionally substituted isopropyl, optionally substituted n-butyl, optionally substituted tert-butyl, optionally substituted sec- butyl, optionally substituted isobutyl, optionally substituted n-pentyl, optionally substituted 3- pentanyl, optionally substituted amyl, optionally substituted neopentyl, optionally substituted 3- methyl-2-butanyl, optionally substituted tert-amyl, or optionally substituted n-hexyl). In certain embodiments, R1is heteroaryl substituted with -SCH3. In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted, monocyclic carbocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered carbocyclyl)). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted, polycyclic carbocyclyl (e.g., optionally substituted, bicyclic or tricyclic, 3- to 14-membered carbocyclyl)). In certain embodiments, R1is heteroaryl substituted with - S(optionally substituted saturated carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted cyclopropyl), -S(optionally substituted cyclobutyl), -S(optionally substituted cyclopentyl), -S(optionally substituted cyclohexyl), -S(optionally substituted cycloheptyl), -S(optionally substituted cyclooctyl), -S(optionally substituted cyclononyl), or - S (optionally substituted cyclodecyl). In certain embodiments, R1is heteroaryl substituted with - S (optionally substituted cyclopropyl). In certain embodiments, R1is heteroaryl substituted with - S(substituted carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -S(substitutedsaturated carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -S(unsubstituted carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -S(unsubstituted saturated carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -S(substituted cyclopropyl). In certain embodiments, R1is heteroaryl substituted with -S(unsubstituted cyclopropyl).

[0214] In certain embodiments, R1is heteroaryl substituted with -SRAsubstituted with at least one halogen. In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted alkyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with - S (optionally substituted C1-12alkyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -S (optionally substituted C1-6alkyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -S(substituted C1-6alkyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with - S(optionally substituted methyl substituted with at least one halogen, optionally substituted ethyl substituted with at least one halogen, optionally substituted n-propyl substituted with at least one halogen, optionally substituted isopropyl substituted with at least one halogen, optionally substituted n-butyl substituted with at least one halogen, optionally substituted tert-butyl substituted with at least one halogen, optionally substituted sec-butyl substituted with at least one halogen, optionally substituted isobutyl substituted with at least one halogen, optionally substituted n-pentyl substituted with at least one halogen, optionally substituted 3-pentanyl substituted with at least one halogen, optionally substituted amyl substituted with at least one halogen, optionally substituted neopentyl substituted with at least one halogen, optionally substituted 3-methyl-2-butanyl substituted with at least one halogen, optionally substituted tert-amyl substituted with at least one halogen, or optionally substituted n -hexyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted, monocyclic carbocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered carbocyclyl substituted with at least one halogen) substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted, polycyclic carbocyclyl (e.g., optionally substituted, bicyclic or tricyclic, 3- to 14-membered carbocyclyl substituted with at least one halogen) substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -S (optionally substituted saturated carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted cyclopropyl substituted with at least one halogen), - S(optionally substituted cyclobutyl substituted with at least one halogen), -S(optionally substituted cyclopentyl substituted with at least one halogen), -S (optionally substituted cyclohexyl substituted with at least one halogen), -S(optionally substituted cycloheptyl substituted with at least one halogen), -S(optionally substituted cyclooctyl substituted with at least one halogen), -S(optionally substituted cyclononyl substituted with at least one halogen), or -S(optionally substituted cyclodecyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -S (optionally substituted cyclopropyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -S(substituted carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -S(substituted saturated carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -S (unsubstituted carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -S(unsubstituted saturated carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -S(substituted cyclopropyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -S(unsubstituted cyclopropyl substituted with at least one halogen).

[0215] In certain embodiments, R1is heteroaryl substituted with -SRAsubstituted with at least one - F. In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted alkyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted C1-12alkyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted C1-6alkyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -S(substituted C1-6alkyl substituted with at least one - F). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted methyl substituted with at least one -F, optionally substituted ethyl substituted with at least one -F, optionally substituted n-propyl substituted with at least one -F, optionally substituted isopropyl substituted with at least one -F, optionally substituted n-butyl substituted with at least one -F, optionally substituted tert-butyl substituted with at least one -F, optionally substituted sec-butyl substituted with at least one -F, optionally substituted isobutyl substituted with at least one -F, optionally substituted n-pentyl substituted with at least one -F, optionally substituted 3-pentanyl substituted with at least one -F, optionally substituted amyl substituted with at least one -F, optionally substituted neopentyl substituted with at least one -F, optionally substituted 3-methyl-2-butanyl substituted with at least one -F, optionally substituted tert-amyl substituted with at least one -F, or optionally substituted n -hexyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -SCF3. In certain embodiments, R1is heteroaryl substituted with -SMe and / or -SCF3. In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted carbocyclyl substituted with at least one - F). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted, monocyclic carbocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered carbocyclyl substituted with at least one -F) substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted, polycyclic carbocyclyl (e.g., optionally substituted, bicyclic or tricyclic, 3- to 14-membered carbocyclyl substituted with at least one -F) substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted saturated carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted cyclopropyl substituted with at least one -F), -S(optionally substituted cyclobutyl substituted with at least one -F), -S(optionally substituted cyclopentyl substituted with atleast one -F), -S(optionally substituted cyclohexyl substituted with at least one -F), -S(optionally substituted cycloheptyl substituted with at least one -F), -S(optionally substituted cyclooctyl substituted with at least one -F), -S(optionally substituted cyclononyl substituted with at least one - F), or -S (optionally substituted cyclodecyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -S(optionally substituted cyclopropyl substituted with at least one - F). In certain embodiments, R1is heteroaryl substituted with -S(substituted carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -S(substituted saturated carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -S(unsubstituted carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -S(unsubstituted saturated carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -S(substituted cyclopropyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -S(unsubstituted cyclopropyl substituted with at least one -F).

[0216] In certain embodiments, R1is heteroaryl substituted with -N(RA)2- In certain embodiments, at least one occurrence of RAis hydrogen. In certain embodiments, at least on occurrence of RAis -CH3. In certain embodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted alkyl). In certain embodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted C1-12alkyl). In certain embodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted C1-6alkyl). In certain embodiments, R1is heteroaryl substituted with -N(RA)(unsubstituted C1-6alkyl). In certain embodiments, R1is heteroaryl substituted with -N(RA)(substituted C1-6alkyl). In certain embodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted methyl, optionally substituted ethyl, optionally substituted n-propyl, optionally substituted isopropyl, optionally substituted n-butyl, optionally substituted tert-butyl, optionally substituted sec-butyl, optionally substituted isobutyl, optionally substituted n-pentyl, optionally substituted 3-pentanyl, optionally substituted amyl, optionally substituted neopentyl, optionally substituted 3-methyl-2-butanyl, optionally substituted tert-amyl, or optionally substituted n-hexyl). In certain embodiments, R1is heteroaryl substituted with -N(RA)CH3. In certain embodiments, R1is heteroaryl substituted with - N(RA) (optionally substituted carbocyclyl). In certain embodiments, R1is heteroaryl substituted with - N(RA) (optionally substituted, monocyclic carbocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered carbocyclyl)). In certain embodiments, R1is heteroaryl substituted with -N(RA) (optionally substituted, polycyclic carbocyclyl (e.g., optionally substituted, bicyclic or tricyclic, 3- to 14-membered carbocyclyl)). In certain embodiments, R1is heteroaryl substituted with - N(RA) (optionally substituted saturated carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -N(RA) (optionally substituted cyclopropyl), -N(RA)(optionally substituted cyclobutyl), -N(RA)(optionally substituted cyclopentyl), -N(RA)(optionally substituted cyclohexyl), - N(RA) (optionally substituted cycloheptyl), -N(RA) (optionally substituted cyclooctyl), -N(RA) (optionally substituted cyclononyl), or -N(RA)(optionally substituted cyclodecyl). In certainembodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted cyclopropyl). In certain embodiments, R1is heteroaryl substituted with -N(RA)(substituted carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -N(RA)(substituted saturated carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -N(RA)(unsubstituted carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -N(RA)(unsubstituted saturated carbocyclyl). In certain embodiments, R1is heteroaryl substituted with -N(RA)(substituted cyclopropyl). In certain embodiments, R1is heteroaryl substituted with -N(RA)(unsubstituted cyclopropyl).

[0217] In certain embodiments, R1is heteroaryl substituted with -N(RA)RAsubstituted with at least one halogen. In certain embodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted alkyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with - N(RA) (optionally substituted C1-12alkyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted C1-6alkyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA) (substituted C1-6alkyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted methyl substituted with at least one halogen, optionally substituted ethyl substituted with at least one halogen, optionally substituted n-propyl substituted with at least one halogen, optionally substituted isopropyl substituted with at least one halogen, optionally substituted n-butyl substituted with at least one halogen, optionally substituted tert-butyl substituted with at least one halogen, optionally substituted sec-butyl substituted with at least one halogen, optionally substituted isobutyl substituted with at least one halogen, optionally substituted n-pentyl substituted with at least one halogen, optionally substituted 3-pentanyl substituted with at least one halogen, optionally substituted amyl substituted with at least one halogen, optionally substituted neopentyl substituted with at least one halogen, optionally substituted 3-methyl-2-butanyl substituted with at least one halogen, optionally substituted tert-amyl substituted with at least one halogen, or optionally substituted n -hexyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA) (optionally substituted, monocyclic carbocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered carbocyclyl substituted with at least one halogen) substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted, polycyclic carbocyclyl (e.g., optionally substituted, bicyclic or bicyclic, 3- to 14-membered carbocyclyl substituted with at least one halogen) substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA) (optionally substituted saturated carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted cyclopropyl substituted with at least one halogen), -N(RA)(optionally substituted cyclobutyl substituted with at least one halogen), -N(RA) (optionally substituted cyclopentyl substituted with at least one halogen), -N(RA)(optionally substituted cyclohexyl substituted with atleast one halogen), -N(RA)(optionally substituted cycloheptyl substituted with at least one halogen), - N(RA) (optionally substituted cyclooctyl substituted with at least one halogen), -N(RA)(optionally substituted cyclononyl substituted with at least one halogen), or -N(RA)(optionally substituted cyclodecyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA) (optionally substituted cyclopropyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA)(substituted carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA)(substituted saturated carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA) (unsubstituted carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA)(unsubstituted saturated carbocyclyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA) (substituted cyclopropyl substituted with at least one halogen). In certain embodiments, R1is heteroaryl substituted with -N(RA)(unsubstituted cyclopropyl substituted with at least one halogen).

[0218] In certain embodiments, R1is heteroaryl substituted with -N(RA)RAsubstituted with at least one -F. In certain embodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted alkyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with - N(RA) (optionally substituted C1-12alkyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted C1-6alkyl substituted with at least one - F). In certain embodiments, R1is heteroaryl substituted with -N(RA)(substituted C1-6alkyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -N(RA) (optionally substituted methyl substituted with at least one -F, optionally substituted ethyl substituted with at least one -F, optionally substituted n-propyl substituted with at least one -F, optionally substituted isopropyl substituted with at least one -F, optionally substituted n-butyl substituted with at least one - F, optionally substituted tert-butyl substituted with at least one -F, optionally substituted sec-butyl substituted with at least one -F, optionally substituted isobutyl substituted with at least one -F, optionally substituted n - pentyl substituted with at least one -F, optionally substituted 3-pentanyl substituted with at least one -F, optionally substituted amyl substituted with at least one -F, optionally substituted neopentyl substituted with at least one -F, optionally substituted 3-methyl-2-butanyl substituted with at least one -F, optionally substituted tert-amyl substituted with at least one -F, or optionally substituted n -hexyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -N(RA)CF3. In certain embodiments, R1is heteroaryl substituted with - N(RA)Me and / or -N(RA)CF3. In certain embodiments, R1is heteroaryl substituted with -N(RA) (optionally substituted carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted, monocyclic carbocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered carbocyclyl substituted with at least one -F) substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -N(RA) (optionally substituted, polycyclic carbocyclyl (e.g., optionally substituted, bicyclic or bicyclic, 3- to 14-membered carbocyclyl substituted with at least one -F) substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -N(RA)(optionally substituted saturated carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with - N(RA) (optionally substituted cyclopropyl substituted with at least one -F), -N(RA)(optionally substituted cyclobutyl substituted with at least one -F), -N(RA)(optionally substituted cyclopentyl substituted with at least one -F), -N(RA)(optionally substituted cyclohexyl substituted with at least one -F), -N(RA)(optionally substituted cycloheptyl substituted with at least one -F), - N(RA) (optionally substituted cyclooctyl substituted with at least one -F), -N(RA)(optionally substituted cyclononyl substituted with at least one -F), or -N(RA)(optionally substituted cyclodecyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with - N(RA) (optionally substituted cyclopropyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -N(RA)(substituted carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -N(RA)(substituted saturated carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with - N(RA)(unsubstituted carbocyclyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with -N(RA)(unsubstituted saturated carbocyclyl substituted with at least one - F). In certain embodiments, R1is heteroaryl substituted with -N(RA)(substituted cyclopropyl substituted with at least one -F). In certain embodiments, R1is heteroaryl substituted with - N(RA) (unsubstituted cyclopropyl substituted with at least one -F).

[0219] In certain embodiments, R1is heteroaryl substituted with optionally substituted carbocyclyl. In certain embodiments, R1is heteroaryl substituted with optionally substituted, monocyclic carbocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered carbocyclyl). In certain embodiments, R1is heteroaryl substituted with optionally substituted, polycyclic carbocyclyl (e.g., optionally substituted, bicyclic or tricyclic, 3- to 14-membered carbocyclyl). In certain embodiments, R1is heteroaryl substituted with optionally substituted saturated carbocyclyl. In certain embodiments, R1is heteroaryl substituted with optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclohexyl, optionally substituted cycloheptyl, optionally substituted cyclooctyl, optionally substituted cyclononyl, or optionally substituted cyclodecyl. In certain embodiments, R1is heteroaryl substituted with optionally substituted cyclopropyl. In certain embodiments, R1is heteroaryl substituted with substituted carbocyclyl. In certain embodiments, R1is heteroaryl substituted with substituted saturated carbocyclyl. In certain embodiments, R1is heteroaryl substituted with unsubstituted carbocyclyl. In certain embodiments, R1is heteroaryl substituted with unsubstituted saturated carbocyclyl. In certain embodiments, R1is heteroaryl substituted with substituted cyclopropyl. In certain embodiments, R1is heteroaryl substituted with unsubstituted cyclopropyl.

[0220] In certain embodiments, R1is heteroaryl substituted with optionally substituted alkenyl. In certain embodiments, R1is heteroaryl substituted with optionally substituted alkynyl. In certainembodiments, R1is heteroaryl substituted with optionally substituted heteroalkyl. In certain embodiments, R1is heteroaryl substituted with optionally substituted heteroalkenyl. In certain embodiments, R1is heteroaryl substituted with optionally substituted heteroalkynyl. In certain embodiments, R1is unsubstituted heteroaryl.independently halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -ORA, -SCN, -SRA, -SSRA, -Ns, -independently halogen, optionally substituted alkyl, optionally substituted carbocyclyl, or -ORA; yl iswherein each R13is independently halogen, optionally substituted C1-3alkyl, optionally substituted C34 carbocyclyl, or -O(optionally substituted C1-3alkyl); yl is 0, 1, or 2; and y2 is 0, 1, or 2. In certain embodiments, R1is of formula:, wherein each R13is independently optionally substituted C1-3alkyl, optionally substituted C3-4carbocyclyl, or - O(optionally substituted C1-3alkyl); yl is 0, 1, or 2; and y2 is 0, 1, or 2. In certain embodiments, R1isindependently unsubstituted C1-3alkyl, unsubstituted C3-4carbocyclyl, or -O(unsubstituted C1-3alkyl); yl is 0, 1, or 2; and y2 is 0, 1, or 2. In certain embodiments,

[0224] In certain embodiments, R1is optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted indolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted pyrrolyl, optionally substituted furanyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted benzimidazolyl, optionally substituted indazolyl, optionally substituted phenyl, optionally substituted thiazolyl, optionally substituted pyridinonyl, optionally substituted imidazolidin-2-onyl, optionally substituted isothiazolyl, optionally substituted pyrazinyl, optionally substituted thiadiazolyl, optionally substituted thiophenyl, or optionally substituted pyridazinyl. In certain embodiments, R1is optionally substituted pyridinyl, optionally substituted phenyl, optionally substituted pyrimidinyl, optionally substituted pyrrolyl, optionally substituted thiazolyl, optionally substituted pyridinonyl, optionally substituted imidazolidin-2-onyl, optionally substituted isothiazolyl, optionally substituted pyrazinyl, optionally substituted isoxazolyl, optionally substituted thiadiazolyl, optionally substituted thiophenyl, or optionally substituted pyridazinyl. In certain embodiments, R1is optionally substituted phenyl. In certain embodiments, R1is optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrrolyl, optionally substituted thiazolyl, optionally substituted pyridinonyl, optionally substituted isothiazolyl, optionally substituted pyrazinyl, optionally substituted isoxazolyl,optionally substituted thiadiazolyl, optionally substituted thiophenyl, or optionally substituted pyridazinyl. In certain embodiments, R1is optionally substituted imidazolidin-2-onyl.R2

[0226] As generally described herein, each occurrence of R2is independently hydrogen, optionally substituted alkyl, or two occurrences of R2are joined together with their intervening carbon atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring.

[0227] In certain embodiments, at least one occurrence of R2is hydrogen. In certain embodiments, at least one occurrence of R2is optionally substituted alkyl. In certain embodiments, at least one occurrence of R2is optionally substituted Cm alkyl. In certain embodiments, at least one occurrenceof R2is optionally substituted C1-6alkyl. In certain embodiments, at least one occurrence of R2is unsubstituted C1-6alkyl. In certain embodiments, at least one occurrence of R2is substituted C1-6alkyl. In certain embodiments, at least one occurrence of R2is optionally substituted methyl, optionally substituted ethyl, optionally substituted n-propyl, optionally substituted isopropyl, optionally substituted n-butyl, optionally substituted tert-butyl, optionally substituted sec-butyl, optionally substituted isobutyl, optionally substituted n-pentyl, optionally substituted 3-pentanyl, optionally substituted amyl, optionally substituted neopentyl, optionally substituted 3-methyl-2-butanyl, optionally substituted tert-amyl, or optionally substituted n -hexyl. In certain embodiments, at least one occurrence of R2is optionally substituted methyl. In certain embodiments, at least one occurrence of R2is substituted methyl. In certain embodiments, at least one occurrence of R2is unsubstituted methyl. In certain embodiments, one occurrence of R2is unsubstituted methyl.

[0228] In certain embodiments, two occurrences of R2are hydrogen. In certain embodiments, two occurrences of R2are optionally substituted alkyl. In certain embodiments, two occurrences of R2are optionally substituted Cm alkyl. In certain embodiments, two occurrences of R2are optionally substituted C1-6alkyl. In certain embodiments, two occurrences of R2are unsubstituted C1-6alkyl. In certain embodiments, two occurrences of R2are substituted C1-6alkyl. In certain embodiments, two occurrences of R2are optionally substituted methyl, optionally substituted ethyl, optionally substituted n-propyl, optionally substituted isopropyl, optionally substituted n-butyl, optionally substituted tertbutyl, optionally substituted sec-butyl, optionally substituted isobutyl, optionally substituted n-pentyl, optionally substituted 3-pentanyl, optionally substituted amyl, optionally substituted neopentyl, optionally substituted 3-methyl-2-butanyl, optionally substituted tert-amyl, or optionally substituted / 7-hcxyl. In certain embodiments, two occurrences of R2are optionally substituted methyl. In certain embodiments, two occurrences of R2are substituted methyl. In certain embodiments, two occurrences of R2are unsubstituted methyl.

[0229] In certain embodiments, two occurrences of R2are joined together with their intervening atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring. In certain embodiments, two occurrences of R2are joined together with their intervening atom to form an optionally substituted carbocyclic ring. In certain embodiments, two occurrences of R2are joined together with their intervening atom to form an optionally substituted C3-12 cycloalkyl. In certain embodiments, two occurrences of R2are joined together with their intervening atom to form an optionally substituted C3-6cycloalkyl. In certain embodiments, two occurrences of R2are joined together with their intervening atom to form an optionally substituted, monocyclic carbocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered carbocyclyl). In certain embodiments, two occurrences of R2are joined together with their intervening atom to form an optionally substituted, polycyclic carbocyclyl (e.g., optionally substituted, bicyclic or tricyclic, 3- to 14-membered carbocyclyl). In certain embodiments, two occurrences of R2are joined together with their intervening atom to form an optionally substituted saturated carbocyclyl. In certain embodiments, twooccurrences of R2are joined together with their intervening atom to form an optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclohexyl, optionally substituted cycloheptyl, optionally substituted cyclooctyl, optionally substituted cyclononyl, or optionally substituted cyclodecyl. In certain embodiments, two occurrences of R2are joined together with their intervening atom to form an optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclohexyl, or optionally substituted cycloheptyl. In certain embodiments, two occurrences of R2are joined together with their intervening atom to form an optionally substituted carbocyclyl substituted with one or more of halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -ORA, -SCN, -SRA, -SSRA, -N3, -NO, -N(RA)2, -NO2, -C(=O)RA, -C(=O)ORA, -C(=O)SRA, - C(=O)N(RA)2, -C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)SRA, -C(=NRA)N(RA)2, -S(=O)RA, - S(=O)ORA, -S(=O)SRA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, -S(=O)2SRA, -S(=O)2N(RA)2, - OC(=O)RA, -OC(=O)ORA, -OC(=O)SRA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, - OC(=NRA)SRA, -OC(=NRA)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)SRA, -OS(=O)N(RA)2, - OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2SRA, -OS(=O)2N(RA)2, -ON(RA)2, -SC(=O)RA, -SC(=O)ORA, -SC(=O)SRA, -SC(=O)N(RA)2, -SC(=NRA)RA, -SC(=NRA)ORA, -SC(=NRA)SRA, - SC(=NRA)N(RA)2, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)SRA, -NRAC(=O)N(RA)2, - NRAC(=NRA)RA, -NRAC(=NRA)ORA, -NRAC(=NRA)SRA, -NRAC(=NRA)N(RA)2, -NRAS(=O)RA, - NRAS(=O)ORA, -NRAS(=O)SRA, -NRAS(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, - NRAS(=O)2SRA, -NRAS(=O)2N(RA)2, -Si(RA)3, -Si(RA)2ORA, -Si(RA)(ORA)2, -Si(ORA)3, -OSi(RA)3, -OSi(RA)2ORA, -OSi(RA)(ORA)2, -OSi(ORA)3, and / or -B(ORA)2groups.

[0230] In certain embodiments, two occurrences of R2are joined together with their intervening atom to form an optionally substituted heterocyclic ring. In certain embodiments, two occurrences of R2are joined together with their intervening atom to form an optionally substituted, monocyclic heterocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered heterocyclyl). In certain embodiments, two occurrences of R2are joined together with their intervening atom to form an optionally substituted, polycyclic heterocyclyl (e.g., optionally substituted, bicyclic or tricyclic, 3- to 14- membered heterocyclyl). In certain embodiments, two occurrences of R2are joined together with their intervening atom to form an optionally substituted saturated heterocyclyl. In certain embodiments, two occurrences of R2are joined together with their intervening atom to form an optionally substituted azirdinyl, optionally substituted oxiranyl, optionally substituted thiiranyl, optionally substituted azetidinyl, optionally substituted oxetanyl, optionally substituted thietanyl, optionally substituted tetrahydrofuranyl, optionally substituted dihydrofuranyl, optionally substituted tetrahydrothiophenyl, optionally substituted dihydrothiophenyl, optionally substituted pyrrolidinyl,optionally substituted dihydropyrrolyl, optionally substituted pyrrolyl-2, 5-dione, optionally substituted dioxolanyl, optionally substituted oxathiolanyl, optionally substituted dithiolanyl, optionally substituted triazolinyl, optionally substituted oxadiazolinyl, optionally substituted thiadiazolinyl, optionally substituted piperidinyl, optionally substituted tetrahydropyranyl, optionally substituted dihydropyridinyl, optionally substituted thianyl, optionally substituted piperazinyl, optionally substituted morpholinyl, optionally substituted dithianyl, optionally substituted dioxanyl, optionally substituted triazinyl, optionally substituted azepanyl, optionally substituted oxepanyl, optionally substituted thiepanyl, optionally substituted azocanyl, optionally substituted oxecanyl, optionally substituted thiocanyl, optionally substituted indolinyl, optionally substituted isoindolinyl, optionally substituted dihydrobenzofuranyl, optionally substituted dihydrobenzothienyl, optionally substituted tetrahydrobenzothienyl, optionally substituted tetrahydrobenzofuranyl, optionally substituted tetrahydroindolyl, optionally substituted tetrahydroquinolinyl, optionally substituted tetrahydroisoquinolinyl, optionally substituted decahydroquinolinyl, optionally substituted decahydroisoquinolinyl, optionally substituted octahydrochromenyl, optionally substituted octahydroisochromenyl, optionally substituted decahydronaphthyridinyl, optionally substituted decahydro-1, 8-naphthyridinyl, optionally substituted octahydropyrrolo[3,2-b]pyrrole, optionally substituted indolinyl, optionally substituted phthalimidyl, optionally substituted naphthalimidyl, optionally substituted chromanyl, optionally substituted chromenyl, optionally substituted 1H- benzo[e][l,4]diazepinyl, optionally substituted l,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl, optionally substituted 5,6-dihydro-4H-furo[3,2-b]pyrrolyl, optionally substituted 6,7-dihydro-5H-furo[3,2- b]pyranyl, optionally substituted 5,7-dihydro-4H-thieno[2,3-c]pyranyl, optionally substituted 2,3- dihydro-lH-pyrrolo[2,3-b]pyridinyl, optionally substituted 2,3-dihydrofuro[2,3-b]pyridinyl, optionally substituted 4,5,6,7-tetrahydro-lH-pyrrolo[2,3-b]pyridinyl, optionally substituted 4, 5,6,7- tetrahydrofuro[3,2-c]pyridinyl, optionally substituted 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl, or optionally substituted l,2,3,4-tetrahydro-l,6-naphthyridinyl. In certain embodiments, two occurrences of R2are joined together with their intervening atom to form a substituted heterocyclyl. In certain embodiments, two occurrences of R2are joined together with their intervening atom to form a substituted saturated heterocyclyl. In certain embodiments, two occurrences of R2are joined together with their intervening atom to form a heterocyclyl substituted with one or more of halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -ORA, -SCN, -SRA, -SSRA, -N3, -NO, -N(RA)2, -NO2, -C(=O)RA, -B(ORA)2groups. In certain embodiments, two occurrences of R2are joined together with their intervening atom to form optionally substituted azetidinyl, optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted morpholinyl, optionally substituted piperazinyl, optionally substituted azepanyl, optionally substituted tetrahydrofuryl, optionally substituted dihydropyranyl, or optionally substituted tetrahydropyranyl.

[0231] In certain embodiments, two occurrences of R2are joined together with their intervening atom to form unsubstituted cyclopropyl or unsubstituted oxetanyl. In certain embodiments, the moiety. in certain embodiments, the moietyis of formula:. In certain embodiments, the moietyis of formula:

[0232] In certain embodiments, at least one occurrence of R2is hydrogen, and at least one occurrence of R2is optionally substituted alkyl. In certain embodiments, at least one occurrence of R2is hydrogen, and at least one occurrence of R2is optionally substituted C1-12alkyl. In certain embodiments, at least one occurrence of R2is hydrogen, and at least one occurrence of R2is optionally substituted C1-6alkyl. In certain embodiments, at least one occurrence of R2is hydrogen, and at least one occurrence of R2is unsubstituted C1-6alkyl. In certain embodiments, at least one occurrence of R2is hydrogen, and at least one occurrence of R2is substituted C1-6alkyl. In certain embodiments, at least one occurrence of R2is hydrogen, and at least one occurrence of R2is optionally substituted methyl, optionally substituted ethyl, optionally substituted n-propyl, optionally substituted isopropyl, optionally substituted n-butyl, optionally substituted tert-butyl, optionally substituted sec-butyl, optionally substituted isobutyl, optionally substituted n-pentyl, optionally substituted 3-pentanyl, optionally substituted amyl, optionally substituted neopentyl, optionally substituted 3-methyl-2-butanyl, optionally substituted tert-amyl, or optionally substituted n -hexyl. In certain embodiments, at least one occurrence of R2is hydrogen, and at least one occurrence of R2is optionally substituted methyl. In certain embodiments, at least one occurrence of R2is hydrogen, and at least one occurrence of R2is substituted methyl. In certain embodiments, at least one occurrence of R2is hydrogen, and at least one occurrence of R2is unsubstituted methyl.R3

[0233] As generally described herein, two occurrences of R3are joined together with their intervening nitrogen atom to form an optionally substituted heterocyclic ring. In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form an optionally substituted, monocyclic heterocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered heterocyclyl). In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form an optionally substituted, polycyclic heterocyclyl (e.g., optionally substituted, bicyclic or tricyclic, 3- to 14-membered heterocyclyl). In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form an optionally substituted saturated heterocyclyl. In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form an optionally substituted azirdinyl, optionally substituted azetidinyl, optionally substituted pyrrolidinyl, optionally substituted dihydropyrrolyl, optionally substituted pyrrolyl-2, 5-dione, optionally substituted piperidinyl, optionally substituted dihydropyridinyl, optionally substituted piperazinyl, optionally substituted morpholinyl, optionally substituted azepanyl, optionally substituted azocanyl, optionally substituted indolinyl, optionally substituted isoindolinyl, optionally substituted tetrahydroindolyl, optionally substituted tetrahydroquinolinyl, optionally substituted tetrahydroisoquinolinyl, optionally substituted decahydroquinolinyl, optionally substituted decahydroisoquinolinyl, optionally substituted decahydronaphthyridinyl, or optionally substituted decahydro-1, 8-naphthyridinyl. In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form a substituted heterocyclyl. In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form a substituted saturated heterocyclyl. In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form a heterocyclyl substituted with one or more of halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, =0, =S, -CN, -ORA, -NRAS(=O)2SRA, -NRAS(=O)2N(RA)2, -Si(RA)3, -Si(RA)2ORA, -Si(RA)(ORA)2, -Si(ORA)3, -OSi(RA)3, -OSi(RA)2ORA, -OSi(RA)(ORA)2, -OSi(ORA)3, and / or -B(ORA)2groups. In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form a saturated heterocyclyl substituted with one or more of halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, =0,B(ORA)2groups. In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form an optionally substituted azetidinyl, optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted morpholinyl, optionally substituted piperazinyl, or optionally substituted azepanyl. In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form an optionally substituted piperidinyl, optionally substituted morpholinyl, or optionally substituted piperazinyl. In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form an optionally substituted piperidinyl. In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form an optionally substituted piperazinyl. In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form an optionally substituted morpholinyl. In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form a substituted morpholinyl. In certain embodiments, two occurrences of R3are joined together with their intervening nitrogen atom to form an unsubstituted morpholinyl.

[0234] In certain embodiments, two occurrences of R3are joined together with their interveningoccurrences of R3are joined together with their intervening nitrogen atom to form

[0235] In certain embodiments, -N(R3)2is an optionally substituted heterocyclic ring. In certain embodiments, -N(R3)2is an optionally substituted, monocyclic heterocyclyl (e.g., optionally substituted, monocyclic, 3- to 10-membered heterocyclyl). In certain embodiments, -N(R3)2is an optionally substituted, polycyclic heterocyclyl (e.g., optionally substituted, bicyclic or tricyclic, 3- to 14-membered heterocyclyl). In certain embodiments, -N(R3)2is an optionally substituted saturated heterocyclyl. In certain embodiments, -N(R3)2is an optionally substituted azirdinyl, optionally substituted azetidinyl, optionally substituted pyrrolidinyl, optionally substituted dihydropyrrolyl, optionally substituted pyrrolyl-2, 5-dione, optionally substituted piperidinyl, optionally substituted dihydropyridinyl, optionally substituted piperazinyl, optionally substituted morpholinyl, optionally substituted azepanyl, optionally substituted azocanyl, optionally substituted indolinyl, optionally substituted isoindolinyl, optionally substituted tetrahydroindolyl, optionally substituted tetrahydroquinolinyl, optionally substituted tetrahydroisoquinolinyl, optionally substituted decahydroquinolinyl, optionally substituted decahydroisoquinolinyl, optionally substituted decahydronaphthyridinyl, or optionally substituted decahydro-1, 8-naphthyridinyl. In certain embodiments, -N(R3)2is a substituted heterocyclyl. In certain embodiments, -N(R3)2is a substituted saturated heterocyclyl. In certain embodiments, -N(R3)2is a heterocyclyl substituted with one or moreof halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, =0, =S, -CN, -0RA, -SCN, -SRA, -SSRA, -Ns, - NO, -N(RA)2, -N02, -C(=0)RA, -C(=0)0RA, -C(=O)SRA, -C(=0)N(RA)2, -C(=NRA)RA, - C(=NRA)0RA, -C(=NRA)SRA, -C(=NRA)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)SRA, - S(=0)N(RA)2, -S(=O)2RA, -S(=O)2ORA, -S(=O)2SRA, -S(=O)2N(RA)2, -0C(=0)RA, -0C(=0)0RA, - OC(=O)SRA, -0C(=0)N(RA)2, -0C(=NRA)RA, -0C(=NRA)0RA, -0C(=NRA)SRA, - 0C(=NRA)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)SRA, -0S(=0)N(RA)2, -OS(=O)2RA, - OS(=O)2ORA, -OS(=O)2SRA, -OS(=O)2N(RA)2, -0N(RA)2, -SC(=O)RA, -SC(=O)ORA, -SC(=O)SRA, -SC(=0)N(RA)2, -SC(=NRA)RA, -SC(=NRA)0RA, -SC(=NRA)SRA, -SC(=NRA)N(RA)2, - NRAC(=0)RA, -NRAC(=0)0RA, -NRAC(=0)SRA, -NRAC(=0)N(RA)2, -NRAC(=NRA)RA, - NRAC(=NRA)0RA, -NRAC(=NRA)SRA, -NRAC(=NRA)N(RA)2, -NRAS(=0)RA, -NRAS(=0)0RA, - NRAS(=0)SRA, -NRAS(=0)N(RA)2, -NRAS(=0)2RA, -NRAS(=0)20RA, -NRAS(=0)2SRA, - NRAS(=O)2N(RA)2, -Si(RA)3, -Si(RA)20RA, -Si(RA)(0RA)2, -Si(ORA)3, -OSi(RA)3, -0Si(RA)20RA, - 0Si(RA)(0RA)2, -OSi(ORA)3, and / or -B(0RA)2groups. In certain embodiments, -N(R3)2is a saturated heterocyclyl substituted with one or more of halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, =0,B(ORA)2groups. In certain embodiments, -N(R3)2is an optionally substituted azetidinyl, optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted morpholinyl, optionally substituted piperazinyl, or optionally substituted azepanyl. In certain embodiments, -N(R3)2is an optionally substituted piperidinyl, optionally substituted morpholinyl, or optionally substituted piperazinyl. In certain embodiments, -N(R3)2is an optionally substituted piperidinyl. Incertain embodiments, -N(R3)2is an optionally substituted piperazinyl. In certain embodiments, -N(R3)2is an optionally substituted morpholinyl. In certain embodiments, -N(R3)2is a substituted morpholinyl. In certain embodiments, -N(R3)2is an unsubstituted morpholinyl.A, R4, L11, RN, and n

[0237] As generally described herein, A is CR4or N.

[0238] As generally described herein, R4is hydrogen, halogen, or optionally substituted alkyl. In certain embodiments, R4is hydrogen or optionally substituted alkyl. In certain embodiments, R4is hydrogen. In certain embodiments, R4is halogen. In certain embodiments, R4is -F, -Cl, -Br, or -I. In certain embodiments, R4is optionally substituted alkyl. In certain embodiments, R4is optionally substituted Ci-12 alkyl. In certain embodiments, R4is optionally substituted C1-6alkyl. In certain embodiments, R4is unsubstituted C1-6alkyl. In certain embodiments, R4is substituted C1-6alkyl. In certain embodiments, R4is optionally substituted methyl, optionally substituted ethyl, optionally substituted n-propyl, optionally substituted isopropyl, optionally substituted n-butyl, optionally substituted tert-butyl, optionally substituted sec-butyl, optionally substituted isobutyl, optionally substituted n-pentyl, optionally substituted 3-pentanyl, optionally substituted amyl, optionally substituted neopentyl, optionally substituted 3-methyl-2-butanyl, optionally substituted tert-amyl, or optionally substituted n -hexyl. In certain embodiments, R4is optionally substituted methyl. In certain embodiments, R4is substituted methyl. In certain embodiments, R4is unsubstituted methyl.

[0239] In certain embodiments, R4is optionally substituted alkyl substituted with at least one halogen. In certain embodiments, R4is optionally substituted C1-12alkyl substituted with at least onehalogen. In certain embodiments, R4is optionally substituted C1-6alkyl substituted with at least one halogen. In certain embodiments, R4is optionally substituted methyl substituted with at least one halogen, optionally substituted ethyl substituted with at least one halogen, optionally substituted n- propyl substituted with at least one halogen, optionally substituted isopropyl substituted with at least one halogen, optionally substituted n-butyl substituted with at least one halogen, optionally substituted tert-butyl substituted with at least one halogen, optionally substituted sec-butyl substituted with at least one halogen, optionally substituted isobutyl substituted with at least one halogen, optionally substituted n- pentyl substituted with at least one halogen, optionally substituted 3-pentanyl substituted with at least one halogen, optionally substituted amyl substituted with at least one halogen, optionally substituted neopentyl substituted with at least one halogen, optionally substituted 3-methyl- 2-butanyl substituted with at least one halogen, optionally substituted tert-amyl substituted with at least one halogen, or optionally substituted n -hexyl substituted with at least one halogen. In certain embodiments, R4is optionally substituted methyl substituted with at least one halogen. In certain embodiments, R4is optionally substituted alkyl substituted with at least one -F. In certain embodiments, R4is optionally substituted Cm alkyl substituted with at least one -F. In certain embodiments, R4is optionally substituted C1-6alkyl substituted with at least one -F. In certain embodiments, R4is optionally substituted methyl substituted with at least one -F, optionally substituted ethyl substituted with at least one -F, optionally substituted n-propyl substituted with at least one -F, optionally substituted isopropyl substituted with at least one -F, optionally substituted n- butyl substituted with at least one -F, optionally substituted tert-butyl substituted with at least one -F, optionally substituted sec-butyl substituted with at least one -F, optionally substituted isobutyl substituted with at least one -F, optionally substituted n- pentyl substituted with at least one -F, optionally substituted 3-pentanyl substituted with at least one -F, optionally substituted amyl substituted with at least one -F, optionally substituted neopentyl substituted with at least one -F, optionally substituted 3-methyl-2-butanyl substituted with at least one -F, optionally substituted tertamyl substituted with at least one -F, or optionally substituted n-hexyl substituted with at least one - F. In certain embodiments, R4is optionally substituted methyl substituted with at least one -F. In certain embodiments, R4is fluoromethyl. In certain embodiments, R4is difluoromethyl. In certain embodiments, R4is trifluoromethyl. In certain embodiments, R4is hydrogen, -CH3, or -CF3.

[0240] In certain embodiments, A is N. In certain embodiments, A is CR4. In certain embodiments, A is CR4, and R4is hydrogen or optionally substituted alkyl. In certain embodiments, A is CR4, and R4is hydrogen. In certain embodiments, A is CR4, and R4is halogen. In certain embodiments, A is CR4, and R4is -F, -Cl, -Br, or -I. In certain embodiments, A is CR4, and R4is optionally substituted alkyl. In certain embodiments, A is CR4, and R4is optionally substituted C1-12alkyl. In certain embodiments, A is CR4, and R4is optionally substituted C1-6alkyl. In certain embodiments, A is CR4, and R4is unsubstituted C1-6alkyl. In certain embodiments, A is CR4, and R4is substituted C1-6alkyl. In certain embodiments, A is CR4, and R4is optionally substituted methyl, optionally substituted ethyl,optionally substituted n-propyl, optionally substituted isopropyl, optionally substituted n-butyl, optionally substituted tert-butyl, optionally substituted sec-butyl, optionally substituted isobutyl, optionally substituted n-pentyl, optionally substituted 3-pentanyl, optionally substituted amyl, optionally substituted neopentyl, optionally substituted 3-methyl-2-butanyl, optionally substituted tert-amyl, or optionally substituted n -hexyl. In certain embodiments, A is CR4, and R4is optionally substituted methyl. In certain embodiments, A is CR4, and R4is substituted methyl. In certain embodiments, A is CR4, and R4is unsubstituted methyl.

[0241] In certain embodiments, A is CR4, and R4is optionally substituted alkyl substituted with at least one halogen. In certain embodiments, A is CR4, and R4is optionally substituted Cm alkyl substituted with at least one halogen. In certain embodiments, A is CR4, and R4is optionally substituted C1-6alkyl substituted with at least one halogen. In certain embodiments, A is CR4, and R4is optionally substituted methyl substituted with at least one halogen, optionally substituted ethyl substituted with at least one halogen, optionally substituted n-propyl substituted with at least one halogen, optionally substituted isopropyl substituted with at least one halogen, optionally substituted n-butyl substituted with at least one halogen, optionally substituted tert-butyl substituted with at least one halogen, optionally substituted sec-butyl substituted with at least one halogen, optionally substituted isobutyl substituted with at least one halogen, optionally substituted n-pentyl substituted with at least one halogen, optionally substituted 3-pentanyl substituted with at least one halogen, optionally substituted amyl substituted with at least one halogen, optionally substituted neopentyl substituted with at least one halogen, optionally substituted 3-methyl-2-butanyl substituted with at least one halogen, optionally substituted tert-amyl substituted with at least one halogen, or optionally substituted n -hexyl substituted with at least one halogen. In certain embodiments, A is CR4, and R4is optionally substituted methyl substituted with at least one halogen. In certain embodiments, A is CR4, and R4is optionally substituted alkyl substituted with at least one -F. In certain embodiments, A is CR4, and R4is optionally substituted Cm alkyl substituted with at least one -F. In certain embodiments, A is CR4, and R4is optionally substituted C1-6alkyl substituted with at least one -F. In certain embodiments, A is CR4, and R4is optionally substituted methyl substituted with at least one - F, optionally substituted ethyl substituted with at least one -F, optionally substituted n-propyl substituted with at least one -F, optionally substituted isopropyl substituted with at least one -F, optionally substituted n-butyl substituted with at least one -F, optionally substituted tert-butyl substituted with at least one -F, optionally substituted sec-butyl substituted with at least one -F, optionally substituted isobutyl substituted with at least one -F, optionally substituted n-pentyl substituted with at least one -F, optionally substituted 3-pentanyl substituted with at least one -F, optionally substituted amyl substituted with at least one -F, optionally substituted neopentyl substituted with at least one -F, optionally substituted 3-methyl-2-butanyl substituted with at least one -F, optionally substituted tert-amyl substituted with at least one -F, or optionally substituted n -hexyl substituted with at least one -F. In certain embodiments, A is CR4, and R4is optionally substitutedmethyl substituted with at least one -F. In certain embodiments, A is CR4, and R4is fluoromethyl. In certain embodiments, A is CR4, and R4is difluoromethyl. In certain embodiments, A is CR4, and R4is trifluoromethyl.

[0242] In certain embodiments, A is CR4or N, and R4is hydrogen, halogen, or optionally substituted alkyl. In certain embodiments, A is CR4or N, and R4is hydrogen or optionally substituted alkyl. In certain embodiments, A is CR4or N, and R4is hydrogen, -CH3, or -CF3. In certain embodiments, A is CR4or N, and R4is hydrogen. In certain embodiments, A is CR4or N, and R4is -CH3. In certain embodiments, A is CR4or N, and R4is -CF3. In certain embodiments, A is CR4, and R4is hydrogen, -CH3, or -CF3. In certain embodiments, A is CR4, and R4is hydrogen. In certain embodiments, A is CH, CCH3, CF3, or N. In certain embodiments, A is CH or N. In certain embodiments, A is CH. In certain embodiments, A is N.

[0243] In certain embodiments of Formula (I'), A is CR4, and RNand R4are joined together with their intervening atoms to form an optionally substituted heterocyclic ring. In certain embodiments of Formula (I'), A is CR4, and RNand R4are joined together with their intervening atoms to form an optionally substituted 5-6 membered heterocyclic ring. In certain embodiments of Formula (I'), A is CR4, and RNand R4are joined together with their intervening atoms to form an optionally substituted heterocyclic ring containing 1 ring N atom. In certain embodiments of Formula (I'), A is CR4, and RNand R4are joined together with their intervening atoms to form an optionally substituted 6-membered heterocyclic ring containing 1 ring N atom.

[0244] As generally described herein for compounds of Formula (I'), L11isorRN

[0245] In certain embodiments of Formula (I'), L” is. In certain embodiments ofFormula (I'), L” is. In certain embodiments of Formula (I'), L” is R2. In certainembodiments of Formula (I'), L11is R2. In certain embodiments of Formula (I'), L11isR2. In certain embodiments of Formula (I'), L11is. In certain embodiments ofFormula (I'), L11is. In certain embodiments of Formula (I'), L11is. In certain embodiments of FormulaRN

[0246] In certain embodiments of Formula (I'), L” is R2R2and RNand R4are joined together with their intervening atoms to form an optionally substituted heterocyclic ring. In certain embodiments of Formula (I'), the moietycertain embodiments of Formula (I'), the moietyf formula:

[0247] In certain embodiments of Formula (I'), L11is. In certain embodiments ofFormulacertain embodiments of Formula (I'), L” iswherein n is 1 or 2. In certain embodiments of Formula

[0248] As generally described herein for compounds of Formula (I'), RNis hydrogen, optionally substituted alkyl, or a nitrogen protecting group, or RNand R4are joined together with their intervening atoms to form an optionally substituted heterocyclic ring.

[0249] In certain embodiments of Formula (I'), RNis hydrogen. In certain embodiments of Formula (I'), RNis optionally substituted alkyl. In certain embodiments of Formula (I'), RNis substituted alkyl. In certain embodiments of Formula (I'), RNis unsubstituted alkyl. In certain embodiments of Formula (I'), RNis optionally substituted C1-6alkyl. In certain embodiments of Formula (I'), RNis optionally substituted Cm alkyl. In certain embodiments of Formula (I'), RNis a nitrogen protecting group.

[0250] In certain embodiments of Formula (I'), RNand R4are joined together with their intervening atoms to form an optionally substituted heterocyclic ring. In certain embodiments of Formula (I'), RNand R4are joined together with their intervening atoms to form an optionally substituted 5-6 membered heterocyclic ring. In certain embodiments of Formula (I'), RNand R4are joined together with their intervening atoms to form an optionally substituted heterocyclic ring containing 1 ring N atom. In certain embodiments of Formula (I'), RNand R4are joined together with their intervening atoms to form an optionally substituted 6-membered heterocyclic ring containing 1 ring N atom.

[0251] As generally described herein for compounds of Formula (I'), each occurrence of n is independently 0, 1 , or 2, provided that at least one occurrence of n is not 0.

[0252] In certain embodiments of Formula (I'), at least one occurrence of n is 0. In certain embodiments of Formula (I'), at least one occurrence of n is 1. In certain embodiments of Formula (I'), at least one occurrence of n is 2.

[0253] In certain embodiments of Formula (I'), one occurrence of n is independently 0, and one occurrence of n is independently 2. In certain embodiments of Formula (I'), each occurrence of n is independently 1.R5

[0254] As generally described herein for compounds of Formula (I'), R5is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

[0255] In certain embodiments of Formula (I'), R5is optionally substituted carbocyclyl. In certain embodiments of Formula (I'), R5is substituted carbocyclyl. In certain embodiments of Formula (I'), R5is unsubstituted carbocyclyl. In certain embodiments of Formula (I'), R5is optionally substituted C3-10carbocyclyl. In certain embodiments of Formula (I'), R5is substituted C3-10carbocyclyl. In certain embodiments of Formula (I'), R5is unsubstituted C3-10carbocyclyl. In certain embodiments of Formula (I'), R5is optionally substituted C5-6carbocyclyl. In certain embodiments of Formula (I'), R5is substituted C5-6carbocyclyl. In certain embodiments of Formula (I'), R5is unsubstituted C5-6carbocyclyl. In certain embodiments of Formula (I'), R5is optionally substituted monocyclic C5-6carbocyclyl. In certain embodiments of Formula (I'), R5is substituted monocyclic C5-6carbocyclyl. In certain embodiments of Formula (I'), R5is unsubstituted monocyclic C5-6carbocyclyl. In certain embodiments of Formula (I'), R5is optionally substituted bicyclic C5-6carbocyclyl. In certain embodiments of Formula (I'), R5is substituted bicyclic C5-6carbocyclyl. In certain embodiments of Formula (I'), R5is unsubstituted bicyclic C5-6carbocyclyl. In certain embodiments of Formula (I'), R5

[0256] In certain embodiments of Formula (I'), R5is optionally substituted heterocyclyl. In certain embodiments of Formula (I'), R5is substituted heterocyclyl. In certain embodiments of Formula (I'), R5is unsubstituted heterocyclyl. In certain embodiments of Formula (I'), R5is optionally substituted 3-10 membered heterocyclyl. In certain embodiments of Formula (I'), R5is substituted 3-10 membered heterocyclyl. In certain embodiments of Formula (I'), R5is unsubstituted 3-10 membered heterocyclyl. In certain embodiments of Formula (I'), R5is optionally substituted 6-10 membered heterocyclyl. In certain embodiments of Formula (I'), R5is substituted 6-10 membered heterocyclyl. In certain embodiments of Formula (I'), R5is unsubstituted 6-10 membered heterocyclyl. In certain embodiments of Formula (I'), R5is optionally substituted heterocyclyl containing at least 1 ring O atom. In certain embodiments of Formula (I'), R5is substituted heterocyclyl containing at least 1 ring O atom. In certain embodiments of Formula (I'), R5is unsubstituted heterocyclyl containing at least 1 ring O atom. In certain embodiments of Formula (I'), R5is optionally substituted 6-10 membered heterocyclyl containing at least 1 ring O atom. In certain embodiments of Formula (I'), R5is substituted 6-10 membered heterocyclyl containing at least 1 ring O atom. In certain embodiments of Formula (I'), R5is unsubstituted 6-10 membered heterocyclyl containing at least 1 ring O atom. In certain embodiments of Formula (I'), R5is

[0257] In certain embodiments of Formula (I'), R5is optionally substituted heteroaryl. In certain embodiments of Formula (I'), R5is substituted heteroaryl. In certain embodiments of Formula (I'), R5is unsubstituted heteroaryl. In certain embodiments of Formula (I'), R5is optionally substituted 5-10 membered heteroaryl. In certain embodiments of Formula (I'), R5is substituted 5-10 membered heteroaryl. In certain embodiments of Formula (I'), R5is unsubstituted 5-10 membered heteroaryl. In certain embodiments of Formula (I'), R5is optionally substituted heteroaryl containing at least 1 ring heteroatom selected from O, N, and S. In certain embodiments of Formula (I'), R5is substituted heteroaryl containing at least 1 ring heteroatom selected from O, N, and S. In certain embodiments of Formula (I'), R5is unsubstituted heteroaryl containing at least 1 ring heteroatom selected from O, N, and S. In certain embodiments of Formula (I'), R5is optionally substituted 5-10 membered heteroaryl containing at least 1 ring heteroatom selected from O, N, and S. In certain embodiments of Formula (I'), R5is substituted 5-10 membered heteroaryl containing at least 1 ring heteroatom selected from O, N, and S. In certain embodiments of Formula (I'), R5is unsubstituted 5-10 membered heteroaryl containing at least 1 ring heteroatom selected from O, N, and S.

[0258] In certain embodiments of Formula (I'), R5is optionally substituted 5-10 membered heteroaryl containing at least 1 ring O atom. In certain embodiments of Formula (I'), R5is substituted 5-10 membered heteroaryl containing at least 1 ring O atom. In certain embodiments of Formula (I'), R5is unsubstituted 5-10 membered heteroaryl containing at least 1 ring O atom. In certain embodiments of Formula (I'), R5is optionally substituted 5-10 membered heteroaryl containing atleast 1 ring N atom. In certain embodiments of Formula (I'), R5is substituted 5-10 membered heteroaryl containing at least 1 ring N atom. In certain embodiments of Formula (I'), R5is unsubstituted 5-10 membered heteroaryl containing at least 1 ring N atom. In certain embodiments of Formula (I'), R5is optionally substituted 5-10 membered heteroaryl containing at least 1 ring S atom. In certain embodiments of Formula (I'), R5is substituted 5-10 membered heteroaryl containing at least 1 ring S atom. In certain embodiments of Formula (I'), R5is unsubstituted 5-10 membered heteroaryl containing at least 1 ring S atom.

[0259] In certain embodiments of Formula (I'), R5is of formula:, wherein each R15is independently halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -ORA, -SCN, -SRA, -SSRA, -N3, -NO, -N(RA)2, -NO2, -C(=O)RA, -C(=O)ORA, -is 0, 1, or 2; x2 is 0, 1, 2, or 3; and x3 is 0, 1, 2, 3, or 4.

[0260] In certain embodiments of Formula (I'), R5is of formula:, wherein each R15is independently halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, or -ORA; xl is 0, 1, or 2; x2 is 0, 1, 2, or 3; and x3 is 0, 1, 2, 3, or 4. In certain embodiments of Formula (I'), R5is of formula:, wherein each R15is independently halogen or optionally substituted Cm alkyl; xl is 0, 1, or 2; x2 is 0, 1, 2, or 3; and x3 is 0, 1, 2, 3, or 4. In certain embodiments of Formula(I'), R5is of formula:

[0261] As generally described herein for compounds of Formula (I), R5is optionally substituted aryl.

[0262] In certain embodiments of Formulae (I') or (I), R5is optionally substituted aryl. In certain embodiments of Formula (I'), R5is optionally substituted aryl. In certain embodiments of Formula (I), R5is optionally substituted aryl.

[0263] In certain embodiments, R5is optionally substituted aryl. In certain embodiments, R5is optionally substituted C6-i4 aryl. In certain embodiments, R5is optionally substituted phenyl. In certain embodiments, R5is substituted phenyl. In certain embodiments, R5is phenyl substituted with one or more of halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -ORA, -SCN, -SRA, -SSRA, -Ns, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, -S(=O)2SRA, -S(=O)2N(RA)2, -OC(=O)RA, -OC(=O)ORA, - OC(=O)SRA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)SRA, - OC(=NRA)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)SRA, -OS(=O)N(RA)2, -OS(=O)2RA, - OS(=O)2ORA, -OS(=O)2SRA, -OS(=O)2N(RA)2, -ON(RA)2, -SC(=O)RA, -SC(=O)ORA, -SC(=O)SRA, -SC(=O)N(RA)2, -SC(=NRA)RA, -SC(=NRA)ORA, -SC(=NRA)SRA, -SC(=NRA)N(RA)2, - NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)SRA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, - NRAC(=NRA)ORA, -NRAC(=NRA)SRA, -NRAC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, - NRAS(=O)SRA, -NRAS(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2SRA, - NRAS(=O)2N(RA)2, -Si(RA)3, -Si(RA)2ORA, -Si(RA)(ORA)2, -Si(ORA)3, -OSi(RA)3, -OSi(RA)2ORA, - OSi(RA)(ORA)2, -OSi(ORA)3, and / or -B(ORA)2groups.

[0264] In certain embodiments, R5is phenyl substituted with halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, -CN, and / or -ORA. In certain embodiments, R5is phenyl substituted with halogen, optionally substituted alkyl, -CN, and / or -ORA. In certain embodiments, R5is phenyl substituted with halogen, optionally substituted C1-3alkyl, -CN, and / or -O(optionally substituted C1-3alkyl ). In certain embodiments, R5is phenyl substituted with halogen, unsubstituted C1-3alkyl, -CN, and / or -O( substituted C1-3alkyl ).

[0265] In certain embodiments, R5is phenyl substituted with halogen. In certain embodiments, R5is phenyl substituted with -F, -Cl, -Br, and / or -I. In certain embodiments, R5is phenyl substituted with -F. In certain embodiments, R5is phenyl substituted with -Cl. In certain embodiments, R5is

[0266] In certain embodiments, R5is phenyl substituted with optionally substituted alkyl. In certain embodiments, R5is phenyl substituted with optionally substituted C6-12alkyl. In certain embodiments, R5is phenyl substituted with optionally substituted C1-6alkyl. In certain embodiments, R5is phenyl substituted with unsubstituted C1-6alkyl. In certain embodiments, R5is phenyl substituted with substituted C1-6alkyl. In certain embodiments, R5is phenyl substituted with optionally substituted methyl, optionally substituted ethyl, optionally substituted n-propyl, optionally substituted isopropyl, optionally substituted n-butyl, optionally substituted tert-butyl, optionally substituted sec-butyl, optionally substituted isobutyl, optionally substituted n-pentyl, optionally substituted 3-pentanyl, optionally substituted amyl, optionally substituted neopentyl, optionally substituted 3-methyl-2- butanyl, optionally substituted tert-amyl, or optionally substituted n -hexyl. In certain embodiments, R5is phenyl substituted with optionally substituted methyl. In certain embodiments, R5is phenyl substituted with substituted methyl. In certain embodiments, R5is phenyl substituted with unsubstituted methyl. In certain embodiments, R5is phenyl substituted with optionally substitutedethyl. In certain embodiments, R5is phenyl substituted with substituted ethyl. In certain embodiments, R5is phenyl substituted with unsubstituted ethyl. In certain embodiments, R5is phenyl substituted with optionally substituted isopropyl. In certain embodiments, R5is phenyl substituted with substituted isopropyl. In certain embodiments, R5is phenyl substituted with unsubstituted isopropyl. In certain embodiments, R5is phenyl substituted with optionally substituted tert-butyl. In certain embodiments, R5is phenyl substituted with substituted tert-butyl. In certain embodiments, R5is phenyl substituted with unsubstituted tert-butyl. In certain embodiments, R5is phenyl substituted with methyl, ethyl, isopropyl, or tert-butyl.

[0267] In certain embodiments, R5is phenyl substituted with optionally substituted alkyl substituted with at least one halogen. In certain embodiments, R5is phenyl substituted with optionally substituted Ci-12 alkyl substituted with at least one halogen. In certain embodiments, R5is phenyl substituted with optionally substituted C1-6alkyl substituted with at least one halogen. In certain embodiments, R5is phenyl substituted with substituted C1-6alkyl substituted with at least one halogen. In certain embodiments, R5is phenyl substituted with optionally substituted methyl substituted with at least one halogen, optionally substituted ethyl substituted with at least one halogen, optionally substituted n- propyl substituted with at least one halogen, optionally substituted isopropyl substituted with at least one halogen, optionally substituted n-butyl substituted with at least one halogen, optionally substituted tert-butyl substituted with at least one halogen, optionally substituted sec-butyl substituted with at least one halogen, optionally substituted isobutyl substituted with at least one halogen, optionally substituted n - pentyl substituted with at least one halogen, optionally substituted 3-pentanyl substituted with at least one halogen, optionally substituted amyl substituted with at least one halogen, optionally substituted neopentyl substituted with at least one halogen, optionally substituted 3-methyl- 2-butanyl substituted with at least one halogen, optionally substituted tert-amyl substituted with at least one halogen, or optionally substituted n -hexyl substituted with at least one halogen.

[0268] In certain embodiments, R5is phenyl substituted with -ORAsubstituted with at least one -F. In certain embodiments, R5is phenyl substituted with optionally substituted alkyl substituted with at least one -F. In certain embodiments, R5is phenyl substituted with optionally substituted Cm alkyl substituted with at least one -F. In certain embodiments, R5is phenyl substituted with optionally substituted C1-6alkyl substituted with at least one -F. In certain embodiments, R5is phenyl substituted with substituted C1-6alkyl substituted with at least one -F. In certain embodiments, R5is phenyl substituted with optionally substituted methyl substituted with at least one -F, optionally substituted ethyl substituted with at least one -F, optionally substituted n-propyl substituted with at least one -F, optionally substituted isopropyl substituted with at least one -F, optionally substituted n-butyl substituted with at least one -F, optionally substituted tert-butyl substituted with at least one -F, optionally substituted sec-butyl substituted with at least one -F, optionally substituted isobutyl substituted with at least one -F, optionally substituted n- pentyl substituted with at least one -F, optionally substituted 3-pentanyl substituted with at least one -F, optionally substituted amylsubstituted with at least one -F, optionally substituted neopentyl substituted with at least one -F, optionally substituted 3-methyl-2-butanyl substituted with at least one -F, optionally substituted tert- amyl substituted with at least one -F, or optionally substituted n-hexyl substituted with at least one - F. In certain embodiments, R5is phenyl substituted with trifluoromethyl. In certain embodiments, R5is phenyl substituted with methyl or trifluoromethyl. In certain embodiments, R5is phenyl substituted with methyl, trifluoromethyl, ethyl, isopropyl, or tert-butyl.

[0269] In certain embodiments, R5is phenyl substituted with -ORA. In certain embodiments, R5is phenyl substituted with -O(optionally substituted alkyl). In certain embodiments, R5is phenyl substituted with -O(optionally substituted C1-12alkyl). In certain embodiments, R5is phenyl substituted with -O(optionally substituted C1-6alkyl). In certain embodiments, R5is phenyl substituted with -O(unsubstituted C1-6alkyl). In certain embodiments, R5is phenyl substituted with - O(substituted C1-6alkyl). In certain embodiments, R5is phenyl substituted with -O(optionally substituted methyl, optionally substituted ethyl, optionally substituted n-propyl, optionally substituted isopropyl, optionally substituted n-butyl, optionally substituted tert-butyl, optionally substituted sec- butyl, optionally substituted isobutyl, optionally substituted n-pentyl, optionally substituted 3- pentanyl, optionally substituted amyl, optionally substituted neopentyl, optionally substituted 3- methyl-2-butanyl, optionally substituted tert-amyl, or optionally substituted n-hexyl). In certain embodiments, R5is phenyl substituted with -OCH3.

[0270] In certain embodiments, R5is phenyl substituted with -ORAsubstituted with at least one halogen. In certain embodiments, R5is phenyl substituted with -O(optionally substituted alkyl substituted with at least one halogen). In certain embodiments, R5is phenyl substituted with - O(optionally substituted C1-12alkyl substituted with at least one halogen). In certain embodiments, R5is phenyl substituted with -O(optionally substituted C1-6alkyl substituted with at least one halogen). In certain embodiments, R5is phenyl substituted with -O(substituted C1-6alkyl substituted with at least one halogen). In certain embodiments, R5is phenyl substituted with -O(optionally substituted methyl substituted with at least one halogen, optionally substituted ethyl substituted with at least one halogen, optionally substituted n-propyl substituted with at least one halogen, optionally substituted isopropyl substituted with at least one halogen, optionally substituted n-butyl substituted with at least one halogen, optionally substituted tert-butyl substituted with at least one halogen, optionally substituted sec-butyl substituted with at least one halogen, optionally substituted isobutyl substituted with at least one halogen, optionally substituted n-pentyl substituted with at least one halogen, optionally substituted 3-pentanyl substituted with at least one halogen, optionally substituted amyl substituted with at least one halogen, optionally substituted neopentyl substituted with at least one halogen, optionally substituted 3-methyl-2-butanyl substituted with at least one halogen, optionally substituted tert-amyl substituted with at least one halogen, or optionally substituted n-hexyl substituted with at least one halogen).

[0271] In certain embodiments, R5is phenyl substituted with -ORAsubstituted with at least one -F. In certain embodiments, R5is phenyl substituted with -O(optionally substituted alkyl substituted with at least one -F). In certain embodiments, R5is phenyl substituted with -O(optionally substituted C1-12alkyl substituted with at least one -F). In certain embodiments, R5is phenyl substituted with - O(optionally substituted C1-6alkyl substituted with at least one -F). In certain embodiments, R5is phenyl substituted with -O(substituted C1-6alkyl substituted with at least one -F). In certain embodiments, R5is phenyl substituted with -O(optionally substituted methyl substituted with at least one -F, optionally substituted ethyl substituted with at least one -F, optionally substituted n-propyl substituted with at least one -F, optionally substituted isopropyl substituted with at least one -F, optionally substituted n-butyl substituted with at least one -F, optionally substituted tert-butyl substituted with at least one -F, optionally substituted sec-butyl substituted with at least one -F, optionally substituted isobutyl substituted with at least one -F, optionally substituted n-pentyl substituted with at least one -F, optionally substituted 3-pentanyl substituted with at least one -F, optionally substituted amyl substituted with at least one -F, optionally substituted neopentyl substituted with at least one -F, optionally substituted 3-methyl-2-butanyl substituted with at least one -F, optionally substituted tert-amyl substituted with at least one -F, or optionally substituted n -hexyl substituted with at least one -F). In certain embodiments, R5is phenyl substituted with -OCF3. In certain embodiments, R5is phenyl substituted with -OMe and / or -OCF3. In certain embodiments, R5is phenyl substituted with -CN.

[0272] In certain embodiments, R5is phenyl substituted with optionally substituted alkenyl. In certain embodiments, R5is phenyl substituted with optionally substituted alkynyl. In certain embodiments, R5is phenyl substituted with optionally substituted heteroalkyl. In certain embodiments, R5is phenyl substituted with optionally substituted heteroalkenyl. In certain embodiments, R5is phenyl substituted with optionally substituted heteroalkynyl. In certain embodiments, R5is unsubstituted phenyl.

[0274] In certain embodiments,, wherein each of R5A, R5B, R5C, R5D, and R 5E is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -ORA, -SCN, -SRA, -SSRA, -N3, -NO, -N(RA)2, -NO2, -C(=O)RA, -C(=O)ORA, -C(=O)SRA, -C(=O)N(RA)2, - C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)SRA, -C(=NRA)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)SRA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, -S(=O)2SRA, -S(=O)2N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)SRA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)SRA, - OC(=NRA)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)SRA, -OS(=O)N(RA)2, -OS(=O)2RA, - OS(=O)2ORA, -OS(=O)2SRA, -OS(=O)2N(RA)2, -ON(RA)2, -SC(=O)RA, -SC(=O)ORA, -SC(=O)SRA, -SC(=O)N(RA)2, -SC(=NRA)RA, -SC(=NRA)ORA, -SC(=NRA)SRA, -SC(=NRA)N(RA)2, - NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)SRA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, - NRAC(=NRA)ORA, -NRAC(=NRA)SRA, -NRAC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, - NRAS(=O)SRA, -NRAS(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2SRA, - NRAS(=O)2N(RA)2, -Si(RA)3, -Si(RA)2ORA, -Si(RA)(ORA)2, -Si(ORA)3, -OSi(RA)3, -OSi(RA)2ORA, - OSi(RA)(ORA)2, -OSi(ORA)3, or -B(ORA)2, or R5Band R5Cor R5Dand R5Care joined with their intervening atoms to form optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, each of R5A, R5B, R5C, R5D, and R5Eis independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, or -ORA, or R5Band R5Cor R5Dand R5Care joined with their intervening atoms to form optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

[0275] In some embodiments, the compound of Formulae (I') or (I) is of Formula (I-c):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein each of R5A, R5B, R5C, R5D, and R5Eis independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -ORA, -SCN, -SRA, -SSRA, -N3, -NO, -N(RA)2, -NO2, -C(=O)RA, -C(=O)ORA, -C(=O)SRA, -C(=O)N(RA)2, - C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)SRA, -C(=NRA)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)SRA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, -S(=O)2SRA, -S(=O)2N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)SRA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)SRA, - OC(=NRA)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)SRA, -OS(=O)N(RA)2, -OS(=O)2RA, - OS(=O)2ORA, -OS(=O)2SRA, -OS(=O)2N(RA)2, -ON(RA)2, -SC(=O)RA, -SC(=O)ORA, -SC(=O)SRA, -SC(=O)N(RA)2, -SC(=NRA)RA, -SC(=NRA)ORA, -SC(=NRA)SRA, -SC(=NRA)N(RA)2, - NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)SRA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, - NRAC(=NRA)ORA, -NRAC(=NRA)SRA, -NRAC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, - NRAS(=O)SRA, -NRAS(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2SRA, - NRAS(=O)2N(RA)2, -Si(RA)3, -Si(RA)2ORA, -Si(RA)(ORA)2, -Si(ORA)3, -OSi(RA)3, -OSi(RA)2ORA, - OSi(RA)(ORA)2, -OSi(ORA)3, or -B(ORA)2, or R5Band R5Cor R5Dand R5Care joined with their intervening atoms to form optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

[0276] In some embodiments, the compound of Formula (I-c) is of Formula (I-d):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0277] In some embodiments, the compound of Formula (I-d) is of Formula (I-d-i):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

[0278] In some embodiments, the compound of Formula (I-d) is of Formula (I-d-ii...

Claims

CLAIMSWhat is claimed is:

1. A compound of Formula (I'):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein:A is CR4or N;L is -C(=O)-, -SO2-, -C(=O)C(R11)2-, or -C(R11)2C(=O)-;L12is absent or -C(R12)2-;R1is optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of R2is independently hydrogen, optionally substituted alkyl, or two occurrences of R2are joined together with their intervening carbon atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring; two occurrences of R3are joined together with their intervening nitrogen atom to form an optionally substituted heterocyclic ring;R4is hydrogen, halogen, or optionally substituted alkyl;RNis hydrogen, optionally substituted alkyl, or a nitrogen protecting group, or RNand R4are joined together with their intervening atoms to form an optionally substituted heterocyclic ring;R5is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of R11is independently hydrogen, optionally substituted alkyl, or two occurrences of R11are joined together with their intervening carbon atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring; each occurrence of R12is independently hydrogen, optionally substituted alkyl, or two occurrences of R12are joined together with their intervening carbon atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring; and each occurrence of n is independently 0, 1 , or 2, provided that at least one occurrence of n is2. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein L is -C(=O)-.

3. The compound of any one of claims 1 or 2, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein4. The compound of any one of claims 1 or 2, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein the moiety5. The compound of any one of claims 1 or 2, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein L12is absent.

7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R5is optionally substituted C3-10carbocyclyl.

8. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R5is optionally substituted 6-10 membered heterocyclyl.

9. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrugeach R15is independently halogen or optionally substituted C1-3alkyl; xl is 0, 1, or 2; x2 is 0, 1, 2, or 3; and x3 is 0, 1, 2, 3, or 4.

10. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R5is of formula:or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein:A is CR4or N;L is — C(=O)— or -SO2-;R1is optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of R2is independently hydrogen, optionally substituted alkyl, or two occurrences of R2are joined together with their intervening carbon atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring; two occurrences of R3are joined together with their intervening nitrogen atom to form an optionally substituted heterocyclic ring;R4is hydrogen, halogen, or optionally substituted alkyl; and R5is optionally substituted aryl.

12. The compound of any one of claims 1 or 11, wherein the compound is of Formula (I-a):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

13. The compound of any one of claims 1, 11, or 12, wherein the compound is of Formula (I-a-i), (I-a-ii), or (I-a-iii):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

14. The compound of any one of claims 1 or 11-13, wherein the compound is of formula:or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

15. The compound of any one of claims 1 or 11-14, wherein the compound is of formula:or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

16. The compound of any one of claims 1 or 11-15, wherein the compound is of formula:-xvii),or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

17. The compound of any one of claims 1 or 11, wherein the compound is of Formula (I-b):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

18. The compound of any one of claims 1, 11, or 17, wherein the compound is of Formula (I-b-i):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

19. The compound of any one of claims 1, 11, 17, or 18, wherein the compound is of formula:or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

20. The compound of any one of claims 1, 11, or 17-19, wherein the compound is of formula:or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

21. The compound of any one of claims 1, 11, or 17-20, wherein the compound is of formula:or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

22. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1is phenyl substituted with halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, and / or -ORA, wherein each occurrence of RAis independently hydrogen, optionally substituted acyl,optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two occurrences of RAare joined together with their intervening atom to form an optionally substituted heterocyclic ring or optionally substituted heteroaryl ring.

23. The compound of claim 22, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1is phenyl substituted with halogen, optionally substituted carbocyclyl, and / or -ORA.

24. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1is optionally substituted heteroaryl.

25. The compound of any one of claims 1-21 or 24, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein:R1is heteroaryl substituted with halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, -ORA, -SRA, and / or -N(RA)2; and each occurrence of RAis independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two occurrences of RAare joined together with their intervening atom to form an optionally substituted heterocyclic ring or optionally substituted heteroaryl ring.

26. The compound of claim 25, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1is heteroaryl substituted with halogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted carbocyclyl, -ORA, -SRA, and / or -N(RA)2-27. The compound of any one of claims 25 or 26, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1is heteroaryl substituted with -ORA, -SRA, -NHRA, and / or -NCH3RA.

28. The compound of any one of claims 25-27, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein each occurrence of RAis independently hydrogen, optionally substituted alkyl, or optionally substituted carbocyclyl.

29. The compound of any one of claims 25-28, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein each occurrence of RAis alkyl substituted with 1-3 halogen substituents or carbocyclyl substituted with 1-3 halogen substituents.

30. The compound of any one of claims 1-29, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1is optionally substituted pyridinyl, optionally substituted phenyl, optionally substituted pyrimidinyl, optionally substituted pyrrolyl, optionally substituted thiazolyl, optionally substituted pyridinonyl, optionally substituted imidazolidin-2-onyl, optionally substituted isothiazolyl, optionally substituted pyrazinyl, optionally substituted isoxazolyl, optionally substituted thiadiazolyl, optionally substituted thiophenyl, or optionally substituted pyridazinyl.

31. The compound of any one of claims 1-21 or 24-30, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1is of formula:independently halogen, optionally substituted alkyl, optionally substituted carbocyclyl, or -ORA; yl is 0, 1, 2, 3, or 4; and y2 is 0, 1, or 2.

32. The compound of claim 31, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof,wherein R1is of formula:wherein eachR13is independently optionally substituted C1-3alkyl, optionally substituted C3-4 carbocyclyl, or - O(optionally substituted C1-3alkyl); yl is 0, 1, or 2; and y2 is 0, 1, or 2.

33. The compound of any one of claims 1-32, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug34. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein35. The compound of any one of claims 1-34, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein at least one occurrence of R2is hydrogen.

36. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein two occurrences of R2are hydrogen.

37. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein at least one occurrence of R2is optionally substituted alkyl.

38. The compound of any one of claims 1-34 or 37, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein two occurrences of R2are optionally substituted alkyl.

39. The compound of any one of claims 1-35, 37, or 38, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein at least one occurrence of R2is optionally substituted C1-6alkyl.

40. The compound of any one of claims 1-34 or 37-39, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein two occurrences of R2are optionally substituted C1-6alkyl.

41. The compound of any one of claims 1-35 or 37-40, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein at least one occurrence of R2is methyl.

42. The compound of any one of claims 1-34 or 37-41, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein two occurrences of R2are methyl.

43. The compound of any one of claims 1-34, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein two occurrences of R2are joined together with their intervening atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring.

44. The compound of any one of claims 1-34 or 43, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein two occurrences of R2are joined together with their intervening atom to form optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclohexyl, or optionally substituted cycloheptyl.

45. The compound of any one of claims 1-34, 43, or 44, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, orprodrug thereof, wherein two occurrences of R2are joined together with their intervening atom to form optionally substituted azetidinyl, optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted morpholinyl, optionally substituted piperazinyl, optionally substituted azepanyl, optionally substituted tetrahydrofuryl, optionally substituted dihydropyranyl, or optionally substituted tetrahydropyranyl.

46. The compound of any one of claims 1-34 or 43-45, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein two occurrences of R2are joined together with their intervening atom to47. The compound of any one of claims 1-46, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein -N(R3)2 is optionally substituted morpholinyl, optionally substituted piperidinyl, or optionally substituted piperazinyl.

48. The compound of any one of claims 1-47, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug49. The compound of any one of claims 1-48, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein50. The compound of any one of claims 1 or 11-49, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R4is hydrogen or optionally substituted alkyl.

51. The compound of any one of claims 1 or 11-50, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R4is hydrogen or -CH3.

52. The compound of any one of claims 1-51, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R5is optionally substituted phenyl.

53. The compound of any one of claims 1-52, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug54. The compound of any one of claims 1-53, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein55. The compound of any one of claims 1 or 11, wherein the compound is of Formula (I-c):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein: each of R5A, R5B, R5C, R5D, and R5Eis independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -ORA, -SCN, -SRA, -SSRA, -N3, -NO, -N(RA)2, -NO2, -C(=O)RA, -C(=O)ORA, -and each occurrence of RAis independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to asulfur atom, or two occurrences of RAare joined together with their intervening atom to form an optionally substituted heterocyclic ring or optionally substituted heteroaryl ring.

56. The compound of claim 55, wherein the compound is of Formula (I-d):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

57. The compound of any one of claims 55 or 56, wherein the compound is of Formula (I-d-i):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

58. The compound of any one of claims 55-57, wherein the compound is of Formula (I-d-iii):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

59. The compound of any one of claims 55-58, wherein the compound is of Formula (I-e-i):or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

60. The compound of any one of claims 55-59, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein at least one of R5A, R5B, R5C, R5D, and R5Eis halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, or -ORA.

61. The compound of any one of claims 55-60, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein at least one of R5A, R5B, R5C, R5D, and R5Eis -Cl.

62. The compound of any one of claims 55-61, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R5Cis -Cl.

63. The compound of any one of claims 55-62, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein each of R5A, R5B, R5C, R5D, and R5Eis independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, or -ORA.

64. The compound of any one of claims 55-63, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R5Cis halogen, optionally substituted alkyl, -CN, or -ORA.

65. The compound of any one of claims 55-64, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R5Cis halogen, unsubstituted Cm alkyl, -CN, or -O(substituted Cm alkyl ).

66. The compound of any one of claims 55-65, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R5Cis -Cl, methyl, -CN, or -OCF3.

67. The compound of any one of claims 55-66, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R5Bor R5Dis halogen or optionally substituted alkyl.

68. The compound of any one of claims 55-67, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R5Bor R5Dis halogen or unsubstituted Cm alkyl.

69. The compound of any one of claims 55-68, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R5Bor R5Dis -Cl or methyl.

70. The compound of any one of claims 1-69, wherein the compound is of formula:or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof.

71. A composition comprising the compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, and an excipient.

72. A method of treating or preventing a disease in a subject in need thereof, comprising administering to the subject in need thereof an effective amount of:the compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof; or the composition of claim 71.

73. The compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, or the composition of claim 71, for use in treating a disease in a subject in need thereof.

74. The compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, or the composition of claim 71 , for use in the manufacture of a medicament for treatment of a disease in a subject in need thereof.

75. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof for use, or composition for use of any one of clams 72-74, wherein the disease is associated with a viral infection.

76. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof for use, or composition for use of any one of clams 72-75, wherein the disease is associated with a coronavirus.

77. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof for use, or composition for use of claim 76, wherein the coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

78. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof for use, or composition for use of any one of clams 76 or 77, wherein the coronavirus is a delta, lambda, mu, or omicron variant.

79. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof foruse, or composition for use of any one of clams 72-78, wherein the disease is coronavirus disease 2019 (COVID-19).

80. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof for use, or composition for use of any one of clams 72-79, wherein the subject has at least one risk factor.

81. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof for use, or composition for use of claim 80, wherein the at least one risk factor is age of over 65 years old, cancer, chronic kidney disease, chronic liver disease, chronic lung disease, cystic fibrosis, dementia, diabetes, a disability, a heart condition, HIV infection, being immunocompromised, a mental health condition, being overweight or obese, physical inactivity, pregnancy, sickle cell disease, thalassemia, smoking, receipt of a solid organ or blood stem cell transplant, stroke or cerebrovascular disease, substance use disorder, and / or tuberculosis.

82. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof for use, or composition for use of any one of clams 72-81, comprising administering to the subject in need thereof of an additional pharmaceutical agent.

83. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof for use, or composition for use of claim 82, wherein the additional pharmaceutical agent inhibits Cathepsin L and / or transmembrane serine protease 2 (TMPRSS2).

84. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof for use, or composition for use of any one of clams 82 or 83, wherein the additional pharmaceutical agent is an antiviral agent.

85. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof for use, or composition for use of any one of clams 82-84, wherein the additional pharmaceutical agent is an anti-SARS-CoV-2 monoclonal antibody (mAh) agent.

86. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof for use, or composition for use of any one of clams 82-85, wherein the additional pharmaceutical agent is an immune modulating agent.

87. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof for use, or composition for use of any one of clams 82-84 or 86, wherein the additional pharmaceutical agent is camostat mesylate, Aloxistatin (E64d), raltegravir, remdesivir, molnupiravir, tixagevimab, cilgavimab, or a combination thereof.

88. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof for use, or composition for use of any one of clams 72-74, wherein the disease is associated with PIKfyve.

89. The method, compound for use, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof for use, or composition for use of any one of clams 72-74 or 88, wherein the disease is B-cell cancer, non-Hodgkin’ s lymphoma, follicular lymphoma, Amyotrophic Lateral Sclerosis, Crohn’s Disease, or Rheumatoid Arthritis.

90. A method of inhibiting entry of a virus in a subject in need thereof or in a cell, tissue, or biological sample, comprising administering to the subject in need thereof or contacting the cell, tissue, or biological sample with an effective amount of: a compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof; or the composition of claim 71.

91. The method of claim 90, wherein the inhibiting entry comprises reducing attachment of the virus in the subject in need thereof or in the cell, tissue, or biological sample.

92. The method of any one of clams 90 or 91, comprising not inhibiting host Cathepsin L and / or host transmembrane serine protease 2 (TMPRSS2).

93. The method of any one of clams 90-92, comprising not altering endosomal pH.

94. A method of inhibiting PIKfyve in a subject in need thereof or in a cell, tissue, or biological sample, comprising administering to the subject in need thereof or contacting the cell, tissue, or biological sample with an effective amount of: a compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof; or the composition of claim 71.

95. A kit comprising: the compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, or the composition of claim 71 ; and instructions for its use.